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Binding Immunoglobulin Protein (BiP) is a member of the HSP70 family and is currently 
being used in clinical trials to treat rheumatoid arthritis. Soluble BiP has been shown to have 
immunoregulatory properties in murine models of arthritis and human immune cells in 
vitro. Regulatory T cells are a subpopulation of T cells which modulate the immune system, 
maintain tolerance to self-antigens, and abrogate autoimmune disease. Published data 
suggest that HSP60 and HSP70 can enhance regulatory T cell function, and therefore the 
ability of soluble BiP ability to affect regulatory T cell frequency and function was examined.  
Using the Whitehall II cohort, the concentration of soluble BiP does not correlate with 
regulatory T cell frequencies. Two hours of BiP pre-treatment did not enhance regulatory T 
cell function as demonstrated in in vitro suppression assays. However, treatment of 
responder T cells with BiP for 4 days following stimulation with anti-CD3/CD28 beads or 
indirectly following co-culture with monocytes treated with BiP reduced their proliferation. 
Since the BiP effect on responder T cells can be observed after 4 days in culture, regulatory 
T cells were cultured with BiP for 4 days. BiP pre-treatment for 4 days of regulatory T cells 
had no effect on the phenotype, cytokine secretion and function of regulatory T cells. Then, 
the effect of BiP on responder T cells was investigated. Responder T cells cultured with BiP 
revealed a significant increase in Foxp3+CD25+ cells and IL-10 secretion within the 
responder T cell population cultured with BiP. The BiP-induced CD25HighFoxp3+ T cell ability 
to suppress responder T cells were variable but these cells can reduce TNF-α secretion from 
autologous responder T cells in the co-culture. In conclusion, BiP may modulate responder T 
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1.1 Heat shock protein (HSP) 
Heat shock proteins were initially identified in the 1960s. HSPs or stress proteins can be 
defined as “proteins whose expression is increased by conditions that cause protein 
denaturation or unfolding in the cells” (Udono, 2012). Various conditions have been 
suggested to induce denaturation or unfolding of the proteins in the cells including 
infection, heat stress, cytokines, oxidative stress and depletion of intracellular calcium (Ca2+) 
stores. HSP was first discovered and reported by Ritossa (1962) in the larvae of Drosophila. 
A puffing pattern was observed in the chromosomes of these larvae when the temperature 
of the incubator was shifted to a higher temperature. This pattern was later recognised as 
heat shock protein and the name was given because it was initially induced by an elevated 
temperature. Since then, more HSP were discovered and there are now more than 100 
individual HSP identified. Since this identification, these proteins are classified into various 
groups according to their molecular weights. Currently, there are 6 families of HSP classified 
according to their molecular weights namely small HSP family, HSP40 family, HSP60 family, 
HSP70 family, HSP90 family and HSP110 family as reviewed by Kampinga and colleagues 
(2009). One of the most studied HSP as reported in the literature is HSP70, as reported by 
Brocchieri et al (2008). However, the laboratory has been studying Binding Immunoglobulin 
Protein (BiP), a member of HSP70 family and that is the focus of the project. 
1.2 Binding Immunoglobulin Protein (BiP) 
BiP was first discovered by Pouyssegur and colleagues (1977) when they induced BiP 
expression in normal chicken fibroblasts. BiP induction was observed when the cells were 
starved of glucose for 24-48 hours, and this protein was named as Glucose Regulated 
Protein 78 (GRP78). However, this protein was known as Binding Immunoglobulin Protein 
(BiP) after Haas and Wabl (1983) discovered that this 78kDa protein can bind non-covalently 
to immunoglobulin heavy chain in B lymphocyte lineage cells. Further work by Munro and 
Pelham (1986) confirmed that both proteins were the same protein. Therefore, this 78kDa 
protein can be identified by using either GPR78 or BiP. Recently, Kampinga and co-workers 
(2009) proposed a new nomenclature of HSP and this protein can be identified as HSPA5. 
However, throughout this document, this protein will be referred to as BiP.  
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1.2.1 BiP protein and gene 
BiP belongs to HSP70 family based on its molecular weight. In addition to having an 
approximately similar molecular weight, BiP and HSP70 display very high homology between 
these two proteins (Munro and Pelham, 1986) and Daugaard and colleagues (2007) 
reported that human HSP70 and BiP share 64% of their amino acid sequences. Furthermore, 
BiP protein is a highly conserved protein structure as HSP70 and shares most of the domains 
with HSP70. Human HSP70 protein is 641 amino acids long and has adenosine triphosphate 
(ATP) binding domain, peptide binding domain, and variable region while human BiP protein 
(654 amino acids) displays two additional domains, namely the localisation signal at the end 
of N terminus and the lysine-aspartate-glutamate-leucine (KDEL) retention signal at the end 
of C terminus (Daugaard et al, 2007). The details of BiP structure can be seen in Figure 1.1. 
Panel (A) shows the linear structure of BiP where the N-terminus is flanked by signal 
sequence and ATPase. The N-terminus is where ATP binds to BiP. Then, the N-terminus and 
C-terminus is connected by a hydrophobic flexible linker before a substrate binding domain 
between amino acid at position 400 until 500 while at the end of C-terminus, a KDEL 
sequence is present. Panel (B) demonstrates the schematic diagram of BiP in its real form. 
However, these two proteins were encoded by two different chromosomes as HSP70 is 
encoded by Chromosome 7 while BiP is encoded by Chromosome 9 (Daugaard et al, 2007).  
A single BiP gene is encoded in Chromosome 9. Since this protein is highly conserved 
among various species, a high homology of protein sequence was reported between human 
BiP and BiP from other species, especially mammals. For instance, human BiP shares 97% of 
homology compared to rat BiP as reported by Corrigall et al (2001).  Furthermore, Ting and 
Lee (1988) reported the homology between BiP from different species. BiP genes from 
humans, rats, and hamsters shared unusual homology especially in the protein-coding and 
3’ untranslated regions. The high degree of homology between human and rodent BiP in 
terms of protein sequence and gene validates the use of rats, hamsters or mice in studying 







Figure 1.1 BiP protein structure. Panel A is reproduced from Lee (2014) and shows the 
linear representative of BiP protein. Panel B from Marcinowski et al (2011) is a schematic 
diagram of BiP. 
NBD – nucleotide binding domain 
SBD – substrate binding domain 
1.2.2 The role of BiP as molecular chaperone  
Molecular chaperones are proteins that assist the non-covalent folding or unfolding 
and the assembly or disassembly of other macromolecular structures. One of the earliest 
evidence of the involvement of HSP in unfolded protein response (UPR) was demonstrated 
in Escherichia coli (E.coli) by Sternberg (1973). His work showed that GroEL was essential for 
phage morphogenesis. GroEL only exists in prokaryotes and the homolog of GroEL in 
eukaryotes is HSP60 as demonstrated by more than 70% sequence homology between 
GroEL and human HSP60 (Bachmaier et al, 1999). The role of human HSP60 as a molecular 
chaperone has been well established in the literature as reviewed by Fink (1999). In 
addition, other HSP family members can act as molecular chaperones including BiP.  
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 BiP was initially located in endoplasmic reticulum (ER), a cell organelle that forms 
from the network of membranes consisting of rough and smooth ER, and serves may 
functions including protein synthesis and protein transport from ER to Golgi. Proteins with 
correct confirmation will be transported into the Golgi. Incorrectly folded proteins induced 
by ER stress will undergo repair and this response is referred to as the UPR (Malhotra and 
Kaufman, 2007). In addition, UPR aims to degrade misfolded proteins and activate the 
signalling pathways that lead to increased production of molecular chaperones involved in 
protein folding. If these objectives are not achieved within a certain time lapse or the 
disruption is prolonged, the UPR aims towards apoptosis. In its inactive form, BiP binds to all 
three signalling branches, namely Protein kinase RNA- like endoplasmic reticulum kinase 
(PERK), inositol requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6). 
However, when ER stress occurs, misfolded proteins bind to BiP to undergo repair and BiP 
will be induced to bind with misfolded proteins. As reviewed by Lee (2014), ER stress can be 
triggered by both intrinsic and extrinsic factors such as altered cell metabolism, 
hyperproliferation, hypoglycaemia, hypoxia, acidosis, viral infection and genetic lesions. All 
these conditions will lead to increased BiP expression in ER to cope with an increase of 
unfolded proteins in ER and induce signalling pathways as shown in Figure 1.2.  
 Signalling pathways which can be induced after BiP binding to misfolded proteins 
consists of three branches; PERK, IRE1 and ATF6. PERK is a type I transmembrane protein 
that control protein translation into ER. This is achieved by PERK activation that inhibits the 
initiation factor eukaryotic initiation factor 2 alpha (eIF2α) by phosphorylation. Schroder 
and Kaufman (2005) showed that inhibition of eIF2α activation can help to alleviate ER 
stress by reducing the amounts of misfolded proteins in the ER. Another branch of ER stress 
signalling is through ATF6. This protein is a transmembrane protein and can be activated by 
proteolysis as reported by Haze et al (1999). Once BiP no longer binds to ATF6, this protein 
will translocate to Golgi and is proteolytically cleaved by Golgi-resident site 1 protease and 
site-2 protease. This process will cause the release of the transcription factor domain from 
the Golgi as reported by Haze et al (1999). The translocation of ATF6 from the Golgi to 
nucleus induced the expression of genes related with protein folding, protein secretion and 
protein degradation. Finally, the IRE1 signalling branch can be activated when released from 
the BiP proteins to achieve the aims of UPR. IRE1 is a protein kinase and endoribonuclease; 
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therefore it can be called as a bifunctional enzyme. Parmar and Schroder (2012) reported 
that IRE1 can be activated after release from BiP by homodimerisation and 
autophosphorylation. Active IRE1 then cleaved the mRNA encoding X box-binding protein 1 
(XBP1) to induce gene expression involved in protein related processes as demonstrated by 
Ron and Hubbard (2008). The activation of all three signalling branches in UPR will 
eventually lead to the induction of ER chaperones, amino acid metabolism, protein 
degradation, and other genes as shown in Figure 1.2.  
 The role of the BiP protein is not only limited to the UPR as has been demonstrated 
in the literature. It has been shown to be involved in the regulation of calcium homeostasis, 
export and degradation of proteins, co-receptor for viral entry into cells and signalling 
transduction (Ni et al, 2011). Multiple biological functions of BiP reflect the localisation of 
BiP which now has been reported to be beyond the ER.  
1.2.3 BiP localisation beyond the endoplasmic reticulum  
 Various reports in the literature suggest that BiP can be localised in other 
compartments inside a cell. Apart from its main location in the ER, BiP can be found to be 
located in other cell organelles such as the nucleus and mitochondria. Matsumoto and 
Hanawalt (2000) showed the presence of BiP in the nuclei of human fibroblasts after 
photoactivation treatment of these fibroblast. On the other hand, translocation of BiP to 
nucleus was reported in cancer cells by Huang et al (2009). They showed that human 
hepatoma HepG2 cells can induce BiP expression in the nucleus following an intracellular 
increase of reactive oxygen species (ROS) concentrations inside these cells. Ni et al (2011) 
hypothesised that BiP localisation in the nucleus may play a role against deoxyribonucleic 
acid (DNA)-damaged induce apoptosis. On the other hand, Sun et al (2006) showed that BiP 
can be present in the mitochondria of rat brain tumour cells. BiP localisation in the 
mitochondria was observed by confocal microscopy and validated by immunoelectron 
microscopy. They suggested that BiP localisation in the mitochondria will enable it to 





Figure 1.2. The role of BiP as a molecular chaperone. This figure is reproduced from 
Schonthal (2012). In normal conditions, BiP binds to PERK, IRE1 and ATF6 as shown in the 
right. However, when cells undergo ER stress, BiP binds to misfolded proteins and the 
signalling cascades were triggered via PERK, IRE1 and ATF6 signalling branch to induce UPR 
gene expression.  
 Not only can BiP be found in the cell organelles such as ER, nucleus and 
mitochondria, it can also be localised outside cell organelles especially on the cell surface. 
Berger and colleagues (1997) first reported BiP presence on the cell surface of human 
cutaneous T-cell lymphoma tumor cells. The protein was initially named as BE2 protein but 
it was later confirmed that it was homologous to BiP as both proteins can bind strongly to 
ATP. The BiP presence of the cell surface was confirmed in cancer cells from cell lines (Xiao 
et al, 1999) or freshly isolated cancer tissues (Shin et al, 2003). Most importantly, Xiao and 
colleagues (1999) demonstrated that BiP present on cell surfaces maintained a similar 
protein structure as the KDEL sequence at the C-terminus of the protein was detected. The 
BiP presence of the cell surface of cancer cells may represent a therapeutic target in cancer.  
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 Furthermore, cell surface BiP was reported to be expressed by normal cells. BiP 
localisation on cell surfaces was observed in murine endothelial cells as reported by 
Bhattacharjee et al (2005). Inhibition of BiP in these cells resulted in increased procoagulant 
activity and they suggested that BiP negatively regulates procoagulant activity by physically 
interacting with the tissue factor (TF) extracellular domain on the cell surface. Cell surface 
BiP can be used by pathogens, especially viruses, to mediate their entry into the cells. BiP 
acted as a co-receptor of coxsackievirus A9 to mediate entry into the cells (Triantafilou et al, 
2002) while BiP may probably functions as part of a receptor complex to mediate dengue 
virus entry into liver cells (Jindadamrongwech et al, 2004). Therefore, BiP localisation in 
different cell compartments in various cell types may represent the pleiotropic nature of 
this protein.  
1.2.4 Active secretion of soluble BiP by different cell types  
 BiP localisation has been reported to be beyond its original location of ER. The 
presence of cell-free or extracellular BiP has been demonstrated in bodily fluids in the 
literature. Soluble BiP present in body fluids was shown to be slightly different in terms of 
protein structure. Munro and Pelham (1987) reported that the KDEL sequence at the end of 
C-terminus may function as a retention signal to keep BiP protein in ER. Therefore, the 
expression of the KDEL sequence was examined in soluble BiP. Using Western blot, Corrigall 
and colleagues (2004) showed that soluble BiP found in the synovial fluid was devoid of this 
sequence. To confirm this finding, Marin-Briggiler and co-workers (2010) investigated the 
structure of soluble BiP found in the oviductal fluids from women in the periovulatory 
period. They demonstrated that soluble BiP present in oviductal fluids was devoid of the 
KDEL sequence confirming that a common mechanism is used to secrete soluble BiP. 
Therefore, Shields et al (2011) postulated that BiP may be cleaved or alternatively spliced to 
generate its soluble form of protein. BiP transport to the extracellular space may be 
mediated by the exosomes as Gupta and Knowlton (2007) showed that HSP60 release into 
the extracellular space used exosomes in rat cardiomyocytes. Having reported that soluble 
BiP can be present in body fluids such as synovial and oviductal fluids, the presence of 
soluble BiP was also reported in circulation.   
Soluble BiP presence in the circulation was first reported by Blass and co-workers 
(1995) as they showed that BiP immunoreaction was most dominant in the majority of the 
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sera of rheumatoid arthritis (RA) patients. Furthermore, Delpino and Castelli (2002) showed 
that small amounts of circulating; free BiP was detected in the sera of healthy individuals. 
The low concentration of extracellular BiP made it difficult for the protein to be detected. 
They suggested that BiP detection from healthy controls can be performed after the 
enrichment by ATP-agarose affinity chromatography. Furthermore, Shields and colleagues 
(2011) reported that BiP concentration in the sera of RA patients can be detected in the 
range of nanogram per millilitre. However, the mean concentration of soluble BiP was 
significantly lower compared to the sera of non-RA patients. The next question was whether 
soluble BiP is actively secreted by cells or the soluble form of this protein present in body 
fluids was merely due to the release of this protein from dead cells. 
 Using human rabdomiosarcoma cells, a type of connective tissue cancer, BiP 
secretion into a cell culture medium was demonstrated by Delpino and Castelli (2002). The 
cells were stimulated with thapsigargin to induce ER stress which subsequently leads to the 
secretion of extracellular BiP. To confirm that the extracellular BiP release into cell culture 
medium was due to active secretion of intact cells, brefeldin A, a drug which blocks the 
transport of ER to Golgi, was added into the culture of these cells. Rabdomiosarcoma cells 
stimulated with thapsigargin in the presence of brefeldin A significantly decreased BiP 
secretion compared to cells cultured without brefeldin A. In addition, other cancer cells 
were shown to induce BiP secretion. Peng et al (2013) showed that human colon cancer cell 
line DLD1 can induce BiP secretion to convert mesenchymal stem cells into cancer-
associated fibroblasts while Kern et al (2009) demonstrated that another colon cancer cell 
line, HRT-18, secreted copious amounts of BiP to block the activity of the bortezomib, an 
anti-tumour drug. In addition, normal cells also were associated with BiP secretion. 
Takemoto and colleagues (1992) showed that rat pancreatic cells can cause the secretion of 
extracellular BiP and the secretion was not due to the release of BiP from dead cells, but 
active secretion by intact cells. Furthermore, Marin-Briggiler et al (2010) showed that 
extracellular or soluble BiP can be secreted by human oviduct epithelial cells and this 
protein plays an important role in the fertilisation process. This shows that soluble or 
extracellular BiP can be actively secreted by different cell types and can therefore be 
detected in bodily fluids.  
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1.3 BiP and the immune response 
One of the most important systems in human physiology is the immune system. The 
immune system consists of several biological structures and processes within an organism. 
By having an immune system, an organism can detect a wide variety of pathogens, 
distinguish them from healthy tissues and fight the pathogens. BiP can be induced in various 
cell types in response to infection in healthy individuals as a part of the UPR response. 
However, ER stress and BiP induction are related to the immune system as ER stress and the 
immune response share key transcription molecules downstream of the signalling pathway. 
IRE1, one of the sensing mechanisms used in ER stress, is the downstream signalling 
molecule of toll-like receptor 4 (TLR-4) as reviewed by Martinon and Glimcher (2011). 
Therefore, cross-talk of ER stress response and immune response is possible and this section 
aims to examine the effect of BiP induction via ER stress in immune cells in modulating 
immune cell functions.   
1.3.1 BiP induction can trigger immune responses 
 BiP induction in immune cells can be divided into innate and adaptive immune cells. 
Innate immune cells include mast cells, monocytes, macrophages, dendritic cells, natural 
killer cells and γδ T cells. Using THP-1 cells and primary human monocytes, Komura and 
colleagues (2013) reported that tunicamycin can induce the expression of ER stress related 
proteins including BiP. They showed that tunicamycin-induced-ER stress can reduce the 
expression of pro-inflammatory cytokines of tumour necrosis factor alpha (TNF-α) and 
interleukin 1 beta (IL-1β) in human monocytes in response to lipopolysaccharides (LPS) 
stimulation. This was due to the attenuation of nuclear factor kappa beta (NFκB) signalling 
in these cells which results in the reduction of the secretion of the cytokines. In addition, 
they showed that ER stress can impair the ability of human monocytes to differentiate into 
macrophages. Menu et al (2012) demonstrated that human macrophages can upregulate IL-
1β when subjected under ER stress using three compounds; tunicamycin, brefeldin A and 
thapsigargin. The release of IL-1β from macrophages was due to the activation of the NOD-
like receptor family, pyrin domain containing protein 3 (NLRP3) inflammasome. NLRP3 
inflammasome is one of the pattern recognition receptors that can sense endogenous 
danger signals and they showed that it can be activated by ER stress. In addition, human 
monocyte-derived dendritic cell (DC) also reported the pro-inflammatory effect of ER stress 
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as shown by Goodall et al (2010). ER stress induced by tunicamycin and TLR-4 stimulation by 
LPS significantly enhanced the transcription and secretion of IL-23 and IL-12, both pro-
inflammatory cytokines compared to LPS stimulation alone. The pro-inflammatory effect of 
ER stress (BiP induction) effect in DC and macrophages was in contrast to the anti-
inflammatory effect reported in the earlier study in monocytes. Since human DC, 
macrophages and monocytes are divided into subsets, it is crucial to observe the effect of 
ER stress on each subsets of these cells. Kenndey and co-workers (2013) examined closely 
the effect of ER stress on different macrophage subsets namely M1 and M2 macrophages. 
This classification is based on their function as M1 macrophages are associated with the pro-
inflammatory phenotype while M2 macrophages are immunomodulatory. Human 
macrophages derived from monocytes were polarised to become either M1 (IFN-γ/LPS) or 
M2 macrophages (IL-4/IL-13) with the appropriate cytokine combination and ER stress was 
induced by using thapsigargin and tunicamycin. The results showed that ER stress can 
upregulate 33 pro-inflammatory genes including TNF-α, IL-8 and IL-6 and most importantly 
activate inflammasome to induce IL-1β secretion compared to M2 macrophages. In 
addition, ER stress caused M1 macrophages to be more susceptible to apopotosis but not in 
M2 macrophages. Therefore, the outcome of BiP induction via ER stress depends on the 
subsets of each immune cell.  
 However, the investigation of BiP induction in adaptive immune cells was limited to 
general cell types namely CD8+ and CD4+ T cells. ER stress had been shown to induce pro-
inflammatory response in CD8+ T cells whilst the effect was contradictory in CD4+ T cells. 
Chang and colleagues (2012) showed that the expression of ER stress related proteins 
including BiP were increased in the animal model of Crohn’s disease. Furthermore, they 
demonstrated that intraepithelial CD8+ T cells from mice with heterozygous BiP phenotype 
had an impaired ability to mediate granzyme-B-dependent cytotoxicity. This indicates that 
ER stress promotes the development and maintenance of the pathogenic intraepithelial 
CD8+ T cells in these mice. In contrast, human CD4+ T cells exhibited a regulatory phenotype 
in response to ER stress as shown by Franco et al (2010). ER stress induced by thapsigargin 
caused an increase of the expression of ER stress related proteins including BiP, C/EBP 
homology protein (CHOP) and growth arrest and DNA damage-inducible protein (GADD34). 
Interestingly, ER stress induction in CD4+ T cells strongly induces IL-10 secretion and IL-10 
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secretion was dependent on the eIF2α as salubrinal, a small molecule inhibitor of eIF2α 
dephosphporylation, dramatically inhibited IL-10 secretion. In conclusion, BiP induction via 
ER stress can induce a variable immune response either pro or anti-inflammatory response 
depending on the cell types.  
1.3.2 Soluble BiP can modulate immune cell functions 
BiP induction can activate either pro or anti-inflammatory immune response in 
immune cells but evidence from literature suggests that soluble BiP can induce 
immunoregulatory phenotypes in immune cells. One early step in investigating the potential 
immunoregulatory property of any molecule is to culture the molecule with peripheral 
blood mononuclear cells (PBMC). Corrigall and colleagues (2004) demonstrated the potency 
of soluble BiP to induce IL-10 in human PBMCs. Upon culture of PBMCs with BiP, IL-10 can 
be significantly upregulated in the culture after 24 hours. The upregulation of IL-10 in the 
culture was paralleled with the downregulation of TNF-α. In addition, supernatants from 
PBMC culture with BiP revealed a reduction of IL-1β secretion, a pro-inflammatory cytokine 
associated with RA and an increase of the soluble TNF-α receptor II (sTNFRII) which act as a 
natural inhibitor of TNF-α. Furthermore, this work showed that soluble BiP can 
downregulate the expression of cluster of differentiation 86 (CD86) and human leukocyte 
antigen-DR (HLA-DR) in human monocytes suggesting that soluble BiP can inhibit the 
antigen-presenting function in monocytes as these two surface proteins were involved in 
activating T cells. To further investigate the effect of soluble BiP on antigen-presenting 
function, dendritic cells were cultured with soluble BiP. Further work by the same group 
(Corrigall et al, 2009) demonstrated that BiP-treated DC can induce the downregulation of 
CD86 and HLA-DR from monocyte-derived DC. Furthermore,  these dendritic cells  increase 
the expression of the intracellular indoleamine 2,3-dioxygenase (IDO) and leukocyte 
immunoglobulin-like receptor subfamily B member 1 (LILRB1) on their surface when 
cultured with BiP and secreted copious amounts of IL-10. However, the effect of soluble BiP 
is not only limited to innate immune cells.  
The effect of soluble BiP on adaptive immune cells had been investigated in CD8+ 
and CD4+ T cells. Bodman-Smith and colleagues (2003) demonstrated the ability of soluble 
BiP to induce IL-10 secretion in CD8+ T cells from healthy individuals. In addition, some of 
the CD8+ T cell clones isolated from healthy individuals can induce the secretion of IL-4 and 
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IL-5, two cytokines associated with Th2 cells when cultured with soluble BiP. These clones 
express CD25, CD28, CD80 and CD86 molecules on the surface but not CD56 or CD57. In 
addition, the T cell phenotype can be modulated indirectly by BiP via BiP-treated DC as 
shown by Corrigall et al (2009). BiP-treated DC can induce the development of human 
regulatory T cells when co-cultured with T cells. These regulatory T cells expressed CD25 and 
CD27 molecules on their surface and had higher levels of intracellular cytotoxic T 
lymphocyte antigen 4 (CTLA-4) compared to T cells after culture with untreated DC, and can 
suppress the proliferation of autologous T cells when co-cultured with autologous 
responder T cells. This shows that soluble BiP has immunomodulatory properties on 
immune cells.   
1.4 BiP and the autoimmune diseases 
In addition to functioning as a molecular chaperone, BiP has been shown to play 
significant roles on immune cells by the induction of BiP via ER stress or the 
immunoregulatory properties of soluble BiP. For this reason, the role of BiP in autoimmune 
diseases was examined. With more than 80 diseases classified as autoimmune diseases, the 
top 5 autoimmune diseases were chosen based on their prevalence in the UK. Boelaert and 
colleagues (2010) listed the top 5 autoimmune diseases as Hashimoto’s disease 
(hypothyroidism), Graves’s disease (hyperthyroidism), rheumatoid arthritis (RA), Type 1 
Diabetes Mellitus (T1DM) and finally inflammatory bowel diseases (IBD). However, after an 
extensive literature search, very few papers (fewer than 5 papers) were found to discuss the 
role of BiP directly or ER stress indirectly in hypothroidism and hyperthyroidism. Therefore, 
the BiP or ER stress role in autoimmune diseases will be discussed in T1DM, IBD and RA.    
1.4.1 Type1 Diabetes Mellitus 
Type 1 Diabetes Mellitus (T1DM) is a form of diabetes mellitus, a group of metabolic 
diseases in which there are high blood sugar levels over a prolonged period. It occurs when 
insulin-producing β cells in the pancreas have been destroyed by an autoimmune reaction 
hence leading to lack of insulin. The expression of ER stress related proteins was examined 
from the pancreatic specimen, as reported by Hopfgarten and colleagues (2014). They 
showed that there was no difference between the expressions of ER stress proteins, 
including BiP and XBP-1 between the specimen from T1DM patients and healthy controls, 
and the pancreatic specimen revealed an increase of ATF4, a transcription factor related to 
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the ER stress gene. However, the role of ER stress including BiP cannot be totally excluded in 
the disease as the sample number used in this data were very small (n=2). To confirm the 
role of BiP in T1DM, an investigation of the role of this protein and ER stress can be obtained 
from animal models. Oyadomari et al (2001) showed that ER stress plays a role in the 
destruction of β cells of the pancreas in murine pancreatic cell lines. Excessive nitric oxide 
(NO) production was identified to induce apopotosis to β cells and they demonstrated that 
ER stress can be induced by NO production marked by the upregulation of CHOP expression, 
a downstream signalling molecule involved in ER stress, hence leading to the death of β 
cells. However, in contrast to Oyadomari et al (2001), Engin et al (2013) showed that 
restoration of ER stress can protect mice from T1DM. The administration of ER stress 
mitigator tauroursodeoxycholic acid (TUDCA) at the prediabetic stage significantly reduced 
the incidence of T1DM in non-obese diabetic (NOD) mice. The reduction of T1DM incidence 
was achieved by lower cellular infiltration in the pancreas, lower apoptosis of β cells in the 
pancreas and most importantly restored expression of ER stress mediators including BiP. 
The conflicting roles shown in the literature may suggest ER stress plays a different role at 
the different stages of the disease but it did emphasize that ER stress may an important role 
in the disease itself.   
1.4.2 Inflammatory Bowel Disease (IBD) 
Inflammatory bowel disease (IBD) can be defined as a group of inflammatory 
conditions of the colon and small intestine. Best know examples of IBD are Crohn’s disease 
(CD) and Ulcerative colitis (UC). In CD, the inflammation occurs in the lining of the digestive 
system, therefore it can affect any part of the digestive system from mouth to the anal canal 
but it commonly occurs in the last section of the small intestine (ileum) or the large intestine 
(colon). However, the inflammation in UC is normally limited to specific areas of the 
digestive system which are the colon and rectum. The involvement of BiP and ER stress was 
confirmed by the presence of BiP from the histology staining of the digestive system from 
IBD patients. Deuring and colleagues (2012) demonstrated that BiP expression was the 
highest in active IBD patients compared to inactive IBD patients and healthy controls from 
the intestinal biopsy. The presence of BiP in active IBD patients was shown in proteins and 
mRNA expression from the biopsies. The same finding was observed by Bogaert and co-
workers (2011) as they reported higher expression of BiP proteins and messenger 
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ribonucleic acid (mRNA) from the biopsies of IBD patients compared to healthy individuals. 
Clearly this suggests that the activation of ER stress which leads to BiP induction can 
consequently cause intestinal inflammation. 
 To further confirm the role of BiP in IBD patients, evidence from the literature 
demonstrates that modulation of ER stress including BiP induction can lead to the reduction 
of the severity of inflammation in the digestive tract. Das et al (2013) showed the 
mechanism of glucocorticoid action in reducing inflammation in mice. Intestinal ER stress 
induced in Winnie mice caused misfolding of the Muc2 mucin and the glucocorticoid 
dexamethasone (DEX) administration can suppress ER stress and the activation of the UPR 
leading to the restoration of the goblet cell Muc2 production. Therefore, they suggested 
that glucocorticoids used in IBD treatment can ameliorate ER stress by promoting the 
correct folding of secreted proteins and enhancing the removal of misfolded proteins from 
the ER. In addition, Hao et al (2012) showed that the BiP expression in human intestinal 
epithelial cells can be modulated by berberine (BBR), an isoquinoline alkaloid isolated from 
Chinese herb Rhizoma coptidis. The BiP expression in these cells was enhanced signiﬁcantly 
in the presence of IFN-γ/TNF-α and tunicamycin, and they could be dampened by BBR. This 
compound was shown to downregulate c-Jun N-terminal kinases (JNK) phosphorylation, the 
level of caspase-12 and cleaved caspase-3. Subsequently it can ameliorate pro-inﬂammatory 
cytokines and induced ER stress in vitro. These works show that ER stress is activated in IBD, 
and modulating ER stress including BiP induction may be a target of treatment for IBD in the 
future.  
1.4.3 Rheumatoid arthritis (RA) 
Rheumatoid arthritis (RA) is an autoimmune disorder that results in a chronic, 
systemic inflammatory disorder that may affect many tissues and organs, but principally 
attacks flexible (synovial) joints. This disease is more common in women than men and 
normally affects people from the age 40 to 70 years old. Rheumatoid arthritis can make 
your joints swell, feel stiff and leave you feeling generally unwell and tired. Symptoms 
usually vary over time, and range from mild to severe. The condition can sometimes be very 
painful, making movement and everyday tasks difficult. There is no cure for the disease at 
the moment, but it can be managed by medication, surgery, supportive treatment or 
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alternative treatment. However, BiP has been identified as the putative autoantigen of RA 
and is now being used in clinical trial to treat RA.   
1.4.3.1 BiP as an autoantigen of rheumatoid arthritis  
BiP plays a special role in RA compared to other immune-mediated conditions as it 
has been identified as a putative autoantigen in RA. Two groups independently identified 
the role of BiP as the putative autoantigen for RA. Corrigall and colleagues (2004) reported 
that soluble BiP was present in the joints of RA patients using Western blot. In addition, 
Blass and co-workers (2001) demonstrated BiP are overexpressed in the joints of RA 
patients by immunostaining compared to osteoarthritis (OA) patients. Yoo and colleagues 
(2012) identified the localisation of BiP in the joints by using the immunostaining technique. 
They showed that BiP was highly expressed in the lining layer of the hyperplastic synovium. 
Further work by Dong et al (2009) showed that BiP was highly expressed in plasma cells that 
infiltrate the synovium in RA patients compared to OA patients. In addition to the joints, BiP 
can also be found in the circulation. In contrast to BiP, soluble BiP concentrations in RA 
patients were reported to be lower in the circulation compared to control diseases as 
reported by Shields et al (2011). Furthermore, not only was BiP protein present in RA 
patients, anti-BiP antibodies and BiP-specific cells were reported in RA patients.  
 To confirm the role of BiP as autoantigen in RA, anti-BiP antibodies were investigated 
in RA patients. Corrigall and co-workers (2001) reported that the sera of 30% of RA patients 
reacted against BiP protein, indicating the presence of anti-BiP antibodies. Further 
investigation by Blass et al (2001) demonstrated that anti-BiP antibody can be detected in 
63% of the sera of RA patients compared to 7% of the sera of other rheumatic diseases. In 
addition, anti-BiP antibodies were present only to a very low degree in the sera of the 
healthy population (1%). Furthermore, Corrigall and colleagues (2004) investigated the 
presence of anti-BiP antibody in various stages of disease in RA patients. Generally, the 
concentrations of anti-BiP antibodies were the highest in the sera of RA patients compared 
to other inflammatory joint diseases (OIJD) and normal controls. Anti-BiP antibodies were 
detected in 71% of patients with established disease while 61% of early RA patients were 
present with anti-BiP antibodies in their sera. The presence of anti-BiP antibodies in RA 
patients supports the contention that BiP is a putative autoantigen in RA. 
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 Finally, the presence of BiP-specific T cells was demonstrated in RA patients. Blass 
and colleagues (1995) reported that T cells from 70% of RA patients produced higher 
proliferation after re-stimulation with BiP in in vitro culture and this effect was dominant in 
RA patients with HLA-DQ phenotype. To accurately determine the presence of BiP-specific T 
cells, Corrigall et al (2001) investigated the proliferative capacity of PBMC from the 
periphery and joints of RA patients and other inflammatory joint diseases (OIJD). PBMCs 
isolated from the joints of RA patients had higher stimulation index in response to BiP 
compared to PBMC from RA patients and cells from OIJD patients. This result was validated 
by showing that this effect was specific to BiP only; not to other proteins. In conclusion, BiP 
can be identified as a putative autoantigen in RA as demonstrated by the presence of the 
protein in the joints or circulation (full length or soluble form), anti-BiP antibodies in the 
sera and finally the presence of BiP-specific T cells.       
1.4.3.2 Soluble BiP can prevent and resolve arthritis in animal models  
 Based on the hypothesis that BiP is an autoantigen in RA, BiP was used to try to 
induce arthritis in animal models. One of the famous Koch’s postulates is that a 
microorganism isolated from disease can cause disease when introduced into a healthy 
organism. Based on this concept, BiP immunisation was used to investigate whether it can 
induce arthritis in animal models. Based on this premise, Corrigall et al (2001) tried to 
investigate this hypothesis by using BiP injection to induce arthritis in rodents. However, BiP 
injection did not induce arthritis in DBA/1 or BALB/c mice. Instead, DBA/1 mice immunised 
by BiP developed anti-BiP antibodies in the sera on the onset of arthritis. The presence of 
these antibodies suggests that immune manipulation by BiP may prevent arthritis 
development. To address this, they envisaged a BiP injection on the onset of arthritis in the 
collagen-induced arthritis (CIA) model. CIA model is induced in DBA/1 mice by intradermal 
injection of Type II Collagen (CII) emulsified in Complete Freund Adjuvant (CFA) at the base 
of the tail. After 21 days, a booster injection of Incomplete Freund Adjuvant (IFA) was given 
as a booster and arthritis development at each footpad was visible after 6-8 weeks. The 
severity of arthritis was examined by the score given to each footpad from 0 to 4 and each 
mouse will get a maximum of 16 scores before being sacrificed. The incidence of arthritis in 
these models was between 50%-80% as reported by Inglis et al (2008). Then, BiP injection 
was performed on the onset of arthritis in the CIA model and shown to prevent the 
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development of arthritis in the CIA model. This was achieved by a lower incidence of RA in 
these mice, intact joint architecture and reduced concentration of the pathogenic CII 
autoantibodies compared to control mice. However, to apply this to human disease, it is 
important to show that BiP injection can reduce arthritis; therefore the role of BiP in 
suppressing arthritis was investigated. 
 The first evidence that BiP injection can work in suppressing active arthritis was 
demonstrated in the adjuvant arthritis (AA) model. AA model is induced in Lewis rat by the 
injection of dimethyl dioctadecyl ammodium bromide (DDA) suspended in PBS in each 
footpad. After 13 days, a second injection of heat-killed Mycobacterium tuberculosis 
emulsified in IFA was given and the same scoring system was used. Corrigall et al (2001) 
demonstrated that pre-BiP immunisation 13 days before the induction of AA significantly 
reduced the mean arthritic scores in these mice compared to PBS-injected mice. In addition, 
further work by Brownlie et al (2006) showed the efficacy of BiP in suppressing active 
arthritis in the CIA model. The efficacy of BiP in treating arthritis has also been 
demonstrated using the adoptive transfer method. Cells from BiP-immunised mice were 
isolated and adoptively transferred into the CIA model and these mice showed a significant 
reduction of arthritis measured by the mean severity score. In addition, Shields et al (2015) 
demonstrated that lentiviral delivery of the BiP gene into the CIA model can resolve 
arthritis. A single intraperitoneal injection of lentiviral vector containing BiP was compared 
with the green fluorescence protein (GFP) transgene in CIA model. CIA mice that received 
lentiviral BiP showed reduced inflammatory cell infiltration, cartilage destruction and 
significantly reduced pathogenic anti-CII antibodies. It is clear now that BiP can resolve 
arthritis via immunisation, adoptive transfer and lentiviral delivery of BiP in the 
experimental arthritis model.  
 Evidence from literature showed that BiP modulation of arthritis in the prevention 
and resolution of arthritis in animal models. However, it is important to investigate whether 
BiP has any effect on human arthritis. Because of ethical limitation, BiP injection was not 
possible to be performed directly on humans without sufficient experimental evidence. 
Therefore, a xenogeneic model can be used to illustrate the effect of BiP on human arthritis. 
By using severe combined immunodeficient (SCID) mice, rheumatoid arthritis synovial 
membranes (RASM) from RA patients who had undergone knee joint replacement were 
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transplanted into these mice. RASM can be successfully transplanted into SCID mice since 
these mice lack functional B and T cells as they have a mutation on the SCID gene on 
Chromosome 16. This gene is responsible for producing an enzyme which is important in the 
DNA recombination mechanism. Since V(D)J recombination process does not occur, 
therefore the development of B and T cells were affected hence humoral and cellular 
immunity fail to mature. Yoshida and colleagues (2011) showed that BiP injection into 
RASM/SCID mice successfully reduce the severity of arthritis in these mice. The severity of 
arthritis was clearly visible as measured by reduced cellular infiltration and antigen 
presentation as measured by co-stimulatory molecules. This work gives an indication that 
BiP modulation may have a therapeutic effect on humans.     
1.4.3.3 The immune mechanisms of BiP action in resolving arthritis in animal models 
 As discussed in detail in the previous subsection, BiP has the ability to suppress 
arthritis in experimental arthritis in mice. Brownlie et al (2006) showed that BiP has the 
ability to prime T cells from normal mice to become Th2 cells by secreting Th2 related 
cytokines, namely IL-4, IL-5 and IL-10. This was confirmed when BiP-primed cells from 
immunised mice increased BiP-specific proliferation and the production of IFN-γ, IL-4, IL-5 
and IL-10 after re-stimulation with BiP in in vitro culture. Most importantly, the severity of 
arthritis was not significantly reduced when BiP injection was performed on IL-4 knockout 
mice. This result highlighted the role of IL-4 as they suggested that BiP can cure arthritis in 
the CIA model by inducing the development of IL-4 secreting regulatory T cells.  
In contrast, Shields et al (2015) explored other possible mechanisms of BiP action in 
suppressing arthritis by lentiviral delivery of BiP. BiP-transfected mice produced higher 
levels of soluble cytotoxic T lymphocytes antigen 4 (sCTLA-4) in their sera compared to 
control mice. In addition, the analysis of splenocytes and lymphocytes isolated from BiP-
transfected mice showed an increase of CTLA-4 positive cell frequencies compared to 
control mice. Finally, a co-culture of pathogenic CII cells with cells from BiP-transfected mice 
or control mice demonstrated an increase in IL-10 and a decrease in IL-17 from the co-
culture implying that BiP may induce regulatory T cell development. The work by Yoshida et 
al (2011) showed the importance of IL-10 in reducing arthritis in the xenogeneic model by 
using neutralising antibodies towards IL-10. In addition, BiP can downregulate pro-
inflammatory cytokines of TNF-α and IL-6 in the joints of these mice. Therefore, BiP is able 
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to modulate arthritis in animal models by reducing pro-inflammatory cytokines (TNF-α, IL-6 
and IL-17), upregulating anti-inflammatory molecules (IL-4, IL-5, IL-10, sCTLA-4 and CTLA-4) 
and inducing regulatory T cell development.       
1.5 Regulatory T cells 
Regulatory T cells are a subset of T cells and central for the maintenance of immune 
homeostasis and central tolerance and consist of between 5-10% of total CD4+ T cells. 
Regulatory T cells are characterised by the presence of CD4 and high expression CD25 
molecules on their surface with forkhead box3 (Foxp3) as the main transcription factor. CD4 
is a glycoprotein found on the surface of immune cells and acts as a co-receptor that assists 
T cell receptor (TCR) communication with antigen presenting cells (APC) while CD25 is an 
alpha (α) chain of the IL-2 receptor. The importance of Foxp3 protein as a transcription 
factor of regulatory T cells was highlighted in patients with Foxp3 mutation. Chatila and 
colleagues (2000) first demonstrated that patients with Foxp3 mutation experienced 
multisystem autoimmunity which was later identified as immundysregulation, 
polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. IPEX syndrome is characterised 
the presence of early onset type 1 diabetes mellitus (T1DM), severe enteropathy, eczema, 
anaemia, thrombocytopenia, and hypothyroidism as described by Wildin and colleagues 
(2002). They compared IPEX patients to scurfy mice which are characterised by over-
proliferation of CD4+CD8− T lymphocytes, extensive multiorgans infiltration and elevation of 
numerous cytokines as described by Brunkow and co-workers (2001). Further work by 
Fontenot et al (2005) demonstrated that Foxp3 protein can be used to identify regulatory T 
cell lineage. In addition to CD4+CD25+Foxp3+ regulatory T cells, more regulatory cells were 
discovered in CD8, B cell or myeloid cell populations. However, the focus of this project is on 
CD4+CD25HighFoxp3+ regulatory T cells.   
1.5.1 CD127 as a reliable surface marker of regulatory T cells 
As mentioned before, regulatory T cells can be identified by the presence of CD4 
molecules, high CD25 expression and intracellular Foxp3 expression. However, activated 
human CD4+ T cells can transiently express CD25 and Foxp3 as reported in several studies 
(Allan et al, 2007, Wang et al, 2007, McMurchy et al, 2013). Therefore, to isolate human 
regulatory T cells from PBMCs, an additional surface marker needs to be identified for 
regulatory T cells. Foxp3 protein is an intracellular protein hence staining Foxp3 with flow 
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cytometry antibody disables the cells to be used in the culture. Various surface markers 
have been reported as being a marker to truly identify human regulatory T cells. However, 
the surface marker discussed in this subsection is a marker related with the mechanism of 
suppression but purely surface markers that correlate with either Foxp3 expression or the 
suppressive function of regulatory T cells.      
One of the most commonly described surface markers for regulatory T cells is CD127. 
CD127 is an α chain of the IL-7 receptor and it was first described as a marker for regulatory 
T cells by two independent groups in 2007. Liu and colleagues (2006) showed that CD127 
downregulation in human CD4+ population indicates a suppressive phenotype and the cells 
were anergic, as regulatory T cells are hypoproliferative in vitro without IL-2 stimulation. In 
the meantime, Seddiki and colleagues (2006) demonstrated that Foxp3 protein expression 
highly correlates with CD127Low population within CD4+CD25High population. Furthermore, 
CD25HighCD127Low cells exist in both effector/memory and naïve phenotype by examining 
CD45RA/RO expression and both populations manifested suppressive activity in vitro, 
whereas CD25HighCD127High cells did not. In addition, Yu and colleagues (2012) performed a 
direct comparison between several surface markers of regulatory T cells. CD127, CD39 and 
CD73 were compared and contrasted with each other in terms of Foxp3 expression and 
suppressive capacity in the in vitro suppression assay. The CD4+CD25HighCD127Low 
population had the highest expression of Foxp3 protein and the best suppressive capacity 
compared to CD4+CD25HighCD39+ and CD4+CD25HighCD73+ populations. Therefore, CD127 
can be used to help distinguish a pure population of regulatory T cells as regulatory T cells 
can be defined as CD4+CD25HighCD127Low population.  
1.5.2 Thymus-derived and peripherally-induced regulatory T cells 
 Regulatory T cells can be divided into various subsets according to the criteria of 
classification but the most important criteria is the origin of differentiation. Based on this 
criterion, regulatory T cells can be divided into two populations, natural regulatory T cells 
and induced or adaptive regulatory T cells. To standardise the nomenclature of regulatory T 
cells, Abbas and colleagues (2013) envisaged the idea of naming different subsets of 
regulatory T cells based on the origin of their differentiation. Natural regulatory T cells were 
correctly re-named as thymus-derived regulatory T cells to reflect the fact that these cells 
were developed in the thymus. In contrast, peripherally-induced regulatory T cells were 
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used to replace induced or adaptive regulatory T cells as these cells were developed on the 
periphery. In addition, they also introduced ‘in-vitro induced regulatory T cells’ and clearly 
distinguish between those regulatory T cell populations generated in vivo versus those 
generated in vitro. 
 This new nomenclature system was partly introduced because there is no consensus 
in the scientific community on the marker that may be used to distinguish between thymus-
derived and peripherally-induced regulatory T cells especially in humans. Several markers 
have been proposed to distinguish these two populations based on regulatory T cell study in 
mice, but so far none of the markers proposed can be used in humans. For instance, Helios, 
a member of the Ikaros transcription factor family, was proposed as a marker to identify 
natural regulatory T cells in mice as reported by Thornton and colleagues (2010). They 
showed that Helios was 100% expressed in CD4+CD8-Foxp3+ thymocytes but the expression 
of Helios was only around 70% from regulatory T cells on the periphery. However, 
subsequent papers published about Helios expression in human regulatory T cells did not 
support this theory. Akimova and co-workers (2011) reported that Helios can be induced 
during human T cell activation and proliferation, but regresses in the same cells under 
resting conditions. Therefore, they suggested that Helios can be used as a marker of T cell 
activation and proliferation. Most importantly, Himmel and colleagues (2013) showed that 
Helios+ and Helios- populations existed within the human natural regulatory T cell 
population and these two populations had similar suppressive capacity, Foxp3 expression 
and surface markers such as CTLA-4 and CD39. A similar story was also reported with the 
neuropilin 1 (Nrp-1) expression which can be used to distinguish thymus-induced and 
peripherally-induced regulatory T cells in mice but not in humans.  Nrp-1 is a 
transmembrane glycoprotein and predominantly co-receptor for another class of proteins 
known as semaphorins. Yadav and colleagues (2012) reported that neuropilin can be used as 
a marker of natural regulatory T cells based on their study in mice using a combination of 
novel TCR transgenic mice with a defined self-antigen specificity and conventional mouse 
models. However, an earlier study in humans by Milpied et al (2009) showed that human 
regulatory T cells did not express Nrp-1 in contrast to murine regulatory T cells. However, a 
small population of Foxp3+ regulatory T cells in secondary lymphoid organs expressed Nrp-1 
42 
 
and this protein expression was induced on peripheral blood T lymphocytes upon in vitro 
activation.  
 Currently there is no surface marker that can be used to distinguish between human 
thymus-derived and peripherally-induced regulatory T cells. Nevertheless, the classification 
is still valid in humans as these two populations can be easily identified based on its origin of 
differentiation.   
 In contrast to thymus-derived regulatory T cells, peripherally-induced regulatory T 
cells have been identified in several different subsets. One of the main factors involved in 
regulatory T cell induction is the presence of antigens. Long and co-workers (2011) reported 
that low dose of self antigen can induce antigen specific Foxp3+ regulatory T cells. Most 
importantly, other members of HSPs can also induce regulatory T cell development which 
will be discussed later. Furthermore, two more subsets of peripherally-induced regulatory T 
cells have been described in the literature. Zheng et al (2002) demonstrated that activated 
human CD4+CD25- T cells can be induced to become regulatory T cells when cultured in the 
presence of TGF-β cytokine. These cells are Foxp3+CD25- cells and the suppressive effect of 
these cells were mediated by TGF-β secretion and contact-dependent mechanism. In 
addition, they described that regulatory T cells can be induced in a TGF-β independent 
mechanism. This brings us to the final subset of peripherally-induced regulatory T cells 
which is TR1 regulatory T cells. These cells lack Foxp3 expression and mainly secrete IL-10 as 
reported by Levings et al (2005). The main cytokine involved in the induction of these cells is 
IL-10 as IL-10-derived from DC (Levings et al (2005)), lentiviral delivery of IL-10 (Andolfi et al 
(2012)) or the presence of exogenous IL-10 in naive CD4+ T cells (Levings et al (2001)) had 
been reported to induce these cells. Furthermore, the suppressive capacity of these cells is 
dependent on IL-10 as reported by Dieckmann et al (2002).  
In addition, the presence of other molecules can also induce regulatory T cell 
development in the periphery. Kang and colleagues (2012) demonstrated that Foxp3+ 
regulatory T cells can be induced when CD4+ T cells were cultured with 1,25-
dihyroxyvitamin D3, the active metabolite of vitamin D. These cells can suppress the 
proliferation of CD4+ T cells and this activity was dependent on Foxp3 expression. Enhanced 
Foxp3 expression was mediated by the binding of this metabolite to the nuclear VD receptor 
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(VDR) that binds target DNA sequences known as the VD response element (VDRE) and 
consequenctly enhancing Foxp3 promoter activity. In addition, the generation of 
peripherally-induced regulatory T cells can be facilitated by the presence of IDO enzyme 
expressed on DC. Chen and co-workers (2008) demonstrated that IDO presence in human 
plasmacytoid DC can induce regulatory T cells from CD4+CD25- T cells with potent 
suppressor cell function. IDO can catalyze tryptophan to become kyneurenine and 
kyneurenine was responsible to generate regulatory T cells. In conclusion, the presence of 
antigens, cytokines and other molecules may influence the development of regulatory T 
cells in the periphery.  
1.5.3 Mechanisms of suppression of regulatory T cells 
The ability of regulatory T cells to maintain homeostasis and peripheral tolerance is 
based on the ability to regulate other immune cell types such as CD4+ T cells, CD8+ T cells 
and monocytes. The mechanisms of suppression can be divided into cell-to-cell and/or 
soluble factors. In addition, the mechanisms of suppression used in murine regulatory T cells 
may be slightly different from human regulatory T cells; therefore this section aims to 
discuss the classical regulatory T cell suppression mechanisms observed from human 
regulatory T cells, namely cytotoxic T lymphocyte antigen (CTLA-4), interleukin 10 (IL-10) 
and transforming growth factor β (TGF-β).  
1.5.3.1 Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) 
Cytotoxic T lymphocyte antigen 4 (CTLA-4) or CD152 is a member of the 
immunoglobulin superfamily and can be expressed on the surface of human T cells. The 
CTLA-4 expression is constitutively expressed on natural regulatory T cells as reported by 
Dieckmann et al (2001). Cederbom and colleagues (2000) reported that CTLA-4 on the 
surface of murine regulatory T cells can engage CD86 molecule on dendritic cells (DC) and 
downregulate the CD80 molecule. The interaction of CTLA-4 on regulatory T cells with the 
CD86 molecule was confirmed using human regulatory T cells from RA patients. Cribbs and 
colleagues (2014) demonstrated that the CTLA-4 defect from RA patients failed to induce 
IDO enzyme expression in RA. In addition, CTLA-4 has been reported as directly affecting 
responder T cell function. By engaging the CD28 molecule on human responder T cells, 
Birebent et al (2004) showed that human regulatory T cell suppression of responder T cells 
was dependent on CTLA-4 while Baecher-Allan et al (2001) demonstrated that human 
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regulatory T cells can suppress responder T cells independently of CTLA-4. Since the 
suppressive capacity of human regulatory T cells can only be evaluated using in vitro 
suppression assay, therefore is it possible that the discrepancy between these two papers 
lies in the different culture system used. Nevertheless, surface CTLA-4 is important in the 
immune system in vivo as CTLA-4 knockout mice developed lymphoproliferative disorders 
and die after 2-3 weeks after birth as reported by Khattri et al (1999).  
 In addition to surface CTLA-4, a newer isoform of CTLA-4 has been described as 
expressed in human regulatory T cells. Soluble CTLA-4 produced by alternative splicing of 
the CTLA-4 gene, not by cleavage of surface CTLA-4, as reported by Magistrelli et al (1999). 
This isoform of CTLA-4 lacks the transmembrane domain of CTLA-4 and Ward and colleagues 
(2013) demonstrated that resting and activated human regulatory T cells expressed sCTLA-4 
and sCTLA-4 produced by regulatory T cells can suppress the proliferation of CD4+ T cells 
and reduce IFN-γ and IL-17 from CD4+ T cells. Clearly CTLA-4 contributes to the mechanism 
of suppression in human regulatory T cells by surface expression or soluble CTLA-4. 
1.5.3.2 Interleukin 10 (IL-10) 
IL-10 protein is an anti-inflammatory cytokine and can be secreted by a wide variety 
of immune cells including monocytes, macrophage, T cells and B cells. The importance of IL-
10 to the immune system was highlighted by the study of IL-10 in mice. IL-10 knockout mice 
did not develop any form of autoimmunity but they were susceptible to developing colitis in 
the presence of triggering flora as reported by Kuhn et al (1993). Ito and colleagues (2008) 
reported that IL-10 secreted by human natural regulatory T cells can modulate DC function. 
IL-10 secretion by regulatory T cells can attenuate DC cell function by downregulating the 
expression of CD86 molecules on DC. However, the suppression of human natural 
regulatory T cells on responder T cell proliferation in in vitro suppression assay was 
independent of IL-10 (reviewed by McMurchy and Levings, 2012). In contrast, IL-10 is used 
as one of the mechanisms of suppression by adaptive or induced regulatory T cells. 
Dieckmann et al (2001) showed that adaptive regulatory T cells or Tr1 regulatory T cells can 
secrete IL-10 to suppress the proliferation of responder T cells. This evidence highlights the 




1.5.3.3 Transforming Growth Factor β (TGF-β) 
Transforming growth factor β (TGF-β) is a pleiotropic cytokine and can be secreted 
by many cell types including immune cells. This protein exists in at least three isoforms 
called TGF-β1, TGF-β2 and TGF-β3 and TGF-β1 is the most commonly studied isoform of 
TGF-β. The role of TGF-β1 in human regulatory T cells in the suppression of responder T cells 
is quite controversial. Oberle et al (2007) and Annunziato et al (2002) showed that the 
suppression of responder T cells was partially dependent on TGF-β whilst Jonuleit et al 
(2001) and Dieckmann et al (2001) argued TGF-β plays no role in the suppression of 
responder T cells in in vitro suppression assay. The discrepancy could be because of the set-
up of the experiments. The role of TGF-β in the development of adaptive regulatory T cells 
from responder T cells was well documented in human in vitro experiments as shown by 
Zheng et al (2002), Fantini et al (2004) and Wang et al (2009). In addition, TGF-β secreting 
regulatory T cells have been shown to modulate DC function. Esquerre and co-workers 
(2008) demonstrated that human regulatory T cells can inhibit T cell polarisation by 
modulating DC cell function. 
 Human regulatory T cells can exert their suppression by using membrane TGF-β in 
addition to TGF-β secretion. Membrane-bound TGF-β was recorded to be present in 
adaptive or induced regulatory T cells. Savage et al (2008) reported that M2 macrophages, 
an immunoregulatory macrophage, can induce the development of human 
CD4+CD25+Foxp3+ glucocorticoid-induced TNF receptor (GITR)+ regulatory T cells. Induced 
regulatory T cells by M2 macrophages express membrane-bound TGF-β1 and can suppress 
responder T cells using cell-to-cell contact. Furthermore, Han et al (2014) reported that 
human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3− regulatory T cells can 
suppress T cell response via membrane-bound TGF-β1.  Therefore, secreted or membrane-
bound TGF-β play an important role in mediating one of the mechanisms of suppression in 
human regulatory T cells. 
1.5.4 HSP and regulatory T cells 
As demonstrated by Corrigall et al (2009), soluble BiP can induce the development of 
regulatory T cells from responder T cells via tolerogenic DC. Reports from the literature 
suggest that other soluble HSP can induce the development of regulatory T cells. For 
instance, de Kleer and colleagues (2010) demonstrated that HSP60 can convert human 
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CD4+CD25- T cells to CD4+CD25+Foxp3+CD30+ regulatory T cells after being co-cultured 
with monocytes and HSP60 for 6 days. Furthermore, van Herwijnen and co-workers (2012) 
reported that HSP70, a member of the HSP70 family can induce CD4+CD25+Foxp3+ which 
can suppress proteoglycan-induced arthritis in mice. These works clearly demonstrate the 
ability of soluble HSP to induce the development of regulatory T cells. 
The aim of this project is to investigate the effect of soluble BiP on regulatory T cell 
function. A literature search revealed that soluble HSP60 and HSP70 had been shown to 
modulate regulatory T cell function. Zanin-Zhorov and colleagues (2006) first described the 
ability of HSP to modulate human regulatory T cell function. They demonstrated that HSP60 
pre-treatment on regulatory T cells can enhance their suppressive function. Regulatory T 
cells pre-treated with HSP60 can further suppress the proliferation of responder T cells and 
reduce IFN-γ and TNF-α level from the co-culture. They proposed that regulatory T cells pre-
treated with HSP60 can suppress responder T cells by cell-to-cell contact and by using anti-
inflammatory cytokines IL-10 and TGF-β. In addition, Wachstein et al (2012) demonstrated 
that HSP70 can also enhance human regulatory T cell function. HSP70 pre-treated 
regulatory T cells can enhance IL-10 and TGF-β secretions and reduce proliferation of 
responder T cells and the levels of pro-inflammatory cytokines IFN-γ and TNF-α in the co-
culture. In addition, HSP70 pre-treatment on regulatory T cells can expand regulatory T cell 
population as measured by Ki-67 staining. Both papers demonstrated that HSP60 and HSP70 
bound to TLR2 and activated the same downstream signalling molecules namely AKT and 
p38 mitogen-activated protein kinases (MAPK) but not ERK signalling. In addition, both 
papers utilised plate-bound anti-CD3 antibodies to activate responder and regulatory T cells 
in the co-culture. To mimic physiological activation, T cells need 2 signals to be activated; 
one via TCR and co-stimulation. Anti-CD3 antibody stimulation represents signal one while 
anti-CD28 antibody stimulation represents signal two. Therefore, co-culture of responder 
and regulatory T cells (pre-treated with BiP) will be performed in the absence (anti-CD3 
antibody) or presence of co-stimulation (anti-CD3/CD28 beads) compared to work by Zanin-




1.6 Project aims 
The aims of the project are as follows:- 
 To investigate the relationship between circulating BiP concentrations and 
regulatory T cell frequencies in healthy populations 
 To examine the effect of soluble BiP on human regulatory T cell phenotype  
 To determine if BiP-induced phenotypic changes may lead to enhanced suppressive 









































2 Materials and Methods 
2.1 Participants/Donor detail 
 
For epidemiological studies, whole peripheral blood was obtained from the Whitehall 
II study. This study was initiated by Professor Michael Marmot to investigate the importance 
of social class, psychosocial factors and life style to CVD development among British civil 
servants. Participants were 600 asymptomatic men and women, aged 50-71, of white 
European decent and donors were selected from a broad socioeconomic status. Donors 
underwent a psychological stress test and dual-source computed tomography (DSCT) 
scanning of their coronary arteries. The data for the present study were collected at the 
time of a follow-up DSCT at which time blood samples were also drawn for analysis. All of 
the clinical/biochemical data measured from these donors were obtained from our 
collaborator, Prof. Andrew Steptoe from the Department of Epidemiology and Public Health, 
University College London (UCL). All of the data were listed in Table 3.2. Thirty (30) ml of 
blood were withdrawn from the Whitehall II study participants into heparinised tubes. The 
ethical approval of the study was obtained under the title of the psychobiology of social 
position REC reference 97/0356. This study was approved by the Joint University College 
London/ University College London Hospital Committees. However, the correlation analyses 
were performed on 68 out of 600 donors as regulatory T cell frequency was measured from 
these donors. 
In contrast, cone bloods and fresh peripheral blood from healthy donors were in the 
functional studies in Chapter 4 and 5. Cone blood is a blood by-product of plasmapheresis 
containing blood cells without any plasma obtained from NHS Blood & Transplant 
(Collindale, UK) and less than 100 ml of fresh blood withdrawn from healthy donors were 
used as permitted by the ethical approval. Cone blood and fresh peripheral blood were used 




Figure 2.1 Cone blood used in in vitro regulatory T cell suppression assay 
2.2 Peripheral Blood Mononuclear Cells isolation  
 
Thirty ml of heparinised blood were diluted with 1x Dulbecco’s phosphate buffer salt 
(PBS) 1X without Calcium and Magnesium (PAA, Pasching, Austria) in 1:1 ratio. As for cone 
bloods, 8 mL of cone blood was diluted to 60 mL with 1x Dulbecco’s PBS 1X without Calcium 
and Magnesium (PAA). Then, 15 mL of LymphoprepTM (Axis Shield, Dundee, Scotland) was 
overlaid on top of 30 mL of diluted cone blood. The tube was centrifuged at 800 g (Top table 
centrifuge - Megafuge 1.0 (Heraeus Instruments, Hanau, Germany)) for 25 minutes at room 
temperature (RT) without any brake. The PBMC layer is an opaque layer located between 
plasma and Lymphoprep as shown in Figure 2.2. The PBMC layer was harvested into cold 
PBS (PAA) and washed twice by centrifugation at 300 g (Centrifuge - Minifuge RF, Heraeus 
Sepatech, Hanau, Germany)) for 10 minutes at 4 degree celcius (°C) (Refrigerator- 
Husqvarna, Huskvarna, Sweeden)). A viability test and cell count were performed with 





Figure 2.2. PBMC layer harvested in between plasma/unidentified liquid and 
Lymphoprep layer. 
PBMC of donors from the Whitehall II cohort were frozen in 10% dimethyl sulfoxide 
(DMSO) (Sigma Aldrich, Missouri, USA) in Fetal Bovine Serum (FBS)(Gold, heat inactivated) 
(PAA) in a cryotube (Thermo Scientific, Waltham, USA) & placed in -80°C freezer (Triple Red 
Laboratory Technology, Bucks, UK) for further analysis while plasma was harvested & frozen 
in  -20°C freezer (LEC, Bognor Regis, UK) for circulating BiP & endogenous cytokine analysis. 
In contrast, PBMC from cone blood and fresh blood from healthy donors were re-suspended 
in 1x PBS (PAA) before isolating appropriate cell populations. 
2.3 Regulatory & Responder T cell isolation 
 
Three (3) to 5 x 108 of PBMC from cone blood were used to isolate regulatory and 
responder T cells using Human CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotech, 
Gladbach, Germany) according to the manufacturer’s instructions. Briefly, 1 x 107 PBMC 
were suspended in 90 µL of MACS buffer (see appendix) and incubated with 10 microlitre 
(µL) CD4+ T cell Biotin-Antibody Cocktail for 10 minutes at 4°C and subsequently with 20 µL 
of Anti-Biotin Microbeads (Miltenyi Biotech) for 15 minutes at 4°C. Then, cell isolation was 
performed using LD column (Miltenyi Biotech) and this column was fitted into MidiMACS 
Separator and rinsed with 2 mL of MACS buffer. The cell suspension was applied onto the 
column and washed with 1 mL of MACS buffer twice. CD4+ T cells were collected as flow 
through of LD column and centrifugated at 300 g for 10 minutes at 4°C.  
After that, 1 x 107 CD4+ T cells were incubated with 10 µL CD25 Microbeads (Miltenyi 
Biotech). An MS column (Miltenyi Biotech) was fitted into MiniMACS Separator and rinsed 
with 500 µL of MACS buffer. Cell suspension was applied onto the column and washed with 
500 µL of MACS buffer three times. Responder T cells, defined as CD4+CD25Low  population,  
were collected as flow through of MS column while regulatory T cells were collected by 
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washing away cells bound to the MS column. To achieve higher purity of regulatory T cells, a 
second MS column was used from PBMCs from cone blood as compared to regulatory T cells 
isolated from one MS column. However, isolation of regulatory T cells from fresh blood used 
one MS column because of limited cell numbers. Viability test & cell counts were performed 
& the purity of responder & regulatory T cell populations were assessed by flow cytometry 
using a combination of anti-CD4 (Becton Dickinson, New Jersey, USA), anti-CD25 (Miltenyi 
Biotech) & anti-CD127 (eBioscience, San Diego, USA) antibodies.  
2.4 Monocyte, regulatory and responder T cell isolation 
 
Three to 5 x 108 of PBMCs from cone blood were used to isolate regulatory and 
responder T cells using Human CD14 MicroBeads Isolation Kit (Miltenyi Biotech) according 
to the manufacturer’s instructions. Briefly, 1 x 107 of PBMC were suspended in 80 µL of 
MACS buffer and incubated with 20 µL of CD14 Microbeads (Miltenyi Biotech) for 15 
minutes at 4°C. Then, cell isolation was performed using an LS column (Miltenyi Biotech) 
and this column was fitted into MidiMACS Separator and rinsed with 3 mL of MACS buffer. 
The cell suspension was applied onto the column and washed with 3 mL of MACS buffer 
three times. CD14+ cells were collected by flushing out labelled CD14+ cells by pushing the 
plunger into the column with 5 mL of MACS buffer. Viability test & cell counts were 
performed & the purity of CD14+ cells was assessed by flow cytometry using anti-human 
CD14 antibody (eBioscience). After that, regulatory and responder T cell isolation were 
performed as described in Section 2.3. However, regulatory T cells were isolated using one 
MS column because of limited cell numbers. 
2.5 Flow cytometry staining 
2.5.1 Surface staining 
2.5.1.1 Cellular staining 
 
Typically 1 x 106 cells were used for staining. Regulatory and responder T cells were 
stained with a combination of anti-CD4 (Becton Dickinson, BD, Franklin Lakes, USA), anti-
CD25 (Miltenyi Biotech) and anti-CD127 (eBioscience) antibodies in staining buffer (see 
appendix), while monocytes were stained with anti-CD14 antibody (eBioscience), thoroughly 
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mixed and incubated at 4°C for 20 minutes in the dark. After that, cell suspensions were 
washed with 1 mL of washing buffer (see appendix) and centrifuged at 300 g for 7 minutes. 
Then, the supernatants were discarded; cells were resuspended by vortexing (Grant 
Instruments, Cambridge, UK) and fixed by the addition of 100 µL of 2% paraformaldehyde 
(Alpha Aesar, Morecombe, UK). The data were acquired using FACS Calibur (BD) using 
appropriate settings. Routinely, 20,000 events in the lymphocyte gate (for regulatory and 
responder T cells) or the monocyte gate (for monocytes) were recorded for each sample and 
analysed using FlowJo 7.6.1 (TreeStar, Oregon, USA).  The complete list of all FACS 
antibodies is listed in Table 2.1. 
2.5.1.2 Whole blood staining 
 
FACS staining was performed on the whole blood of a subset of the Whitehall II 
study donors. One hundred (100) µL of whole blood was stained with anti-CD4 (BD), anti-
CD25 (Miltenyi Biotech) & anti-CD127 (eBioscience) antibodies, mixed thoroughly and 
incubated at RT for 20 minutes in the dark. After that, 1 mL of 1X Lysing solution (BD) was 
added to cell suspension and incubated for 15 minutes at RT. The, cell suspension was 
centrifuged at 300 g for 7 minutes. Then, the supernatants were discarded; cell suspension 
was resuspended using a vortex and fixed by the addition of 100 µL of 2% paraformaldehyde 
(Alpha Aesar) added into cell suspensions to fix the cells. Cell suspensions were acquired 
using FACS Calibur using appropriate settings. 20,000 events in the lymphocyte gate were 
recorded for each sample and analysed using FlowJo software. The data were acquired 
using FACS Calibur using appropriate settings. Routinely, 20,000 events in the lymphocyte 
gate (for regulatory and responder T cells) were recorded for each sample and analysed 
















































































2.5.2 Intracellular staining 
 
Typically 1 x 106 PBMC were used for staining purpose. PBMCs were stained with 
anti-CD4 (BD), anti-CD25 (Miltenyi Biotech) and anti-CD127 (eBioscience) antibodies, 
thoroughly mixed and incubated at 4°C for 20 minutes in the dark. Cells were washed with 
washing buffer and centrifuged at 300 g for 5 minutes. One (1) mL of 1X Foxp3 Fix/Perm 
buffer (BioLegend) was added to the cell suspension and incubated at RT in the dark for 20 
minutes. The supernatants were removed and the cell suspension was washed with staining 
buffer and centrifuged at 300 g for 5 minutes. Again, the supernatants were removed and 
washed with 1 ml of 1X Foxp3 Perm buffer (BioLegend) and centrifuged at 300 g for 5 
minutes.  
Cells were resuspended in 1 ml of Foxp3 Perm buffer (BioLegend) and incubated at 
RT in the dark for 15 minutes. The cells were centrifuged and the supernatants were 
discarded. Cells were incubated with anti-human Foxp3 antibody (BioLegend) at 4°C in the 
dark for 30 minutes. The cells were washed away with staining buffer twice before 
resuspending the cells in 0.5 mL of staining buffer. Cell suspensions were acquired using 
FACS Calibur using appropriate settings. Twenty thounds (20,000) events in the lymphocyte 
gate were recorded for each sample and analysed using FlowJo software.    
2.5.3 Propidium iodide staining (viability assay) 
 
Cell suspensions were alioquoted into a FACS tube and 2 μL of propidium iodide (PI) 
(Sigma) was added into the tube. Cell suspensions were incubated in 4°C for 10minutes 
before being acquired using FACS Calibur. Ten thousand (10,000) events in the Forward 
versus Side Scatter were recorded for each sample and analysed using FlowJo software.    
2.6 Cell culture 
 
Cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (PAA) media 
supplemented with 10% FBS (PAA) with 200 U/ml Penicillin/Streptomycin (Lonza, Basel, 
Switzerland), 5 mM Sodium Pyruvate (Lonza), 5 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Lonza) and 20 mM of L-Glutamine (Lonza) in an 
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incubator (Research CO2 Incubator (LEEC, Nottingham, UK)) at 37°C in an atmosphere of 5% 
carbon dioxide (CO2). One million (1 x 10
6) cells were suspended in 1 mL of media in a 48-
well flat bottom sterile tissue culture plate (Greiner Bio-One (GBO), Kremsmunster, Austria).  
2.6.1 Two hours of HSP pre-treatment 
 
Regulatory T cells were incubated with 1 nanogram per millilitre (ng/ml) human 
recombinant HSP60 protein (low endotoxin, Enzo Life Sciences, New York, USA) for 2 hours 
at 37°C before being washed twice with media. Various doses of human recombinant 
human BiP protein (Good Manufacturing Protocol (GMP) quality, free endotoxin kindly 
donated by Dr Valerie Corrigall, Department of Academic Rheumatology, KCL) was used as 
indicated in each experiment for BiP pre-treatment on regulatory T cells for 2 hours at 37°C 
in a 48-well flat-bottom sterile tissue culture plate (GBO) before being washed twice and re-
suspended in 1 mL of media per 1 x 106 regulatory T cells. Cells were cultured at 37°C in an 
atmosphere of 5% CO2 for 24 hours before a co-stain of  anti-CD4 (BD), anti-CD25 (Miltenyi 
Biotech) and anti-CD127 (eBioscience) antibodies was performed as described in Section 
2.5.1.1 or co-cultured with responder T cells.  
2.6.2 Suppression assay or co-culture without monocytes 
 
The stimulus was prepared first before any cells were plated into the 48-well flat-
bottom sterile tissue culture plate (GBO). For plate-bound anti-CD3 (clone:OKT3, BioLegend) 
stimulation, 200 μL of 5 microgram per millilitre (μg/ml) of antibody suspension in 1X PBS 
(PAA) was layered on the bottom of the well of a 48-well plate (GBO) and incubated for 4 
hours at 37°C before being washed twice with 1X PBS (PAA). Dynabeads Human T-Activator 
CD3/CD28 beads (Invitrogen, Carlsbad, USA) were re-suspended in excess media and 
centrifuged at 300 g for 10 minutes before being re-suspended in fresh media. Two 
hundreds and fifty thounds (2.5 x 105) of anti-CD3/CD28 beads (Invitrogen) were re-
suspended into 10 μL of media and used in the culture at various concentrations stated in 
each experiment.  
After that, cells were plated into the 48-well sterile tissue culture plate (GBO). Two 
hundreds and fifty thounds of responder T cells were added into 48-well culture plate under 
various conditions. Two hundreds and fifty thounds or 8.3 x 104 of regulatory T cells were 
57 
 
added into the wells for co-culture of responder T cells and regulatory T cells in a ratio of 1:1 
or 1:0.3. Co-culture or suppression assay was performed for either 3 or 4 days unless stated 
otherwise. The final volume of culture for each well was 1 mL. 
Seven hundred (700) µL of supernatants were harvested for cytokine analysis and 
replaced with fresh media. Five replicates of 200 μL were transferred into each well of 96-
well sterile U bottom tissue culture plates (GBO) for the addition of 0.5 micro Curie per 
millilitre (µCi/ml) of tritiated thymidine (Perkin Elmer, Waltham, USA). Plates were 
incubated for 16-18 hours at 37°C with 5% CO2 before being harvested onto filter mats 
(Wallac, Turku, Finland). After that, scintillation fluid (Betaplate Scint for Betaplate, Perkin 
Elmer) was put to the filter mats (Wallac) and harvested using a Mach III harvester 96 
(TOMTEC, Orange USA). Conventional liquid procedures were used to measure the amount 
of tritiated thymidine (Perkin Elmer) incorporation by responder T cells with a rackbeta 
counter, 1450 Micro Beta Plus (Wallac). Results were presented as the mean counts per 
minute (CPM) from all replicates. Percentage of suppression was calculated using the 
following formula:-  
% of suppression = 100 -                       (CPM of co-culture)                                            x 100 
                                                     (CPM of responder + CPM of regulatory T cells))        
 
2.6.3 Co-culture of responder, regulatory T cells and monocytes 
 
A 48-well flat-bottom sterile tissue culture plate (GBO) was coated with 5 μg/ml anti-
CD3 antibody (BioLegend) and cell isolation was performed as described in Section 2.6.4. 
Each cell population (monocytes, regulatory and responder T cells) was placed into fresh 
media (Section 2.6). Two hour of 10 ng/ml of BiP pre-treatment was performed either on 
monocytes or regulatory T cells before they were washed twice. Eight thousands and three 
hundreds (8.3 x 104) of regulatory T cells or monocytes were added into the plate and 
incubated for 24 hours before responder T cells were added later and cultured for another 
48 hours as indicated. After that, proliferation and cytokine measurements were 






2.6.4 Cell culture with BiP  
 
Two hundreds and fifty thounds of responder T cells or 1 x 105 of regulatory T cells 
were added into 48-well flat-bottom sterile tissue culture plate (GBO). Under certain 
conditions, 100 unit per mililtre (U/ml) of human recombinant IL-2 (Peprotech, Rocky Hill, 
USA) was added into the culture together with 10 ng/ml of BiP as indicated. The final 
volume of the culture was 1 mL. 
Seven hundred µL of supernatants were harvested for cytokine analysis and replaced 
with fresh media. Regulatory T cells were co-stained with anti-Foxp3 (BioLegend) and anti-
CD25 (Miltenyi Biotech) antibodies while responder T cells were co-stained with anti-Foxp3 
(BioLegend) and anti-CTLA-4 (eBioscience) antibodies. The surface cell staining was 
performed as described in Section 2.5.1.1 followed by the intracellular staining protocol as 
described in Section 2.5.2 for responder T cell. For regulatory T cells, an intracellular staining 
protocol was used as described in Section 2.5.2.  
2.6.5 Co-culture of autologous responder T cells with responder or regulatory T cells treated with 10 
ng/ml of BiP for 4 days 
 
Regulatory or responder T cells were cultured with 10 ng/ml BiP as indicated in the 
previous section. Cell suspensions were aliquoted, re-counted, washed and re-suspended 
into fresh media. In the meantime, autologous responder T cells were cultured in T25 
culture flasks (Corning, New York, USA) for 4 days and re-counted, washed and re-
suspended into fresh media. 
Mock-treated or BiP-treated regulatory (8.3 x 104 cells) or responder T cells (2.5 x 105 
cells) were co-cultured with 2.5 x 105 of autologous responder T cells for 3 days in the 
presence of anti-CD3/CD28 beads (8.3 x 104 beads) (Invitrogen) so the ratio of autologous 
responder T cells and anti-CD3/CD28 beads (Invitrogen) was 5 cells to 1 bead. After that, 




2.7.1 Cytokines  
2.7.1.1 IFN-γ, TNF-α and IL-10 cytokines 
 
Ninety six (96) well plates (Nunc Maxisorp, Thermo Scientific) were used for all 
ELISAs. Plates were washed 4 times after incubation with each antibody or enzyme-
conjugate with washing buffer (see appendix). All antibodies or enzyme conjugates were 
used in 1 to 250 dilutions in assay buffer (eBioscience). All wells were filled with 50 µl of 
aliquot. The capture antibody was added into each well & incubated at 4°C overnight. Plates 
were blocked with assay buffer (eBioscience) for 1 hour at RT. Then, culture supernatants or 
plasmas were aliquoted into each well in triplicates & incubated at 4°C overnight. The 
standard was serially diluted in blocking buffer & blocking buffer was used as background.  
 Detection antibody was added & incubated for 1 hour at RT. After that, enzyme-
conjugate was added and incubated for 30 minutes at RT. The final washing step was 
performed 6 times before 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate (eBioscience) was 
added into each well & incubated for 15 minutes at RT. The reaction of TMB substrate 
(eBioscience) was stopped by adding 2N sulphuric acid (see appendix) into each well. Plates 
were read at 450 nm absorbance with 570 nm as a reference wavelength using ELISA reader 
(Dynex MRX 2, Chantilly, USA). All antibodies are listed in Table 2.2. The optical reading (OD) 
of measurements were converted into concentrations using MasterPlex 2010 (Hitachi, 
Tokyo, Japan). 
 
2.7.1.2 TGF-β1 cytokine 
 
TGF-β1 was measured using two kits; one for measuring circulating TGF-β1 
(eBioscience) and another kit for measuring TGF-β1 (Mabtech, Nacka Strand, Sweden) for 
the supernatants. The kit used for measuring TGF-β1 from eBioscience measured TGF-β1 
after the activation step. This activation step included the addition of 2N hydrochloric acid 
(see appendix) into each well for 10 minutes at RT and neutralisation with 2N sodium 
hydrochloride (see appendix). 10 μL aliquot of acid and base was added into each well. The 
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pipette used to aliquot these solutions can take up a minimum of 10 μL, therefore repeated 
steps of aliquoting small volume of acid and base may introduce inconsistent volume of acid 
and base. This was not the problem with measuring circulating TGF-β1 from the plasma 
because of the abundance of samples but it can cause a problem with measuring TGF-β1 
from culture supernatants with limited samples.  The kit from Mabtech however did not 
require the activation step since it is measuring latent TGF-β1.  
2.7.1.2.1 Circulating TGF-β1  
 
All the steps involved in this ELISA were described in Section 2.6.12 except the 
neutralisation step. This step was performed before the samples were incubated. Ten (10) 
μL of sulphuric acid (see appendix) was added into 50 μL of plasma and incubated at room 
temperature for 10 minutes. After that, 10 μL of sodium hydroxide (see appendix) was 
added to neutralise the acid. The detail of each antibody is listed on Table 2.2. 
2.7.1.2.2 Supernatant TGF-β1 
 
Ninety six well plates (Nunc Maxisorp) were used for this ELISA. The plates were 
coated with 100 μL of α-TGF-β monocloncal antibody (Clone MT593, Mabtech) suspension 
in 1X PBS (PAA) at the concentration of 2 μg/ml overnight at 4°C. After that, the plates were 
washed with 1X PBS (PAA) twice before blocking the plate by adding 200 μL per well of PBS 
(PAA) with 0.05% Tween (Thermo Scientific) containing 0.1% BSA (30% solution, PAA) 
(blocking buffer). The blocking step was performed for 1 hour at RT and washed with 
washing buffer (see appendix) for 5 times. 
Before samples can be aliqouted into each well, the standard was prepared by 
diluting the stock to make up a 120nM solution in 1X PBS (PAA) with 1% BSA (PAA). The 
stock was left at room temperature for 15 minutes and the mixture was vortexed. The serial 
dilution was performed with the top end concentration of standard of 100 pM (equivalent 
to 8000 pg/ml of latent TGF-β1). After that, 100 μL of supernatants were added into each 




Next, 100 μL of 1 μg/ml of biotinylated antibody (Mabtech, clone MT517) was 
suspended in blocking buffer and incubated for 1 hour at RT. After washing the plate, 100 μL 
of streptavidin-alkaline phosphatase (Mabtech) diluted 1:1000 in the blocking buffer was 
added into the plates and incubated for 1 hour at RT. The final washing step was performed 
and 100 μL of phosphatase substrate (Sigma Aldrich) suspended in coating buffer was added 
into the plates and incubated overnight at 4°C. The reaction of phosphatase substrate was 
read after overnight incubation at a wavelength of 410 nm using the ELISA reader and the 
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2.7.2 Circulating BiP  
 
Ninety six well plates were used for all ELISAs. Plates were washed 4 times with 
washing buffer (see appendix) after incubation with 100 μL of each antibody or enzyme-
conjugate. All antibodies were diluted in 2% BSA (PAA) in washing buffer. Zero point five 
(0.5) μg/ml of monoclonal mouse anti-BiP antibody (BD, clone:BD-610979) was added as a 
capture antibody into each well & incubated at 4°C overnight. Plates were blocked with 2% 
BSA (PAA) in 1X PBS (PAA) for 1 hour at RT. Then, plasmas were aliquoted into each well in 
triplicates & incubated at 37°C for 2 hours. The standard (Kindly donated by Dr. Corrigall, 
detection range: 300 – 1 μg/ml) was serially diluted in blocking buffer & blocking buffer was 
used as background.  
 Zero point five μg/ml of polyclonal rabbit anti-BiP antibody (Santa Cruz, San Diego, 
USA, clone: H-129) was added as a detection antibody & incubated at 37°C for 2 hours. 
Then, biotinylated polyclonal goat anti-rabbit IgG antibody (DAKO, Golstrup, Denmark) was 
added as a secondary antibody and incubated for 1 hour at 37°C. After that, streptavidin-
HRP (BioLegend) enzyme-conjugate was added and incubated for 30 minutes at RT. The final 
washing step was performed 6 times before TMB substrate (eBioscience) was added into 
each well & incubated for 15 minutes at RT. The reaction of TMB substrate was stopped by 
adding 2N sulphuric acid into each well. Plates were read at 450 nm absorbance with 570 
nm as a reference wavelength using the ELISA reader and the OD measurements were 
converted into concentrations using MasterPlex 2010. 
2.8 Statistical analysis 
 
The detail of the statistical analysis can be divided into two parts; correlation analysis 
performed in the Whitehall II study as shown in Chapter 3 and comparison between means 
between mock treatment and BiP-treatment in functional experiments as presented in 





2.8.1 Correlation analysis of the Whitehall II study 
 
All data were checked for distribution by normality testing. The data obtained from 
ELISA were converted to natural log (LN) before normality test was performed using the 
Kolmogorov-Smirnov test. Then, correlation between data sets was performed using the 
appropriate test based on the distribution of the data. Data with Gaussian distribution was 
correlated using the Pearson correlation test while data with non-Gaussian distribution was 
correlated using the Spearman correlation test. An R value from both tests indicates the 
nature (positive or negative correlation) and strength of the correlation and correlations 
with p <0.05 were considered statistically significant. All of the analyses were performed 
using SPSS Version 20 (IBM, Armonk, USA).  
2.8.2  Correlation analysis for functional experiments 
 
In Chapter 4 and 5, data obtained from the experiments were assumed to display 
non-Gaussian distribution as the sample number of each experiment is quite small (n=5-11). 
Therefore, all the statistical tests used were non-parametric tests. The Wilcoxon signed rank 
test was used to compare related data (data from the same pair) while the Mann-Whitney 
test was used to compare unrelated data. P value of less than 0.05 were considered 
statistically significant. All of the analyses were performed using GraphPad Prism Version 5.0 










The relationship between regulatory T cell frequency 









3 The relationship between regulatory T cell frequency and circulating BiP 
concentration 
3.1 Introduction 
The aim of this chapter is to determine the relationship between regulatory T cell 
frequency and circulating BiP concentration. BiP, a member of the HSP70 family has been 
shown to be associated with various pathological conditions such as rheumatoid arthritis, 
tumour and cardiovascular disease (CVD). Intracellular BiP has been shown to play an 
important role in the development of CVD. Feaver et al (2008) showed that intracellular BiP 
upregulation in an in vitro model that mimics the environment of human blood vessels can 
be protective within atherosclerotic lesions. Hence, the role of extracellular BiP is being 
investigated in relation to CVD development. To study this, circulating BiP concentration 
was measured from plasma samples of the Whitehall II study.  
Circulating regulatory T cell frequency was measured from the whole peripheral blood 
from the cohort. Evidence from literature indicates the importance of regulatory T cells in 
the protection against atherosclerosis, a condition in which an artery wall thickens as a 
result of the accumulation of fatty materials, which is a common cause of CVD. Several 
studies (Ait-Oufella et al, 2006, Herbin et al, 2012, Klingenberg et al, 2010, Mor et al, 2007 
and Dietrich et al, 2012) showed that regulatory T cells were pivotal in reducing 
atherosclerosis in animal models of CVD. Several mechanisms have been proposed as to 
how regulatory T cells work to reduce atherosclerosis in animal models of CVD. Regulatory T 
cells can induce the differentiation of the anti-inflammatory M2 macrophage and inhibit 
pro-inflammatory M1 macrophage differentiation as shown by Liu et al (2011). In addition, 
immunization of mice with the low density lipoprotein (LDL) protein induces antigen specific 
regulatory T cells that can reduce atherosclerotic lesions as demonstrated by Klingenberg et 
al (2010) and Herbin et al (2012). Furthermore, Lin et al (2010) indicated that regulatory T 
cells can inhibit macrophage foam cell formation in atherosclerosis by cell-to-cell contact 
and soluble factors, namely IL-10 and TGF-β. Hence, the aim of this study was to investigate 
the relationship between circulating regulatory T cell frequency and CVD risk factors from 
the Whitehall II cohort.  
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Regulatory T cell can mediate suppression on various immune cells by cell-to-cell 
contact and/or soluble factors. IL-10 and TGF-β are the most commonly associated 
cytokines with regulatory T cell suppression. Although the role of both cytokines in in vitro 
suppression remains controversial, both cytokines have been shown to play an important 
role in regulatory T cell suppression in several in vivo experimental models. The role of both 
cytokines can be observed in a colitis model induced by the transfer of CD45RBHigh CD4+ T 
cells into Recombination activation gene (RAG-2) -/- mice. Asseman and co-workers (1999) 
highlighted the role of IL-10 secreted by regulatory T cells in the colitis model. Adoptive 
transfer of CD45RBLow regulatory T cells from wild type mice was able to inhibit colitis 
development in this model but not with adoptive transfer of CD45RBLow regulatory T cells 
from IL-10-/- mice. In addition, Powrie and colleagues (1996) demonstrated the significance 
of TGF-β in this model of colitis. The severity of colitis can be reduced when CD45RBLow 
regulatory T cells were adoptively transferred into these mice but the effect was reversed 
when anti-TGF-β antibodies was injected. These results showed the pivotal role played by 
both anti-inflammatory cytokines namely IL-10 and TGF-β in regulatory T cells in in vivo 
models and therefore these two cytokines will be measured and used for the association 
studies reported in this chapter.  
Cytokines can be generally divided into pro and anti-inflammatory cytokines. In 
addition to measuring anti-inflammatory cytokines, pro-inflammatory cytokines were also 
measured in the cohort. Literature searches also focused on pro-inflammatory cytokines 
associated with BiP. Extracellular BiP has been shown to cause the downregulation of TNF-α 
and the upregulation of sTNFRII and IL-1 receptor antagonist when PBMCs were cultured in 
the presence of soluble BiP (Corrigall et al, 2004). In contrast, Yoo et al (2012) showed that 
TNF-α and IL-1β cytokines can upregulate BiP expression in human synoviocytes. Therefore, 
circulating TNF-α and IL-1β concentrations were measured from the Whitehall II cohort. All 
these cytokine measurements will be used in the correlation analysis presented in this 
chapter.  
One of the aims of the Whitehall II study is to investigate the importance of various 
factors that contribute to CVD development. By measuring circulating BiP concentration, 
circulating regulatory T cell frequency, and circulating cytokines, the focus is to investigate 
associations between these measurement and clinical/biochemical parameters related to 
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CVD. The complete list of all clinical/biochemical parameters measured is shown in Table 
3.2.  
Most of the parameters are established risk factors of CVD such as anthropometric 
measures and blood pressure. One of the parameters measured in great detail is the lipid 
profile and each lipid form represents a different risk for CVD. Total cholesterol, triglyceride, 
High Density Lipoprotein (HDL), LDL and pericardial fat were measured. Cholesterol is an 
organic compound and is essential for the structural component of animal cell membranes 
and also serves as a precursor for the biosynthesis of steroid hormones, bile acids and 
vitamin D. Hypercholesterolemia or high cholesterol levels are strongly associated with CVD 
because these promote the development of atheroma, an accumulation and swelling in 
arterial walls, in the arteries thus leading to CVD. Triglycerides are blood lipids that help 
enable the bidirectional transference of adipose fat and blood glucose from the liver. 
Evidence from epidemiological studies indicates that high triglyceride levels in blood have 
been associated with CVD. HDL is the smallest lipoprotein particle and its main function is to 
transport cholesterol mostly to the liver. In contrast, LDL, the second largest lipoprotein 
particle, transports cholesterol into the arterial wall. Because of their respective functions, 
HDL is often known as good cholesterol while LDL has been labelled as bad cholesterol. All 
lipid profiles can be directly measured from the blood except pericardial fat. This refers to 
the local visceral fat depot with close proximity to the heart and can only be viewed via 
imaging techniques using Magnetic Resonance Imaging (MRI) or Computerised Tomography 
Scan (CT Scan). Various studies have reported strong associations of pericardial fat with 
other CVD risk factors such as body mass index (BMI) (Sicari et al, 2011) triglycerides (Sicari 
et al, 2011) and blood pressure (Rosito et al, 2008).  
 Another important clinical parameter measured from the cohort was coronary 
artery calcification (CAC). CAC was measured from the cohort because the presence of 
calcium in arteries was recorded in 96% of all heart attack victims. CAC measured using a CT 
scan can be detected years before any symptoms of cardiovascular events such as chest 
pain or shortness of breath appear. The last biochemical parameter measured was glycated 
haemoglobin (HBA1c). HBA1c measures the amount of glycated haemoglobin when a 
nonenzymatic reaction occurs between glucose and the N-chain of the beta chain of 
haemoglobin. This measurement is used to indicate blood glucose control over time and is 
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commonly used in diabetic patients. High value of HBA1c indicates poorer control of blood 
glucose which has been associated with cardiovascular complications among diabetic 
patients. Khaw and Wareham (2006) in their review suggested HBA1c measurement can be 
used as a marker of CVD risk in both diabetic patients and healthy populations. All of these 
clinical/biochemical measurements were provided by our collaborator, Prof. Andrew 
Steptoe.  
All clinical/biochemical measurements will be used in correlation analysis using either 
the Pearson or Spearman test. The aim of this chapter is to investigate the relationship 
between regulatory T cell frequency and circulating BiP concentration. In this statistical 
analysis p<0.05 was regarded as significant whereas the R value indicates the strength of the 
association.   
3.2 Objectives 
 
Regulatory T cell frequency was measured in whole peripheral blood and acquired 
using flow cytometry while plasma concentration of endogenous circulating BiP and other 
circulating cytokines were measured in this cohort using specific ELISAs. Clinical/biochemical 
parameters were measured from matching subjects and the data were provided by our 
collaborator, Prof. Andrew Steptoe. In brief, the objectives of this chapter are as follows:- 
 To measure endogenous circulating BiP concentration in plasmas from donors of the 
Whitehall II study using ELISA 
 To measure various endogenous circulating cytokines in plasmas from donors of the 
Whitehall II study using ELISA 
 To measure regulatory T cell frequency from whole blood in donors of the Whitehall 
II study using flow cytometry 
 To investigate the relationship between endogenous circulating BiP concentration 
and regulatory T cell frequency 
 To investigate the relationship between endogenous circulating BiP concentration 
and circulating cytokines 
 To investigate the relationship between endogenous BiP concentration, 




3.3.1 Circulating BiP concentration 
Investigating the immunomodulatory properties of BiP has been the focus of the lab 
for the past 10 years. Therefore, endogenous circulating BiP concentration was measured 
from plasmas of the Whitehall II study donors. As illustrated in Figure 3.1, circulating BiP 
levels display a wide range of concentration from 1 to 268 µg/ml.  
3.3.2 Endogenous circulating cytokine concentrations 
Circulating cytokine concentrations were measured in plasmas from the Whitehall II 
study donors. Both pro and anti-inflammatory cytokines were measured. Figure 3.2 shows 
levels of endogenous circulating cytokines measured in the plasma samples. All cytokines 
namely TNF-α, IL-1β, IL-10 and TGF-β display a wide range of concentration from 
undetectable up to very high levels. Figure 3.2(A) demonstrates levels of TNF-α that were 
detectable in 66% of donors ranging from 2 pg/ml to 1000 pg/ml ml in the 68 donors of the 
Whitehall II study whilst Figure 3.2(B) illustrates levels of plasma IL-1β that were detectable 
in 60% of samples ranging from 2 pg/ml to 35 pg/ml. The major anti-inflammatory cytokine, 
IL-10 was detectable in 85% of donors ranging from 2 pg/ml to 34 pg/ml in 68 donors 
(shown in Figure 3.2(C)) while Figure 3.2(D) portrays levels of plasma TGF-β that were 
detectable in 88% of donors ranging from 60 pg/ml to 1723 pg/ml.   
 Data in Figure 3.2(A-C) were originally generated by Dr. Frank Kaiser, a postdoctoral 
research associate working in the lab. To ensure the reproducibility of the data, re-
measurement of plasma levels of TNF-α, IL-1β and IL-10 were performed as shown in Figure 
3.3. Re-measurement of all cytokines except TGF-β showed reduction in the percentage of 
detection in donors. The discrepancy between these 2 measurements raises a question on 
which measurement should be used for the correlation study. For instance, TNF-α levels 
were detected in 66% of donors (Figure 3.2(A)) were reduced to only 23% on repeat 
measurements (Figure 3.3(A)). This pattern also can be observed on IL-1β (60% to 8%) and 
IL-10 levels (85% to 4%). Furthermore, the cytokine levels reduced dramatically upon re-
measurement. An example can be seen in the plasma level of TNF-α of donor 417. The level 
of TNF-α was significantly reduced from 16 pg/ml (1st measurement) to undetectable (2nd 
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measurement) and similar observations can be seen in plasma levels of IL-1β (20 pg/ml to 
undetectable) and IL-10 (35 pg/ml to 8 pg/ml).  
The initial measurements were performed by a postdoctoral research associate, Dr 
Frank Kaiser and the plasma samples were kept at -20 degree celcius (°C). The second 
measurements of cytokine levels were performed 2 years after the initial measurement. The 
discrepancy between these two measurements may be explained by two important 
variables; temperature and duration of storage. The recommended storage temperature of 
plasma for cytokine analysis is -70°C as suggested by Aziz et al (1999). In addition, they 
showed that plasma storage at temperatures of -20°C can cause cytokine degradation at 
faster rates compared to storage at -70°C. Furthermore, de Jager and colleagues (2009) 
demonstrated that plasmas even stored at -70°C can degrade after a few years of storage, 
especially with IL-1β which can degrade up to 30% of the baseline level after 2 years of 
storage. This may provide explanation on lower cytokine levels of the second measurement 
compared to the cytokine levels of the first measurement. Therefore, the correlation 
analysis of plasma cytokines will be performed using the first measurements. 
3.3.3 Gating strategy to obtain circulating regulatory T cell (CD4+CD25HighCD127Low) frequencies from 
whole blood samples 
Figure 3.4 shows the gating strategy used to measure regulatory T cell frequency in 
whole blood from 68 donors of the Whitehall II study. Each donor underwent the same 
regulatory T cell enumeration based on the gating strategy as shown. Regulatory T cells are 
defined in this study as the CD4+CD25HighCD127Low population. Regulatory T cells were 
identified by gating the cells from (A) Lymphocyte gate followed by (B) CD4+ T cell gate & (C) 
CD25+CD127- population based on the CD25 against CD127 dot plot. To control for antibody 
staining, comparison between anti-CD4, CD25 and CD127 staining and isotype control was 
performed as shown in Figure 3.4 (D-F). Responder T cell (CD4+CD25LowCD127High), CD4+ T 
cells and ratio of responder to regulatory T cells were obtained from the staining to be 
compared with regulatory T cell frequency.  
Regulatory T cell frequency measurement was performed on the whole peripheral 
blood of the Whitehall II cohort. To assess the consistency hence the reliability of regulatory 
T cell frequency staining a number of replicate samples were stained from individual donors 
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Figure 3.5 demonstrates the consistency of regulatory T cell frequencies obtained in 
triplicate measurements as regulatory T cell frequencies obtained were 6.53%, 6.70% and 
6.36% respectively. As they showed little variability single measurements were employed 
for the bulk of the cohort. 
3.3.4 Intracellular Foxp3 staining 
Human natural regulatory T cells are characterised by the presence of high Foxp3 
expression, a master regulator in the development and function of regulatory T cells.  
Therefore, intracellular Foxp3 staining was performed to validate the gating strategy used in 
Figure 3.6 as regulatory T cell was defined as the CD4+CD25HighCD127Low population. This 
procedure can only be performed on PBMC and not on whole blood. Hence, the staining 
procedure was performed after surface staining of PBMC with anti-CD4, CD25 & CD127 
antibodies. 
Figure 3.6 illustrates that 75% of the CD4+CD25HighCD127Low population are Foxp3+ 
cells in 3 different donors from the Whitehall II study. In comparison, responder T cells or 
CD4+CD25LowCD127High population consists of 12% Fopx3+ cells which confirms that human 
responder T cells can express low levels Foxp3. These data support the use of gating 
strategy validating the regulatory T cell frequency gating strategy. 
3.3.5 Regulatory T cell frequency measurement 
Regulatory T cell frequencies were measured in the whole blood of Whitehall II 
donors using flow cytometry using a combination of anti-human CD4, CD25 & CD127 
antibodies. Regulatory T cell frequency as shown in Figure 3.7 displays a wide range from 
2.59% to 12.9% of total CD4+ T cell.  
3.3.6 The relationship between regulatory T cell frequency, BiP and circulating cytokines 
Table 3.1 shows correlation analysis performed between circulating BiP and various 
immunological parameters. Regulatory T cell frequency negatively correlates with responder 
T cell frequency (R=-0.742, p<0.001) and CD4+ T cell frequency (R=-0.998, p<0.001). 
Therefore, any significant correlation between regulatory T cell frequency and any 
parameters can be cross-checked with responder T cell frequency and CD4+ T cell 
frequency. As mentioned before, the aim of this chapter is to investigate the relationship 
between regulatory T cell frequency and circulating BiP concentration. As shown in Table 
73 
 
3.1, regulatory T cell frequency correlation with circulating BiP concentration is statistically 
insignificant as demonstrated in scatter plot in Figure 3.8(A) (R=0.006,p=0.958). To confirm 
that circulating BiP concentration does not correlate with any cell frequency, correlation 
analyses were performed. Both responder T cell and CD4+ T cell frequency measurements 
exhibit non-significant correlations with circulating BiP concentration as demonstrated in 
Table 3.1 and shown in the scatter plot in Figure 3.8(B-C) (Responder T cell frequency: 
R=0.097,p=0.431, CD4+ T cell frequency: R=-0.008, p=0.951).  
In contrast, circulating BiP concentration correlates positively with most of the 
cytokines except TGF-β. Circulating BiP concentration strongly correlates with circulating 
TNF-α as shown in scatter plot in Figure 3.9(A) (R=0.767, p<0.001). In addition, circulating 
BiP concentration correlates with IL-1β (R=0.271, p=0.025) (Figure 3.9(B)) and IL-10 
(R=0.356, p=0.003) (Figure 3.9(C)). The scatter plot shown in Figure 3.9(D) confirmed non-
significant correlation between circulating BiP concentration with TGF-β (R=0.005, p=0.969).  
Correlation analyses between circulating cytokines revealed specific correlations. 
TNF-α correlates with IL-1β (R=0.332, p=0.006) and IL-10 (R=0.372, p=0.002) but not with 
TGF-β (R=-0.008, p=0.945) (not shown). Similarly, IL-1β correlates with IL-10 (R=0.352, 
p=0.003) but not with TGF-β (R=0.109, p=0.377) (not shown). However, TGF-β only 
correlates with IL-10 (R=0.268, p=0.027). These correlations were demonstrated in the 
scatter plots as shown in Figure 3.10.  
3.3.7 Clinical/biochemical parameter measurement 
 The list of all clinical/biochemical parameters measured were listed in Table 3.2. 
These measurements were recorded and obtained from Prof. Andrew Steptoe from UCL.  
3.3.8 The relationship between clinical/biochemical parameters, circulating BiP and immunological 
parameters  
To test how robust are the data sets obtained from our collaborator, correlation 
analysis was performed for known associations between the various clinical parameters. For 
instance, it is known from the literature that weight correlates with BMI while systolic blood 
pressure correlates with diastolic blood pressure. This is confirmed in these data sets as 
shown in Figure 3.11. Weight strongly correlates with BMI as expected with R value of 0.846 
(Figure 3.11(A)) while systolic blood pressure strongly correlates with diastolic blood 
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pressure with R value of 0.7901 (Figure 3.11(B)) (both value were p<0.0001). In addition, 
this shows that the analyses were performed correctly as these variables are expected to 
correlate with each other (weight & BMI, MSBP & MDBP). These correlations may explain a 
relationship between 2 variables. It can describe a linear relationship as denoted by positive 
R value or negative R value. Therefore, a literature search explaining the relationship 
between variables was performed to support these correlations.  
The appropriate correlation analyses were performed between immunogical and 
clinical/biochemical parameters and only significant correlations (p<0.05) are shown in 
Table 3.3 as most of the correlations were non-significant. Correlation analyses revealed 
that regulatory T cell frequency does not correlate with any established CVD risk except 
body weight. The only correlation found between regulatory T cell frequency and clinical 
parameters is a negative correlation between regulatory T cell frequency and weight (R=-
0.252, p=0.038) (Figure 3.12(A)), but not with BMI (R=-0.194, p=0.113) (Figure 3.12(B)). To 
confirm that this association is specific between regulatory T cell frequency and body 
weight, correlation analysis was performed between responder T cell frequency and body 
weight and the correlation is statistically insignificant (R=0.217, p=0.07) (Figure 3.12(C)) but 
CD4+ T cell frequency positively correlates with body weight (R=0.257, p=0.035) (Figure 
3.12(D)).  
 Weak correlations can be found between immunological parameters and 
clinical/biochemical parameters. IL-10 correlates with body weight (R=0.256, p=0.03) and 
pericardial fat (R=0.264, p=0.03) as illustrated in Figure 3.13(A&C). Similar to regulatory T 
cell frequency, circulating IL-10 does not correlate with BMI (R=0.143, p=0.243) (Figure 
3.13(B)). As for IL-10 and pericardial fat association, this is the first time such correlation 
was reported after extensive literature search. The only correlation between circulating BiP 
concentration and clinical/biochemical parameters is between circulating BiP and 
triglyceride level in the blood of the Whitehall II study donors. BiP negatively associates with 
blood triglycerides (R=-0.265, P=0.029) as shown in Figure 3.14. However, no associations 
were found between other blood lipids such as total cholesterol, HDL and LDL and BiP, 





























































3.4 Discussion  
3.4.1 Regulatory T cell frequency does not correlates with circulating BiP nor circulating cytokine 
concentrations  
Data obtained from these correlation analyses performed on various parameters 
should be carefully interpreted. Based on Table 3.1 and Table 3.3, most of the correlations 
are weak correlations as denoted by low R value of less than 0.5. Therefore, these 
correlations must be supported or validated by other epidemiological or mechanistic 
studies. Furthermore, the size of the sample used for the correlation analysis is small (n=68) 
and the conclusion inferred from the correlation analysis cannot be applied to the general 
population as the mean age of this cohort is 62.2 years. Furthermore, these data were 
obtained from a cohort of healthy individuals; therefore the conclusions inferred from the 
correlation analysis cannot be applied to people with pathological conditions such as 
cardiovascular disease and diabetes mellitus.  
The main focus of this chapter is to investigate the relationship between regulatory T 
cell frequencies and circulating BiP. Previous work by Shields et al (2011) showed that 
concentration of circulating soluble BiP in the range of ng/ml either in sera of non-
rheumatoid arthritis or rheumatoid arthritis subjects. This discrepancy may be due to 
several factors. Circulating BiP detected in this assay involves full length BiP that may be 
released into the circulation and soluble BiP whereas previous work by Shields and co-
workers (2011) only detected soluble BiP (lacks KDEL sequence). In addition, it may be 
possible that the assay can detect BiP in free form or antibody-bound form. Another 
difference is that BiP measurement was performed from plasma samples while the latter 
was performed in sera. Donors with very high level of circulating BiP concentration such as 
donor 344 (268 µg/ml), donor 369 (227 µg/ml) and donor 448 (140 µg/ml) may have been 
experiencing subclinical infection or other pathologies when the blood was taken. Viral 
infection has been reported to induce an increase in BiP expression. For instance, human 
cytomegalovirus infection which causes few symptoms in most people can induce an 




Correlation analyses revealed that association between regulatory T cell and BiP is 
statistically insignificant (Table 3.1 and Figure 3.8(A)). These data are in concordance with 
correlation of circulating regulatory T cells with HSPs as shown by Dempsey and co-workers 
(2010). In their study, they demonstrated that no correlation was observed between 
regulatory T cell frequency and HSP27, 72 and 90 in both chronic lymphocytic leukemia 
patients and normal healthy controls. Non-significant correlations between BiP and 
regulatory T cells can be partly explained by the fact that all nucleated cells express BiP 
(Zimmerman & Dudek, 2009); therefore BiP present in the circulation is not limited to BiP 
secreted by regulatory T cells only. No association between regulatory T cell frequency and 
all cytokines can be explained by the same fact that cytokine secretion is not limited to 
regulatory T cells only (Table 3.1). IL-10 can be secreted by other immune cells such as DC, 
macrophages, and T cells (Saraiva & O’Garra, 2010) while other cells such as platelet 
(Grainger et al, 2000); lymphocytes, macrophage and dendritic cells can secrete TGF-β 
(Letterio & Roberts, 1998) hence no association between regulatory T cell frequency and IL-
10 or TGF-β.  
3.4.2 Regulatory T cell frequency negatively correlates with body weight; not with other 
clinical/biochemical parameters   
As shown in Table 3.3 and Figure 3.12(A), circulating regulatory T cell frequency 
negatively correlates with body weight and this association is in concordance with Wagner 
et al (2013). Their study reported a negative correlation between regulatory T cell frequency 
and body weight, and the data from the Whitehall II cohort reported the same correlation. 
However, they reported that circulating regulatory T cell frequency negatively correlates 
with BMI; not from our analysis (Figure 3.12(B)). The discrepancy between the data and 
their result because of different population used as regulatory T cell frequency. They 
defined circulatory regulatory T cell frequency as CD4+CD25HighCD127LowFoxp3+ population 
while CD4+CD25HighCD127Low population is defined as regulatory T cells in the study. 
Therefore, the data demonstrate non-significant correlation between regulatory T cell 
frequency and BMI (R=-0.194, p=0.113).  
To further support these data, correlation analyses were performed on CD4+ T cells 
and body weight as illustrated in Figure 3.12(D). The data indicate positive correlation 
between CD4+ T cells and body weight (R=0.257, p=0.035) and these data are supported by 
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van der Weerd et al (2012) where they showed increased CD4+ T cells in morbidly obese 
subjects. Circulating regulatory T cell negative correlation with body weight could be partly 
explained by the effect of leptin on regulatory T cell function. Leptin is a hormone involved 
in the control of appetite and obesity and manufactured primarily in the adipocytes of white 
adipose tissue. High levels of leptin have been associated with obese people as reviewed by 
Ahima (2008). An interesting observation was made by Matarese and co-workers (2005) 
where they observed a negative correlation between serum leptin and CD4+CD25+ 
regulatory T cells in a group of multiple sclerosis patients. De Rosa et al (2007) further 
demonstrated that leptin can negatively regulate regulatory T cells by inducing anergy and 
unresponsiveness when leptin binds to leptin receptor on regulatory T cells themselves. In 
contrast to regulatory T cells, leptin acts in a positive feedback on CD4+CD25- effector T 
cells by further encouraging effector T cell proliferation. However, to further confirm this 
observation, an accurate measurement of regulatory T cell could be performed by 
measuring regulatory T cell count instead of frequency on more donors (n>90).    
Despite various literature suggesting the important role played by regulatory T in 
reducing atherosclerosis, correlation analyses revealed regulatory T cell frequency 
association with body weight only; not with any clinical/biochemical parameters. Ammirati 
and colleagues (2010) demonstrated that circulating regulatory T cells do not reflect the 
severity of atherosclerosis in patients with the history of CVD events. In addition, most of 
the studies about regulatory T cells in animal model of atherosclerosis focus on regulatory T 
cells present in atherosclerotic plaques and its function in reducing atherosclerosis; while 
this study measured circulating regulatory T cell frequencies in the circulation. A study 
performed by Kyriakakis and colleagues (2010) demonstrated the presence of invariant 
natural killer T (iNKT) cells in human atherosclerotic plaque and they reported that iNKT cells 
were diminished in the circulation of symptomatic atherosclerosis patients. Therefore, iNKT 
frequency is a better alternative than regulatory T cell frequency for association studies with 




3.4.3 Circulating IL-10 levels correlate with body weight and pericardial fat suggesting that IL-10 may be 
used as a marker of systemic inflammation 
IL-10 is one of the cytokines measured in plasmas from the cohort. Correlation 
analysis revealed IL-10 association with body weight (R=0.256, p=0.035) and pericardial fat 
(0.264, p=0.03) as demonstrated in Table 3.3 and Figure 3.13 (A&C). Circulating IL-10 
cytokine correlation with body weight may be explained by 2 factors; reaction to low, 
chronic grade of inflammation and the fact that obese individuals are more prone to 
infection. Obesity is associated with low, chronic inflammation. Adipocytes play a 
contrasting role in lean versus obese individuals. In consensus, lean adipose tissue contains 
regulatory immune cells such as reg. T cells, Th2 cells, M2 macrophage and eosinopils that 
suppress inflammatory immune cells (Han & Levings, 2013) in lean individuals while 
inflammatory immune cells including Th1 cells, M1 macrophages, CD8+ T cells, B cells, 
dendritic cells, mast cells and neutrophils dominate in obese adipocytes. In addition, 
Fabbrini and colleagues (2013) reported an increased frequency of Th17 and Th22 
phenotype in adipocytes that can secrete IL-17 and IL-22 in obese individuals compared to 
lean subjects. These 2 cytokines are associated with pro-inflammatory phenotype and 
contributes to insulin resistance in obese individuals. Furthermore, inflammatory condition 
in obese visceral adipose tissue is worsened by adipocyte secretion. Yehuda-Shnaidman and 
Schwartz (2012) compared different soluble factors secreted by adipose tissue from lean 
and obese visceral adipose tissue and clearly adipocytes from obese individuals secreted 
more pro-inflammatory factors such as TNF-α, leptin, IL-1β, IL-6 and IL-8 and reduced anti-
inflammatory factors, namely IL-10 and adiponectin. In various pathological conditions such 
as rheumatoid arthritis, the presence of pro and anti-inflammatory factors have been 
reported on the site of active inflammation suggesting that anti-inflammatory factors are 
secreted to counter act the effect of pro-inflammatory factors even though inflammation 
persists (Bogdan et al, 1992). Therefore, it is possible that the presence of IL-10 in the 
circulation is counter-acts the effect of pro-inflammatory factors secreted by adipocytes into 
the circulation. 
 Another reason to support the IL-10 association with body weight is that obesity is 
associated with infection. Supporting evidence from literature shows that obesity is an 
independent risk factor in infection. Saliba and co-workers (2013) showed that obesity is 
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independently associated with urinary tract infection especially in males. Clostridium difficile 
infection, a type of bacterial infection affecting digestive system, is also prominent in obese 
hospitalised patients in a study conducted by Bishara et al (2013). In addition, obesity has 
also been shown to influence viral infection. A cohort study in the Swedish population 
showed that obesity in children and adults is associated with adenovirus infection as 
demonstrated by Almgren et al (2012). Following the H1N1 outbreak worldwide in 2009, 
van Kerkhove and colleagues (2011) published a report to identify risk factors associated 
with H1N1 infection. One of the risk factors associated with H1N1 infection is obesity 
especially for people with BMI of 30 or more. Based on this evidence, Kanneganti & Dixit 
(2012) proposed defective immunological surveillance as one of the consequences of 
obesity on the immune system. Therefore, obese individuals are more prone to infection 
compared to lean individuals. We proposed that the obesity association with infection is due 
to higher circulating IL-10 compared to people with normal BMI. By culturing PBMC with IL-
10 cytokine, Levitz et al (1996) indicated that TNF-α & IL-1β secretions are significantly 
reduced when PBMC were simulated with LPS, Candida albicans or Cryptococcus 
neoformans. When PBMCs are infected with LPS, C.albicans or C.neoformans, TNF-α and IL-
1β secretions upon challenge with LPS, C.albicans or C.neoformans are important to 
promote inflammation to help clearing up the infection. Furthermore, Malavige et al (2013) 
demonstrated that IL-10 contributes in inhibiting IFN-γ response in dengue peptide specific 
T cells in dengue viral infection. Therefore, this evidence supports IL-10 association with 
body weight. 
In addition, circulating IL-10 correlates with another risk factor of CVD which is 
pericardial fat (R=0.269, p=0.027) (Table 3.3 and Figure 3.13 (C)). Correlation analysis from 
the cohort reveals that pericardial fat is strongly associated with other CVD risk factors such 
as weight (R=0.647, p<0.0001), triglycerides (R=0.448, p<0.0001) and BMI (R=0.531, 
p<0.0001) (not shown). Pericardial fat has been identified as a CVD risk factor either 
independently (Mahabadi et al, 2009, Yun et al, 2012, and Miao et al, 2011) or dependently 
on other CVD risk factors (Greif et al, 2013 and Lee et al, 2014). Our association is indirectly 
supported by an epidemiological study conducted by Welsh and colleagues (2011). They 
showed that circulating IL-10 negatively correlates with HDL and positively correlates with 
IL-6 and CRP, both factors associated with CVD risk factors. In addition, they demonstrated 
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higher IL-10 in the circulation of people with CVD events. These associations were not 
expected as the role of IL-10 in arterial plaques has been shown to be anti-inflammatory, 
not pro-inflammatory. Therefore, a negative association is expected between circulating IL-
10 and CVD risk factors. Furthermore, Lakoski and co-workers (2008) demonstrated that 
elevated IL-10 concentration was associated with increased risk for future cardiovascular 
events in post-menopausal women with established coronary atherosclerosis. 
One of the potential mechanisms of action explaining the positive association 
between IL-10 and pericardial fat is that IL-10 secretion is used to counter deleterious effect 
of pro-inflammatory mediators released by pericardial fat. Mazurek and colleagues (2003) 
demonstrated that epicardial fat, one component of pericardial fat as argued by Carr & Ding 
(2009), is a source of inflammatory mediators. They showed that epicardial fat expressed 
higher mRNA and protein levels of IL-1β, IL-6, MCP-1 and TNF-α compared to subcutaneous 
fat. To counter the effect of these pro-inflammatory mediators, IL-10 is an essential cytokine 
since Lumeng et al (2007) showed that IL-10 protects adipocytes from the deleterious effect 
of MCP-1 and TNF-α. IL-10 treatment on adipocytes reduced MCP-1 secretion from 
adipocytes by antagonising NF-κB-mediated gene transcription. In addition, IL-10 can 
protect adipocytes from TNF-α-induced downregulation of insulin receptors and glucose 
transported 4 expressions; both of which molecules are important for normal physiological 
function. Hence, circulating IL-10 has been suggested not only as a marker to be used for 
predicting CVD but also as a surrogate marker for ongoing systemic inflammation and 
related pathophysiological processes as suggested by Welsh et al (2011). 
3.4.4 Circulating BiP concentrations correlate with most cytokines and triglycerides 
In contrast to regulatory T cell frequency, circulating BiP concentration correlates 
with 3 of 4 circulating cytokines measured namely TNF-α (R=0.767, p<0.0001), IL-1β 
(R=0.271, p=0.025),  and IL-10 (R=0.356, p=0.003); but not with TGF-β(R=0.005,p=0.969) as 
shown in Table 3.1 and Figure 3.9. TGF-β measured in plasma can be contributed by the 
secretion from non-immune cells. In addition to TGF-β secretion by leukocytes, Grainger et 
al (2000) argued that plasma TGF-β contributed partly by in vivo platelet degranulation. 
Platelets are small, disk shaped clear cell fragments derived from megakaryocytes and most 
importantly have no nuclei. Non-significant associations between BiP and TGF-β can be 
partly explained by the fact that BiP can only be expressed and secreted by nucleated cells; 
107 
 
therefore BiP could not be expressed or secreted by platelets. However, evidence from 
literature supports BiP association with other cytokines measured.  
IL-1β and TNF-α are both pro-inflammatory cytokines involved in early stages of 
inflammation. Various articles suggest that these cytokines can stimulate various cell types 
to upregulate BiP expression. Yoo et al (2012) showed that culturing human synoviocytes, a 
specialised cell type located inside joints in the synovium, with TNF-α and IL-1β can increase 
BiP expression. In addition, Verma and Datta (2010) demonstrated that incubating human 
pancreatic epithelial cells with IL-1β can induce ER stress markers including BiP. However, 
our correlation analysis reveals that TNF-  association with BiP is stronger compared to IL-
1β association with BiP as denoted by higher R value. This can be explained by the fact that 
TNF-  secretion can also be induced by BiP upregulation but not with Il-1β. Using a human 
cancer cell line, Hu and colleagues (2006) showed that ER stress induction which 
upregulates BiP expression can lead to TNF-α secretion. ER stress induced IRE1α 
upregulation which subsequently lead to NF-κB activation and thus inducing TNF-α 
secretion from these cells. Furthermore, Lu and colleagues (2010) demonstrated that BiP 
can indirectly induce TNF-  production in human monocytes. TNF-α production is induced 
when anti-citrullinated protein antibodies bind to surface BiP on monocytes by enhancing 
NF-κB activity. This evidence leads to proposed cross talk between ER stress and innate 
immune system as suggested by Martinon and Glimcher (2011). However, the effect of ER 
stress, especially BiP upregulation is not limited to TNF-α secretion only. 
The correlation analysis show that BiP correlates positively with IL-10. As a major 
anti-inflammatory cytokine, IL-10 secretion is essential to counteract the effect of pro-
inflammatory cytokines including TNF-α and IL-1β. Bodman-Smith and co-workers (2003) 
showed that extracellular recombinant BiP protein can stimulate IL-10 production from 
CD8+ T cells from healthy individuals. Further work by the same group later demonstrated 
that PBMC cultured in the presence of recombinant BiP protein can secrete IL-10 (Corrigall 
et al, 2004). In the presence of BiP, PBMC cultured in the absence of any stimulus 
upregulated TNF-α after 7 hours but TNF-α production was reduced after 24 hours of 
culture. In contrast, IL-10 production was increased from 7 to 24 hours of culture and IL-10 
production in culture was sustained until 96 hours of culture. IL-10 production in PBMC 
cultured with BiP was mainly produced by monocytes via the p38 MAPK pathway; not the 
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ERK pathway.  This evidence supports the data that show association between circulating 
BiP and cytokines.  
Circulating cytokines correlates with each other as shown in Table 3.1 and Figure 
3.10. TNF-α and IL-1 correlates with each other (R=0.332, p=0.006) as both cytokines are 
pro-inflammatory cytokines. This correlation can be partly explained by the fact both 
cytokines can be induced by the same transcription factor. Both cytokines can be induced in 
cells after the activation of NFκB transcription factor as reviewed by Caamano and Hunter 
(2002). Interestingly, both cytokines correlates with IL-10 (R=0.372, p=0.002) (R=0.352, 
p=0.003), the major anti-inflammatory cytokine. TNF-α and IL-1β are some of the cytokines 
involved in the early stage of immune response since these two cytokines can be secreted 
by innate immune cells. However, IL-10 as major anti-inflammatory cytokine can be released 
in the later stage of immune response to counter act the effect of pro-inflammatory 
cytokines and restore homeostasis. Wang and co-workers (1995) demonstrated that IL-10 
can block the induction of pro-inflammatory cytokines such as TNF-α and IL-1β in human 
monocytes by blocking the activation of NFκB transcription factor. This could partly explain 
the positive correlation between IL-10 and TNF-α & IL-1β. On the other hand, IL-10 
positively correlates with TGF-β, a pleiotropic cytokine. IL-10 and TGF-β had been reported 
to act together in anti-tumour immunity (Jarnicki et al, 2006), and the induction of 
regulatory T cells (Chen et al, 2003). Most importantly, Huss and colleagues (2011) 
demonstrated that TGF-β signalling in murine Th1 cells can induce IL-10 secretion via 
SMAD4 transcription factor.  
Significant correlation between different cytokines may be because of false positive 
results. Donors with high circulating cytokine levels may record higher cytokine 
concentrations than the actual concentrations because of the interference of heterophilic 
antibodies. Heterophilic antibodies are defined as antibodies that can be induced by 
external antigens. Todd and co-workers (2011) reported that heterophilic antibodies can 
interfere with cytokine and chemokine measurements including TNF-α and IL-1β. An 
example of heterophlic antibody is rheumatoid factor (RF). It is an autoantibody against the 
Fc portion of immunoglobulin (IgG) and normally can be used in the diagnosis of RA. 
However, Kyburz et al (1999) reported that RF can be detected in up to 30% of normal 
individuals. Therefore, it is possible that the cytokines measured by ELISA could be detecting 
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RF from these donors hence the correlation analyses performed showed significant 
correlation between various cytokines. The presence of heterophilic antibodies such as RF 
can be removed to ensure that the cytokine measurements are accurate. De Jager and 
colleagues (2005) compared between three different methods of removing heterophilic 
antibodies especially RF in human plasma samples. They showed that preabsorption of 
human plasma with protein-L was the best method to remove interfering antibodies. 
Preabsorption of plasma with protein-L can reduce RF IgM levels by 89% whereas total IgM, 
IgG and IgA levels were reduced by 60%. Therefore, future cytokine measurements should 
consider removing heterophilic antibodies to get accurate measurement of cytokines.  
In addition, the presence of soluble cytokine receptors may interfere with the 
cytokine measurements even though Mosmann and Fong (1989) reported that cytokine 
ELISA are exquisitely specific because antibodies directed against two or more distinct 
epitopes. In addition, Callard and Gearing (1994) in their review mentioned about the role 
played by these receptors. These receptors may act as antagonists such as soluble TNF-α 
receptor or as carrier proteins in vivo and may serve as disease markers in in vitro tests. 
Furthermore, Carter and Swain (1997) demonstrated that cytokines detected by ELISA may 
or may not correlate directly with the levels of bioactive cytokine protein. For instance, an 
ELISA may utilize anti-cytokine antibodies that cannot discriminate between the precursor 
(inactive) and mature (bioactive) forms of a cytokine protein such as TGF-β. Moreover, an 
ELISA may detect partially-degraded cytokine proteins which have retained their 
immunoreactive propertiesbut may have lost their bioactivity. Cytokine sandwich ELISAs is 
useful indicators of the presence and levels of cytokines but they do not actually provide 
information concerning the biological potency of the detected proteins. Therefore, the 
correlation data between different cytokines may be validated by examining cytokine 
production in specific cell subset and specific stimulus as these two factors are important in 
cytokine production as reported by Ehlers and Smith (1991).  
Correlation analyses were performed between circulating BiP and 
clinical/biochemical parameters. The only significant correlation was between circulating BiP 
and triglyceride concentrations from the cohort as shown in Table 3.3 and Figure 3.14. 
Indirect evidence shows a direct association between BiP and triglycerides, in contrast to 
the data. Werstuck et al (2001) demonstrated that BiP overexpression in human endothelial 
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cells can play a role in the activation of cholesterol/triglycerides biosynthesis. The 
discrepancy between the result and Werstuck et al (2001) could be partly explained by the 
system used in the experiment. The data obtained was looking at triglyceride levels in the 
circulation whilst Werstuck and co-workers (2001) investigated the effect of BiP on 
specialised in vitro culture system.  
 In conclusion, data obtained from correlation analysis can give a clue to the possible 
role of immunological parameters in predicting CVD. However, given that the size of the 
cohort is small (n=68) and this study is only limited to the elderly population, further 
mechanistic study could help to elucidate the exact role of each immunological parameter 
measured from this cohort. The data indicate associations between circulating BiP and 
cytokine concentrations suggesting cross talk between ER stress and immune system.  
3.5 Conclusion 
 The main question of this chapter is to investigate the relationship between 
regulatory T cell frequency and circulating BiP concentration.  Data obtained from the 
Whitehall II cohort revealed no association between regulatory T cell and BiP. Correlation 
analyses can explain relationship between two variables but cannot explain whether one 
variable can affect or modulate the function of the other variable. Therefore, the question 
remains whether BiP can affect or modulate regulatory T cell function and this question will 



















4 The effect of soluble BiP on regulatory T cell phenotype and function 
4.1 Introduction 
In the previous chapter, data from the Whitehall II cohort showed that soluble BiP 
concentration does not correlate with regulatory T cell frequencies. Correlation analysis can 
only detect linear relationships between two variables. Therefore, it is possible that soluble 
BiP has no relationship with regulatory T cell frequencies but it may affect regulatory T cell 
function. 
The aim of this chapter is to determine if soluble BiP has any effect on regulatory T 
cell function. Other heat shock proteins have been shown to affect regulatory T cell 
function. HSP60 (Zanin-Zhorov et al, 2006) and HSP70 (Wachstein et al, 2012) have been 
shown to enhance regulatory T cell function by enhancing regulatory T cell ability to 
suppress responder T cell proliferation and IFN-γ and TNF-α levels from the co-culture. In 
addition, HSP60 and HSP70 pre-treatment on regulatory T cells can induce enhanced IL-10 
and TGF-β secretions, both cytokines are anti-inflammatory cytokines. To achieve the aim of 
this chapter, experiments were performed using cone bloods. Regulatory T cells and 
responder T cells were isolated using magnetic beads before co-culture experiments were 
performed. BiP pre-treatments on regulatory T cells were performed and washed away 
before being co-cultured with responder T cells. The readout of the suppression assays is 
responder T cell proliferation measured by tritiated thymidine incorporation and levels of 
cytokines, namely IFN-γ, TNF-α and IL-10, measured from culture supernatants using ELISA.  
4.2 Objectives 
The objectives of this chapter are as follows:- 
 To optimise regulatory T cell and responder T cell isolation 
 To optimise suppression assay of regulatory T cell 
 To replicate the effect of HSP60 on regulatory T cell function as shown by Zanin-
Zhorov et al (2006) 
 To investigate the effect of BiP pre-treatment on regulatory T cell phenotype 





4.3.1 Regulatory and responder T cell isolation  
Baecher-Allan et al (2001) showed that human regulatory T cells can be 
differentiated from activated T cells by looking at the intensity of CD25 expression. 
Regulatory T cells express high CD25 level with constitutive expression while activated T 
cells can express low levels CD25 transiently. This difference can be clearly seen in greater 
suppressive capacity of CD25High cells compared to CD25Low cells.  
Regulatory and responder T cells were isolated from cone bloods. The isolation was 
performed by first diluting cone blood with 1X PBS up to 60 ml. Then, gradient density 
centrifugation was performed and PBMCs were obtained. Typically a cone blood can yield 
from 3 to 5 x 108 PBMCs. Then, a further isolation step to obtain regulatory and responder T 
cells was performed using magnetic beads. The isolation steps are illustrated in Figure 4.1. 
CD25 can be expressed not only by human regulatory T cells but can also be expressed by 
activated responder T cells.  
As a control, the percentage of responder and regulatory T cells defined 
CD4+CD25LowCD127High and CD4+CD25HighCD127Low populations were demonstrated in 
PBMC. Cells gated on the whole population (A) were further sub-gated on CD4 expression 
(B). As shown in Figure 4.2(C), 87.5% of the population are responder T cells and 7.7% are 
regulatory T cells. Therefore, further isolation step is needed to achieve higher purity for 
functional studies can be performed. The purity of responder T cells as defined 
CD4+CD25LowCD127High cells (Figure 4.3) as the gating strategy was explained in this figure. 
Cells were gated on lymphocyte (A), then further sub-gated on CD4 expression (B) and 
responder T cells were defined as CD25LowCD127High (C). The mean purity of responder T 
cells were 92.6% and the antibody staining was validated by comparing between antibody 
staining (red line) and isotype control staining (blue line) as depicted by histograms of CD4 
(D), CD25 (E) and CD127 (F). Responder T cells isolated using magnetic beads using one MS 
column yielded 5 x 107 to 1 x 108 cells with a high purity of 93.2% of CD4+CD25Low CD127High 
as shown in Figure 4.2. 
 Various additional markers have been suggested to further differentiate between 
regulatory T cells and other types of T cell subsets including activated T cells. One of the 
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surface markers suggested for this is CD127. CD127 is an alpha chain of IL-7 receptor and it 
has been suggested it may be absent from regulatory T cell subsets. Liu et al (2006) were 
looking at the relationship between CD127 expression, Foxp3 expression and the 
suppressive function of regulatory T cells. CD127 expression was found to be inversely 
correlated with Foxp3 expression and the suppressive function of human regulatory T cells. 
Therefore, regulatory T cells isolated for the experiments were checked for CD127 
expression and regulatory T cells are defined as CD4+CD25HighCD127Low cells (Figure 4.4).   
Regulatory T cell purity depends on the number of MS columns used in the isolation. 
As shown in Figure 4.4, a similar gating strategy was used to define regulatory T cell 
population. Panel (A-C) show the purity of regulatory T cells was compared between 
isolation using 2 MS columns while panel (D-E) demonstrate the purity of regulatory T cells 
using 1 MS column. Similarly with responder T cells, antibody staining of regulatory T cells 
were compared to isotype control as shown in Panel (G-I). Regulatory T cells defined as 
CD4+CD25High CD127Low population isolated using 2 MS columns achieved higher purity (95%) 
compared to regulatory T cells isolated using 1 MS column (83.5%). Regulatory T cell 
isolated with higher purity are important to these experiment since the main objective is to 
examine the effect of BiP treatment on regulatory T cells, not responder T cells. 
To further confirm the purity of regulatory and responder T cells, intracellular Foxp3 
staining was performed. Foxp3 protein is an important transcription factor which appears to 
function as a master regulator in the development and function of regulatory T cells. Figure 
4.5 demonstrates Foxp3 staining of regulatory T cells (A) and responder T cells (C) compared 
to isotype control staining respectively (Panel B&D). Regulatory T cells consist of 82.3% of 
Foxp3+ cells while 11.4% of responder T cells are Foxp3+ cells. In addition, Corrigall et al 
(2004) demonstrated that soluble BiP can affect phenotype and function of CD14 
monocytes. Hence, CD14 staining was performed to ensure that no CD14+ cells were 
present after isolation. Figure 4.6 shows CD14 staining performed on regulatory and 
responder T cells. Respective cell populations were gated based on forward versus side 
scatter (A,C&E) and further sub-gated according to CD14 expression (B,D&F). Monocytes 
were used as a positive control and CD14 is a lineage marker of monocytes. The table in 
Figure 4.5 shows a very small percentage of CD14+ cells can be found in regulatory (1.2%) 
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and responder T cells (0.78%) after isolation. It was viewed that the purity of the cell 
populations was sufficient to proceed with the co-culture for in vitro suppression assay.    
4.3.2 Two hours of HSP60 pre-treatment maintains regulatory T cell phenotype yet enhances regulatory 
function. 
It is important to reproduce the findings of Zanin-Zhorov et al (2006) to show that 
HSP60 can enhance regulatory T cell function. The set-up of this experiment was performed 
exactly as shown in their paper. In addition, Wachstein and colleagues (2012) showed that 
functional change in regulatory T cells by HSP70 pre-treatment can be correlated with the 
expansion of regulatory T cells as measured by Ki-67 staining, a marker associated with cell 
proliferation when incubated with HSP70. To confirm the previous observation, regulatory T 
cells were cultured with HSP60 and the surface markers were assessed and compared with 
regulatory T cells cultured in the absence of HSP60.     
Figure 4.7 shows the effect of HSP60 pre-treatment on regulatory T cell phenotype 
as shown by CD4, CD25 and CD127 expression. However, HSP60 pre-treatment maintained 
and did not alter the regulatory T cell phenotype as shown in Panel the histogram of CD4, 
CD25 and CD127 by the overlapping lines between mock treated and HSP60-treated 
regulatory T cells (Panel B-D) in one donor and multiple donors as shown in Panel (E-G) even 
though CD127 expression was reduced in one donor. Next, the suppressive function of 
HSP60 pre-treated regulatory T cells were assessed using in vitro suppression assay (Figure 
4.8). Regulatory T cells were co-cultured with responder T cell for 96 hours in the presence 
of plate-bound anti-CD3 antibodies and the proliferation and cytokines were measured. 
Responder T cell proliferation was measured by using tritiated thymidine incorporation and 
cytokines were measured using ELISA from culture supernatants. HSP60 pre-treatment of 
regulatory T cells reduced the proliferation of responder T cells (Panel A) and all supernatant 
cytokine levels (IFN-γ, TNF-α and IL-10) (Panel (C,E,G). However, the mean effect of HSP60 
pre-treatment on regulatory T cells in multiple donors (Panel B,D,F,H) can be clearly seen in 
certain cytokine levels in the co-culture; not with the suppression of responder T cell 
proliferation. Co-culture of responder and regulatory T cells treated with HSP60 did not 
affect TNF-α and IL-10 but significantly reduced IFN-γ, a pro-inflammatory cytokine in 
agreement with Zanin-Zhorov et al (2006).    
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4.3.3 Optimisation of suppression assay 
Using a similar experimental set-up as used for HSP60 pre-treatment, an in vitro 
suppression assay was performed to investigate the effect of soluble BiP on regulatory T cell 
function. 1 ng/ml of BiP was used in pre-treatment with regulatory T cells before being co-
cultured with responder T cells in the presence of 5 µg/ml plate-bound anti-CD3 antibody 
for 96 hours. As shown in Figure 4.9, BiP pre-treatment on regulatory T cells did not affect 
responder T cell proliferation (Panel A), and slightly increased cytokine levels of IFN-γ, TNF-α 
and IL-10 from the co-culture compared to mock treated regulatory T cells. The ratio of 
responder to regulatory T cells used in this experiment was 1 to 1; therefore it is possible 
that the effect of BiP was masked by the fact that mock treated regulatory T cells achieved 
maximal suppressive capacity. Therefore, the suppression assay has to be optimised.   
The first step of optimisation is to determine the kinetics of responder T cell 
proliferation to ensure that responder T cells reach their maximum proliferation in the 
presence of plate-bound anti-CD3 antibodies. To activate responder T cells and make them 
proliferate, TCR stimulation and co-stimulation is necessary to enable them to reach 
maximal proliferative capacity. TCR stimulation can be achieved by using anti-CD3 
antibodies while co-stimulation can be provided in the form of anti-CD28 antibody. 
Therefore, the kinetics of responder T cell proliferation was determined using both anti-CD3 
antibodies alone or anti-CD3/CD28 beads.  
Figure 4.10 shows responder T cell proliferation with and without the presence of 
plate-bound anti-CD3 antibodies and anti-CD3/CD28 beads. Responder T cells stimulated in 
the presence of 5 µg/ml plate-bound anti-CD3 antibodies and 1 anti-CD3/CD28 bead to 5 
cells achieved higher proliferation levels compared to proliferation in the presence of 1 
µg/ml anti-CD3 antibody and 1 anti-CD3/CD28 beads to 10 cells (Panel A-B). Responder T 
cell proliferation peaked at Day 3 in the presence of all stimuli except for 1 µg/ml anti-CD3 
antibody. Therefore, future suppression assays were performed and compared at Day 3.  
To ensure optimal levels of suppression, the kinetics of the suppression assay was 
investigated. The suppression assay was performed on cone bloods for 3 or 4 days in the 
presence of both stimuli and the level of suppression compared to suppression assays 
between 3 and 4 days as shown by Figure 4.11. A higher percentage of suppression was 
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observed after 4 days in the co-culture compared to 3 days in the presence of both stimuli 
either in one (Panel A,B,D,E) and multiple donors (Panel C&F). Therefore, suppression assays 
will be performed in the presence of 5 µg/ml anti-CD3 antibody and 1 anti-CD3/CD28 bead 
to 5 cells for 4 days. 
The last step for optimisation of the suppression assay was to find a sub-optimum 
level of suppression in the presence of anti-CD3 antibodies and anti-CD3/CD28 beads so 
that any enhanced suppression mediated by BiP pre-treatment can be seen as co-culture of 
responder and regulatory T cells in a ratio of 1 to 1 achieved very high levels of suppression. 
Next, a titration of regulatory T cells to responder T cells in co-culture was performed to find 
a sub-optimal level of suppression. As shown in Figure 4.12, co-culture of responder and 
regulatory T cells in a ratio of 1 to 1 achieved 89% (anti-CD3 antibody, Panel B) and 80% 
(anti-CD3/CD28 beads, Panel C) suppression compared to 55% (both stimuli, Panel B&C) 
suppression when responder and regulatory T cells were co-cultured in ratio of 1 to 0.3. 
Therefore, the ratio that will be used for further suppression assays will be 1 responder T 
cell to 0.3 regulatory T cell. 
 In conclusion, the suppression assay has been optimised. Future suppression assays 
will be performed for 4 days in the presence of 5 µg/ml anti-CD3 antibodies or 1 anti-
CD3/CD28 bead to 5 cells in the ratio of 1 responder T cell to 0.3 regulatory T cells.   
To further confirm that the enhanced suppression observed at 4 days is not due to 
an increase in dying cells, PI staining was performed as shown in Figure 4.13. Cells with 
positive PI staining can be acquired by flow cytometry with a fluorescence excitation 
maximum of 535 nm and an emission maximum of 617 nm. Comparison of PI positive cells 
between stimulated responder T cells (9% for anti-CD3 antibody and 12% for anti-CD3/CD28 
beads) and a co-culture of responder to regulatory T cells (10% for anti-CD3 antibody and 
10% for anti-CD3/CD28 beads) was performed and shown in multiple donors (Panel I-J). This 
data reveal a similar percentage of dead cells between stimulated responder T cells and the 
co-culture of responder and regulatory T cells in both stimuli.  
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4.3.4 Two hours of BiP pre-treatment does not enhance regulatory T cell function in the presence of 
anti-CD3 antibodies or anti-CD3/CD28 beads 
Various doses of BiP ranging from 0.1 ng/ml to 1 µg/ml were incubated with 
regulatory T cells before suppression assays were performed in the presence of both stimuli 
(Panel A-B). BiP pre-treatment of 0.1 until 10 ng/ml showed a dose-dependent suppression 
in the presence of anti-CD3 antibody (Panel A) while no enhanced suppression observed 
with BiP pre-treatment in the presence of anti-CD3/CD28 beads (Panel B). Data from Panel A 
indicated that 10 ng/ml is the optimum dose to be used in future experiments concerning 
BiP pre-treatment of regulatory T cells as shown in Figure 4.14 because these achieved the 
highest reduction of responder T cell proliferation. After that, 10 ng/ml of BiP was used for 
BiP pre-treatment on regulatory T cells before being co-cultured with responder T cells for 4 
days as shown in Figure 4.15.    
BiP pre-treatment of regulatory T cells in suppression assays using anti-CD3 
antibodies had a variable effect on the level of suppression. Data from one donor showed 
that 10 ng/ml of BiP pre-treatment can reduce the proliferation of responder T cells in the 
presence of anti-CD3 antibody (blue bars, Panel A) but not anti-CD3/CD28 beads (Yellow 
bars, Panel C). To control for any carry over effect of BiP pre-treatment on regulatory T cells, 
responder T cells were cultured with BiP in the presence of both stimuli (1st bar from right) 
(Panel A&C).  
However, the mean effect of BiP pre-treatment in multiple donors showed different 
effect. In the presence of anti-CD3 antibody (Panel B), 4 donors achieved higher level of 
suppressions when comparing with BiP treated regulatory T cells and mock treated 
regulatory T cells while another 4 donors obtained a lower level of suppression compared to 
mock treated regulatory T cells. This variability brings no significant change in term of 
suppression level when compared with mock treated regulatory T cells and BiP-treated 
regulatory T cells (p=1, n=8). On the other hand, the effect of BiP pre-treatment in 
suppression assays using anti-CD3/CD28 beads were measured from 6 donors. 2 donors 
were excluded because of high variability in suppression. In 5 out of 6 donors, BiP pre-
treatment on regulatory T cells slightly increased the suppression level but the difference 
between mock treated and BiP treated regulatory T cells in terms of the percentage level of 
suppression is not statistically significant (p=0.44, n=6) (Panel D).  
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To further confirm that BiP pre-treatment has no effect on regulatory T cell function, 
supernatant cytokine levels of IFN-γ, TNF-α and IL-10 were measured as shown in Figure 
4.16. In the presence of anti-CD3 antibodies or anti-CD3/CD28 beads, no significant 
difference was observed between cytokine levels of the co-culture of mock treated or BiP 
treated regulatory T cells and responder T cells of IFN-γ (Panel A&D), TNF-α (Panel B&E) and 
IL-10 (Panel C&F). 
4.3.5 Two hours of BiP pre-treatment maintains regulatory T cell phenotype 
To confirm that BiP pre-treatment has no effect on regulatory T cell phenotype, the 
surface marker expression of CD4, CD25 and CD127 were assessed and compared between 
mock treated and BiP treated regulatory T cells. Phenotypic changes in regulatory T cells 
were assessed using flow cytometry. Surface markers assessed were CD4, CD25 and CD127, 
and the markers that were used to validate regulatory T cell staining as regulatory T cells are 
defined as CD4+CD25HighCD127Low population. Figure 4.17 shows histograms of CD4, CD25 
and CD127 expression on regulatory T cells. The red line indicates regulatory T cells cultured 
in the absence of BiP while the blue, orange and green lines represents regulatory T cells 
cultured in the presence of various doses of BiP (0.1,1,10 ng/ml) for 24 hours respectively 
(Panel B-D). Clearly there is no difference as all lines overlap and this figure is a 
representative experiment in 4 donors as no changes were observed. In addition, the mean 
fluorescence intensity (MFI) of each marker was examined in multiple donors (Panel E-G). 
Regulatory T cells cultured in the presence of various doses of BiP demonstrated variable 
effect of MFI of CD4, CD25 and CD127 between mock treated and BiP treated regulatory T 
cells. This result further confirms the earlier finding that BiP pre-treatment on regulatory T 
cells has no effect on responder T cell proliferation and supernatant cytokines from the 
suppression assay. In conclusion, 2 hours of BiP pre-treatment does not change the 
phenotype and function of regulatory T cells.  
4.3.6 BiP can reduce responder T cell proliferation in the presence of anti-CD3/CD28 beads but not the 
cytokine levels from the culture 
To control for any effect of left over BiP not removed during the washing step of 
regulatory T cells on responder T cells, responder T cells were cultured with BiP in the 
presence of both stimuli as shown in Figure 4.15 (Panel A&B). Interestingly, BiP can 
significantly reduce proliferation of responder T cells after 4 days in the culture in the 
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presence of anti-CD3/CD28 beads in multiple donors as shown in Figure 4.18 (B) (p=0.0078, 
n=8), but not in the presence of anti-CD3 antibodies only (Panel A) (p=0.94, n=8). BiP effect 
on responder T cells was further investigated on the cytokine profile secreted from 
responder T cells (Figure 4.19). IFN-γ, TNF-α and IL-10 measured from the culture of 
responder T cells with BiP showed variability hence no significant effect was observed when 
compared to responder T cells cultured without BiP either in the presence of anti-CD3 
antibody (Panel A-C) or anti-CD3/CD28 beads (D-F).  
4.3.7 Optimisation of suppression assay in the presence of monocytes 
The use of anti-CD3 antibodies and anti-CD3/CD28 beads to activate responder T 
cells in co-culture with regulatory T cells does not mimic the physiological situation. 
Therefore, it is possible that BiP may affect regulatory T cell function when co-cultured with 
APC. To perform a co-culture of monocytes, responder and regulatory T cells, isolation of 
the cell populations was performed using magnetic beads as shown in Figure 4.20. The 
purity of monocytes isolated from magnetic beads was assessed using anti-CD14 staining as 
the gating strategy was shown in Figure 4.20(A-B). CD14 is a lineage marker of monocytes 
and the antibody staining of CD14 was validated when compared with isotype staining 
control as demonstrated in Figure 4.21(C). Monocytes isolated using magnetic beads 
achieved high purity of 73.6% of CD14+ cells in multiple donors (n=5) as demonstrated in 
Figure 4.20.  
 Before the suppression assay can be performed, optimisation of co-cultures has to 
be performed. Responder T cells cultured with monocytes achieved high proliferation even 
in the absence of anti-CD3 antibody. However, in the presence of anti-CD3 antibody, co-
culture of responder T cells with monocytes recorded higher proliferation (30639 CPM) 
compared to co-culture of responder T cells with monocytes in the absence of anti-CD3 
antibody (15962 CPM). Responder T cells cultured with monocytes in the presence of anti-
CD3 antibodies peak at Day 2 as illustrated in Figure 4.22; by contrast to 3 days of responder 
T cell culture in the presence of anti-CD3 antibodies or anti-CD3/CD28 beads (Figure 4.10).   
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4.3.8 Two hours of BiP pre-treatment on regulatory T cells does not enhance their function even in the 
presence of monocytes 
Corrigall et al (2004) demonstrated that BiP can affect monocyte function; therefore 
the effect of BiP on regulatory T cells may be facilitated via interaction with monocytes. 
Walter et al (2013) reported that activated human monocytes can interact with regulatory T 
cells and cause an increase of the frequency of IL-17 secreting regulatory T cells. However, 
these regulatory T cells had enhanced capacity to suppress responder T cell proliferation 
and IL-17 secretion from the co-culture. This clearly shows that cross-talk between 
monocytes and regulatory T cells can happen. Therefore, BiP pre-treatment was performed 
on regulatory T cells and co-cultured with monocytes before responder T cells were added 
24 hours later to examine the suppressive capacity of responder T cell.  
Figure 4.23(A) shows the proliferation measured from responder T cells proliferation 
from one donor. The proliferation of responder T cells cultured in the presence of 
monocytes and anti-CD3 antibody (3rd bar from right) was reduced in the presence of mock-
treated regulatory T cells (2nd bar from right). However, responder T cells achieved higher 
proliferation level in the presence of BiP treated regulatory T cells (1st bar from right) 
compared to mock treated regulatory T cells. The similar effect can be observed with IFN-γ 
levels measured from the co-culture (Panel B). However, no change was observed with TNF-
α and IL-10 levels measured from the co-culture with BiP treated regulatory T cells 
compared to mock treated regulatory T cells (Panel C-D). The data from multiple donors 
showed that 2 hours of BiP pre-treatment does not enhance regulatory T cell function as 
measured by proliferation of responder T cells and supernatant cytokines from the co-
culture. 
4.3.9 Two hours of BiP pre-treatment on monocytes does not enhance regulatory T cell in co-culture 
but reduces proliferation of responder T cells 
Two hours of BiP pre-treatment was performed on monocytes before being co-
cultured with regulatory T cells. Responder T cells were added into the culture 24 hours 
later as shown in Figure 4.24 and the proliferation of one donor was shown in Panel A. The 
co-culture of regulatory, responder and mock treated monocytes shows the reduction of 
proliferation (2nd bar from right) compared to the co-culture of responder T cells and mock-
treated monocytes (4th bar from right) indicating that regulatory T cells can suppress the 
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proliferation of responder T cells. Similarly, regulatory T cells can suppress responder T cells 
in the presence of BiP-treated monocytes (comparing between 3rd bar and 1st bar from 
right). The proliferation data were converted into percentage of suppression of multiple 
donors as shown in Panel (B). The effect of BiP pre-treatment on monocytes on regulatory T 
cell suppressive capacity is variable as 3 of 5 donors showed the percentage of suppression 
reduced upon BiP pre-treatment of monocytes, while the remaining donors showed 
enhanced suppression therefore the indirect effect of BiP on regulatory T cells via 
monocytes is not statistically significant (p=0.31, n=5).  
In addition, supernatant cytokines were measured from the co-culture. Supernatant 
IFN-γ measured from the co-culture showed similar trend with the proliferation data (Panel 
C&D) with 3 donors showed increased IFN-γ levels with BiP treated monocytes in the co-
culture compared to mock treated monocytes whilst the remaining donors showed 
otherwise (p=0.62). The variable effect of BiP pre-treatment on monocytes on the 
suppressive capacity of regulatory T cells and IFN-γ levels from the co-culture was replicated 
in TNF-α and IL-10 levels. 4 of 5 donors showed higher levels of TNF-α and IL-10 levels in the 
co-culture with BiP-treated monocytes compared to mock treated monocytes as shown in 
Panel (E-G). Hence, no significant difference was observed between TNF-α (p=1) and IL-10 
(p=0.32) levels between BiP treated and mock treated monocytes.  
 However, Figure 4.24(A) suggests that BiP-treated monocytes can reduce the 
proliferation of responder T cells without the addition of regulatory T cells (comparing 
between 4th bar and 3rd bar from right). Therefore, the effect of BiP treated monocytes on 
responder T cells was examined. As shown in Figure 4.25(A), BiP treated monocytes can 
reduce the proliferation of responder T cells compared to mock treated monocytes in all 5 
donors even though this is not statistically significant (p=0.06). The effect of BiP indirectly on 
responder T cells is limited to responder T cell proliferation only as variable effect was 
observed with the supernatant cytokine levels of IFN-γ (p=0.82), TNF-α (p=0.62) and IL-10 
(p=0.18) measured from the co-culture as demonstrated in Figure 4.25(B-D).  
4.3.10 Regulatory T cells must be cultured in the presence of IL-2  
In this chapter, it has been shown that BiP can affect responder T cell proliferation 
directly in the presence of anti-CD3/CD28 beads (Figure 4.18) or indirectly via BiP-treated 
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monocytes (Figure 4.25). This shows that BiP can affect responder T cells by reducing their 
proliferation when cultured with BiP in a period longer than 2 hours. Therefore, the effect of 
BiP on regulatory T cells could be visible if incubated for more than 2 hours. Since the effect 
of BiP on responder T cell proliferation can be seen after 4 days in culture, regulatory T cells 
were cultured for 4 days. It has been established that IL-2 is an important survival factor for 
regulatory T cells and shown in Figure 4.26 where regulatory T cells cultured in the absence 
of IL-2 had higher percentage of death cells (20.1%) (Panel C) compared to regulatory T cells 
cultured in the presence of IL-2 (6.45%) (Panel D). This effect is clear in multiple donors as 
shown in Panel (E) where regulatory T cells cultured in the absence of IL-2 had an 
approximately 6-fold increase in dying cells (35% propidium iodide+ cells) compared to 
regulatory T cells cultured in the presence of IL-2 (6% propidium iodide+ cells). Therefore 
regulatory T cells were cultured with or without BiP in the presence of IL-2 to investigate the 
effect of BiP on regulatory T cells over 4 days.  
4.3.11. The kinetics of BiP effect on regulatory T cells  
To investigate the effect of BiP on regulatory T cells, regulatory T cells were cultured 
in the presence of IL-2 with or without 10 ng/ml of BiP. As BiP can reduce responder T cell 
proliferation in the presence of anti-CD3/CD28 beads after 4 days in culture as shown in 
Figure 4.18 while BiP can indirectly reduce responder T cell proliferation via BiP-treated 
monocytes after 2 days in culture as demonstrated in Figure 4.25. Therefore, regulatory T 
cells will be cultured with BiP for 3 time periods; 2, 4 and 6 days (Panel A-F). Regulatory T 
cells cultured with or without BiP in the presence of IL-2 showed similar levels of dying cells 
on Day 2 (4.4%) and 4 (5.4%) as shown in Figure 4.27(G). However, the percentage of PI+ 
cells in regulatory T cells cultured without BiP increased 2 fold at Day 6 (10.7%) compared to 
Day 4 (5.4%). Regulatory T cells cultured with BiP always recorded a lower percentage of PI+ 
cells compared to regulatory T cells cultured without BiP throughout 3 different time points.  
 The effect of BiP on regulatory T cell phenotype was investigated by looking at the 
expression of Foxp3 and CD25, two important molecules used in the identification of human 
regulatory T cells. Regulatory T cells used in this experiment were isolated using 1 MS 
column as fresh bloods were used. Therefore, the purity of regulatory T cells from most 
donors were lower compared to regulatory T cells isolated using 2 MS columns as 
demonstrated in Figure 4.4. Foxp3 versus CD25 expression of regulatory T cells cultured 
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with or without BiP gated from the lymphocyte gate of one donor was demonstrated in 
Figure 4.28(A-F) throughout 3 different time points. The effect of BiP on regulatory T cell 
frequency varies at 3 different time points. The histogram in Panel (G-H) show the histogram 
of CD25 and Foxp3 of regulatory T cell cultured with (blue line) or without BiP (red line). 
Foxp3 and CD25 expression were enhanced in the presence of BiP as shown by the MFI of 
Foxp3 and CD25 of regulatory T cells cultured with BiP which is higher compared to 
regulatory T cells cultured without BiP (Foxp3: 224 versus 168, CD25: 586 versus 557). The 
comparison between Foxp3 and CD25 antibody staining and isotype control staining was 
performed and shown in Panel (I-J) to confirm that the antibody staining is working.  
The cumulative data of BiP effect on regulatory T cells can be observed in Panel (K-
M). The frequency of the Foxp3+CD25+ population was not affected on Day 2 and 4 with BiP 
in the culture while the frequency of Foxp3+CD25+ population was reduced on Day 6 
(shown in Panel K). Both Foxp3 and CD25 expression measured by their MFI expression 
were modulated by BiP treatment on regulatory T cells (Panel L-M) compared to the 
frequency of the Foxp3+CD25+ population. Foxp3 and CD25 expression showed a trend of 
higher expression in regulatory T cells cultured with BiP compared to regulatory T cells 
cultured without BiP at Day 2 and 4 although the differences are statistically insignificant 
(Foxp3: Day 2 & 4, p=0.8, CD25: Day 2, p=0.8, Day 4, p=0.6) . However, the mean MFI of 
Foxp3 and CD25 of regulatory T cells were the highest at Day 4 and went down at Day 6 
perhaps because of the increase in cell death as shown in the previous figure.  
 In addition to investigating the phenotype of regulatory T cells, the cytokines- 
associated with regulatory T cells were measured using ELISA, namely IL-10 and TGF-β1. 
Latent TGF-β1 was measured from the culture because it does not need to be activated. 
Activation of TGF-β1 using a neutralisation step introduced a great variability as indicated by 
the standard error. Therefore, TGF-β measured from the culture represents latent TGF-β1 
measurement. Figure 4.29(A) demonstrates that IL-10 produced by regulatory T cells 
cultured without BiP in the presence of IL-2 was slightly higher compared to regulatory T 
cells cultured with BiP (Day 2 & 6, p=0.3, Day 4, p=0.6). However, the opposite effect was 
observed on TGF-β produced in the culture (Panel B). Regulatory T cells cultured with BiP 
showed a trend toward higher TGF-β secretion compared to regulatory T cells cultured 
without BiP at all Day 2 (p=0.6) and 6 (p=1.0) although the differences are statistically 
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insignificant. Both IL-10 and TGF-β secretion were the highest at Day 6 therefore Day 6 
could be used to investigate cytokine production in regulatory T cell in cultures. However, a 
literature search revealed that TGF-β can be secreted by macrophages upon phagocytosis of 
apoptotic cells (Barker et al, 2002). Therefore, further investigation of the BiP effect on 
regulatory T cells was performed at Day 4 instead of Day 6 as more cells started to die and 
apoptotic cells may induce TGF-β secretion which may interfere with secretion from 
regulatory T cells cultured with BiP.  
4.3.12 Four day treatment of BiP on regulatory T cells does not change Foxp3 and CD25 
expression and IL-10 and TGF-β secretion 
Phenotypic analysis of CD25 and Foxp3 was further performed on 13 donors after 4 
day treatment with BiP as shown in Figure 4.30. The frequency of Foxp3+CD25+ cells was 
slightly increased by 4 day BiP treatment as demonstrated in Panel (A-B). However, the 
histogram of Foxp3 (Panel C) shows that Foxp3 expression regulatory T cells cultured with 
BiP (blue) was enhanced compared to regulatory T cells cultured without BiP (red line) and 
indicated by the MFI value but CD25 expression was lower in BiP-treated regulatory T cells 
compared to mock-treated regulatory T cells (shown in Panel (D)). However, the cumulative 
effect of 4 day BiP treatment on regulatory T cells did not change Foxp3+CD25+ frequency 
(p=0.44) and CD25 MFI (p=1) in multiple donors as demonstrated in Panel (E-F). In contrast, 
4 day BiP treatment on regulatory T cells can increase Foxp3 expression as measured by 
Foxp3 MFI (310) compared to regulatory T cells cultured without BiP (310) although the 
increase is statistically insignificant (p=0.06) as illustrated in Panel (G).  
Panel A demonstrate regulatory T cells secrete lower levels of IL-10 in the culture 
with BiP (5 pg/ml) compared to regulatory T cells cultured with BiP (9 pg/ml) (p=0.8, n=15). 
In contrast, TGF-β secretion in regulatory T cells was higher when cultured with BiP (365 
pg/ml) compared to regulatory T cells cultured without BiP (279 pg/ml) (Panel B). This is a 
similar trend with Foxp3 expression as the increase in TGF-β secretion in regulatory T cells 
cultured with BiP is not significant compared to regulatory T cells cultured without BiP 
(p=0.09, n=15).  
In conclusion, BiP may affect the regulatory T cell phenotype. Although the 
differences in Foxp3 expression and TGF-β secretion are statistically insignificant, BiP 
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treatment of regulatory T cells showed higher Foxp3 expression and TGF-β secretion. As 
demonstrated by HSP60 data, HSP60 pre-treatment can affect regulatory T cell function to 
reduce IFN-γ although no phenotypic change was observed with HSP60 pre-treatment. 
Therefore, it is important to investigate whether 4 days of BiP treatment may induce 
changes to regulatory T cell function by using in vitro suppression assay.  
4.3.13 Four day treatment of BiP on regulatory T cells does not enhance their regulatory function 
As regulatory T cells cultured with BiP for 4 days can enhance Foxp3 expression and 
induce TGF-β secretion, it is therefore important to assess whether these changes can 
contribute to enhanced suppressive function of regulatory T cells. The suppressive function 
of regulatory T cells must be investigated after being cultured for 4 days in the presence of 
IL-2. Figure 4.32 (A) shows that regulatory T cells can still suppress the proliferation of 
responder T cells in the presence of anti-CD3/CD28 beads (comparing between 3rd bar and 
2nd bar from right). The addition of BiP-treated regulatory T cells can further enhance the 
suppression of the proliferation of autologous responder T cells (comparing between 2nd bar 
and 1st bar from right). However, the effect was variable as 3 of 6 donors showed enhanced 
suppression with BiP-treated regulatory T cells in the co-culture, while the remaining donors 
showed opposite effect; therefore the difference is not statistically significant (p=0.6875).  
 Supernatant cytokine levels of IFN-γ, TNF-α and IL-10 were measured from the co-
culture. BiP-treated regulatory T cells can reduce the IFN-γ in the co-culture compared to 
mock treated regulatory T cells (Panel C) whilst TNF-α (Panel E) and IL-10 levels (Panel G) 
were higher in the co-culture of BiP-treated regulatory T cells and autologous responder T 
cells compared to mock treated regulatory T cells in the co-culture. However, the effect of 4 
day BiP treatment is variable in multiple donors of supernatant cytokine levels of IFN-γ 
(Panel D), TNF-α (Panel F) and IL-10 (Panel H) therefore the difference is not statistically 





























































































In vitro suppression assays are now widely used to determine the suppressive 
capacity of regulatory T cells. Before suppression assay can be performed, regulatory and 
responder T cells were isolated using magnetic beads. After that, the purity of regulatory 
and responder T cells were examined. As shown in Figure 4.3, responder T cells defined as 
CD4+CD25LowCD127High population achieved the mean purity of 92% while regulatory T cells 
isolated from 2 MS columns achieved the mean purity of 95% as regulatory T cells are 
defined as CD4+CD25HighCD127Low population as illustrated in Figure 4.4. To further confirm 
these two populations, intracellular Foxp3 staining was performed. As demonstrated in 
Figure 4.5, 82.3% of regulatory T cells were Foxp3+ cells while 11.4% of responder T cells 
were Foxp3+ cells. As Foxp3 protein can be expressed by responder T cells especially after 
activation of responder T cells (Allan et al, 2007, Wang et al, 2007, McMurchy et al, 2013), it 
is important to validate that regulatory T cells isolated are truly regulatory T cells as 
regulatory T cells can express high levels of Foxp3. Furthermore, regulatory T cells isolated 
using magnetic beads can suppress the proliferation of responder T cells and cannot 
proliferate in vitro as demonstrated throughout this chapter. This evidence further supports 
that regulatory T cells isolated using this method were true regulatory T cells as Hombach et 
al (2007) demonstrated that human regulatory T cells cannot proliferate in in vitro culture 
without any IL-2 stimulation. 
Before investigating the effect of BiP on regulatory T cell function, it was pivotal to 
reproduce the findings of Zanin-Zhorov and colleagues (2006) as they demonstrated that 
HSP60 pre-treatment on regulatory T cells can enhance their suppressive ability on 
responder T cell proliferation and reduce pro-inflammatory cytokines namely TNF-α and 
IFN-γ in the co-culture. Figure 4.7 shows that no phenotypic change on regulatory T cells 
pre-treated with HSP60 compared to mock treated regulatory T cells and Figure 4.8 
demonstrates that HSP60 pre-treatment of regulatory T cells had no effect on the ability of 
regulatory T cells to suppress responder T cell proliferation but can modulate their ability to 
suppress IFN-γ levels in the co-culture. Zanin-Zhorov et al (2006) utilised 3-(4,5-
Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay, a colorimetric assay for 
measuring the activity of cellular enzymes that reduce the tetrazolium dye, MTT, to its 
insoluble formazan, giving a purple colour to represent the responder T cell proliferation, 
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which is a more sensitive measurement compared to measuring responder T cell 
proliferation by uptake of tritiated thymidine which detects newly synthesized DNA in the 
entire cell population. Therefore, the different method used to measure responder T cell 
proliferation may explain the discrepancy between the results in Figure 4.8 and Zanin-
Zhorov et al (2006). This observation suggests that HSP60 may not induce phenotypic 
change but can modulate the function of regulatory T cells by the downregulation of IFN-γ in 
the co-culture. 
Then, the role of BiP on regulatory T cells was investigated. Two hours of BiP pre-
treatment was not enough to induce any changes in gene induction and transcription thus 
no change was observed in the phenotype and function of regulatory T cells cultured with 
BiP in various experimental settings (shown in Figure 4.14-4.17). This is in contrast with 
HSP60 and HSP70 where Zanin-Zhorov et al (2006) and Wachstein et al (2012) showed that 
two hours of HSP pre-treatment can enhance the ability of regulatory T cells to suppress 
responder T cell proliferation. Furthermore, both HSPs had been shown to modulate 
regulatory T cell function via TLR2. Therefore, it is highly unlikely that BiP binds to TLR2 on 
immune cells to mediate biological effects as shown in Figure 4.15. Since BiP has been 
shown to modulate monocyte function (Corrigall et al, 2004), co-cultures of BiP-treated 
monocytes and regulatory T cells were performed and the suppressive capacity of 
regulatory T cells on responder T cells was examined after the addition of responder T cells. 
As demonstrated in Figure 4.24, regulatory T cell suppressive function was not influenced by 
the presence of BiP-treated monocytes but BiP-treated monocytes can reduce the 
proliferation of responder T cells (shown in Figure 4.25). In addition, BiP can directly 
modulate responder T cell function by reducing their proliferation in the presence of anti-
CD3/CD28 beads; but no change in cytokine secretion profile as demonstrated in Figure 4.15 
and 4.16. 
Clearly, data from responder T cells showed that BiP may take longer time to 
modulate responder T cell function hence regulatory T cells were cultured with BiP for a 
period of longer than 2 hours. The kinetic of BiP treatment on regulatory T cells were 
performed and examined (demonstrated in Figure 4.27-4.29) by several readouts. Any BiP 
effect on regulatory T cells were investigated using Foxp3 and CD25 expression and IL-10 
and TGF-β cytokine secretions from regulatory T cells. Based on the kinetic experiments, 
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regulatory T cells were cultured with BiP for 4 days. Figure 4.30 illustrates that regulatory T 
cells cultured with BiP may increase their Foxp3 expression although the increase is 
statistically insignificant (p=0.06). The importance of Foxp3 in regulatory T cells was 
highlighted by Ferraro and colleagues (2014) by investigating the heterogeneity of human 
regulatory T cells. Foxp3 and other genes associated with regulatory T cells were examined 
from peripheral blood of healthy donors and they observed that Foxp3 gene expression was 
tightly clustered between individuals showing the importance of this gene to regulatory T 
cells. In addition, Wan and Flavell (2007) demonstrated that reduction of Foxp3 expression 
in murine regulatory T cells lead to impaired suppressive function and altered surface 
properties. These mice also developed an aggressive autoimmune syndrome. Therefore, a 
small increase of Foxp3 expression in regulatory T cells may lead to enhanced suppressive 
capacity. Again the same trend was observed with TGF-β secretion. Figure 4.31 shows that 
TGF-β secretion was increased although the increase is statistically insignificant (p=0.09) 
However, since regulatory T cells used for these experiments were isolated from 1 MS 
column, it is possible that these cells were contaminated with high frequency of responder T 
cells and monocytes. In conclusion, 4 days of BiP treatment of regulatory T cells may 
enhance Foxp3 expression and induce TGF-β secretion. 
The main question now is whether these changes induced by BiP on regulatory T 
cells are translated to enhanced suppression of regulatory T cells on responder T cells. 
However, these changes do not modulate the ability of regulatory T cells to further enhance 
their suppression of responder T cells or cytokine levels in the co-culture (shown in Figure 
4.32). This can be partly explained by the fact that in vitro suppression assays do not require 
TGF-β to suppress responder T cells. Conflicting evidence has been reported in the 
literature. Oberle et al (2007) and Annunziato et al (2002) demonstrated that TGF-β plays a 
partial role in the suppression of human regulatory T cells towards responder T cells, by 
using blocking antibodies. In contrast, Jonuleit et al (2001) and Dieckmann et al (2001) 
argued otherwise using the same strategy. An elegant experiment was performed by 
Ferraro et al (2014) showing the correlation between expression of different genes 
associated with human regulatory T cells and the ability of regulatory T cells to suppress 
proliferation of responder T cells. The only gene that highly correlates with suppressive 
capacity of regulatory T cells is T cell immunoglobulin and ITIM domain (TIGIT), a surface 
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protein expressed on memory, activated and regulatory T cells, but not the TGF-β gene. In 
addition, it is possible that TGF-β secretion of regulatory T cells may enhance the 
suppressive capacity of regulatory T cells on the proliferation of responder T cells in the 
presence of dendritic cells or monocytes in the co-cultures because the co-culture here was 
performed in the presence of anti-CD3/CD28 beads only.  
A small increase in Foxp3 expression and TGF-β secretion by regulatory T cells 
induced by BiP did not lead to better suppressive capacity of regulatory T cells on responder 
T cells. However, TGF-β is a cytokine with pleiotropic effect: it can induce various biological 
effects on other immune cells. It is well established that TGF-β is an important cytokine in 
inducing the development of regulatory T cells. Zheng et al (2002), Fantini et al (2004) and 
Wang et al (2009) demonstrated the role played by TGF-β in inducing regulatory T cell 
development. Zheng et al (2002) demonstrated that TGF-β and a low-dose antigen can 
induce human CD4+CD25- to become Th3 suppressor cells, an induced regulatory T cell 
characterised by the presence of Foxp3, and they can secrete TGF-β while Wang et al (2009) 
showed that TGF-β and retinoic acid can convert naïve human CD4+ T cells into Foxp3+ 
regulatory T cells with stable Foxp3 expression and potent suppressive capability. 
Furthermore, TGF-β can induce the upregulation of CD73 molecule on murine CD4+ T cells 
as demonstrated by Regateiro et al (2011). CD73 is an important ectoenzyme that will 
catalyse the conversion of adenosine monophosphate (AMP) into adenosine, which in turn 
will help to suppress CD4+ T cell proliferation. In addition, TGF-β can exert an 
immunosuppressive effect on monocytes, B cells and dendritic cells. Musso et al (1990) 
reported that TGF-β can downregulate IL-1 secretion from human monocytes induced by IL-
6. TGF-β can modulate human B cell function by directing the immunoglobulin (Ig) A 
switching process as demonstrated by van Vlasselaer and co-workers (1992). Furthermore, 
Pallotta and colleagues (2011) indicates that TGF-β treatment on murine plasmacytoid 
dendritic cells (pDC) can induce an increased expression of IDO, an immunomodulatory 
enzyme important in suppressing responder T cell proliferation. Most importantly, Esquerre 
and colleagues (2008) showed that human regulatory T cells can inhibit the polarisation of T 
helper cells toward APCs via a TGF-β dependent mechanism. TGF-β secreted from 
regulatory T cells interfered with the polarisation of the T helper secretory machinery 
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toward APC thus affecting antigen delivery from APC to T helper cells so no polarisation of T 
helper cell takes place.  
BiP-induced changes to regulatory T cells pose another question about how BiP may 
signal to mediate these effects. Corrigall et al (2003) reported that BiP has a specific 
receptor that is expressed by more than 95% in human monocytes, up to 50% in B cells and 
10% in T cells. However, the identity of this receptor remains elusive. Therefore, we can only 
speculate about the signalling pathways involved in mediating a small increase in Foxp3 
expression and TGF-β secretion upon BiP ligation with this unknown receptor on regulatory 
T cells. There are several key signalling pathways that might be involved in the upregulation 
of Foxp3, namely: TCR signalling pathway, PI3-Akt-mammalian target of rapamycin (mTOR) 
pathway, NF-kB-CRel pathway or IL-2-signal transduction and transcription 5 (STAT5) axis. 
These pathways were listed by Yuan and Malek (2012) as key signalling pathways involved in 
the development of regulatory T cells. However, STAT5 is probably the most important 
adaptor molecule involved in the upregulation of Foxp3 as indicated by Yuan and Malek 
(2012) because of its location. STAT5 can bind to the Foxp3 promoter and at the same time 
it can also bind to the enhancer region (CNS2) of Foxp3 gene to stabilise Foxp3 expression in 
regulatory T cells. Most importantly, the pivotal role played by STAT5 can be demonstrated 
through an animal model. Burchill et al (2007) showed that STAT5 deletion in T cells can 
prevent regulatory T cell development in mice and they demonstrated STAT5 binding to 
Foxp3 promoter promotes regulatory T cell development.  
Another effect of BiP on regulatory T cells is an increase of TGF-β secretion although 
the increase is statistically insignificant. The signalling pathways involving TGF-β signalling 
via its receptor has been the focus of most of the research in TGF-β downstream signalling. 
Using Jurkat cells to study TGF-β regulation in response to apoptotic cells, Xiao et al (2008) 
demonstrated the involvement of p38 MAPK, ERK and JNK in TGF-β transcription, whereas 
translation required activation of Rho GTPase, PI3K, Akt, and mTOR. One of the most 
important findings drawn from their work was that the induction of TGF-β in response to 
apoptotic cells used different induction pathways compared to cells stimulated with either 
phorbol myristate (PMA) or LPS. To add to the complexity of TGF-β induction, Furler and 
Uittenbogaart (2012) reported that the transcription factor GLI2 is important in regulating 
TGF-β expression in human CD4+ T cells. They proposed that GLI2 can bind to TGF-β 
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promoter and the knockdown of GLI2 in human regulatory T cells significantly decreased 
TGF-β transcription. Therefore, further investigation into the signalling pathways involved in 
increased Foxp3 expression and increased TGF-β will be conducted in the future to confirm 
the effect of BiP pre-treatment on regulatory T cells. In conclusion, BiP may induce 
immunoregulatory phenotypes in regulatory T cells after 4 days of treatment. 
These results may add further support to the hypothesis proposed by Shields et al 
(2012), suggesting BiP as a member of resolution associated molecular patterns (RAMP). 
RAMPs are defined as ‘highly evolutionarily conserved, multi-functional, constitutively 
expressed proteins whose immunoregulatory activity is dependent upon their rapid 
decompartmentalization from the intracellular environment either actively, following cell 
stress, or passively, via necrotic cell death’ (Shields et al, 2012). It is suggested that RAMP is 
involved in the resolution stage, the final stage of immunological response; therefore BiP 
may be considered a RAMP by further potentiating an immunregulatory phenotype in 
regulatory T cells.  Another interesting observation from this chapter is that BiP can directly 
reduce responder T cell proliferation in the presence of co-stimulation or indirectly via BiP 
treated monocytes but does not affect the cytokine profile of these cells. This raises another 
important question about what changes BiP makes to these cells to cause them to reduce 
their proliferative capacity compared to responder T cells cultured with media alone. This 
question will be addressed and investigated in the next chapter. 
4.5 Conclusion 
The conclusions of this chapter are as follows:- 
 Two hours of BiP pre-treatment does not enhance regulatory T cell phenotype or 
function either in the presence of anti-CD3 antibody, anti-CD3/CD28 beads or 
monocytes 
 Four days of BiP pre-treatment may increase Foxp3 expression and TGF-β secretion 
from regulatory T cells although the differences are statistically insignificant but does 
not enhance the suppressive capacity of regulatory T cells 
 BiP can indirectly reduce responder T cell proliferation via BiP treated monocytes  
 BiP can reduce responder T cell proliferation in the presence of anti-CD3/CD28 beads 


















5 The effect of soluble BiP on responder T cell phenotype and function 
5.1 Introduction 
Soluble BiP may modulate regulatory T cell phenotype by an increase in Foxp3 
expression and TGF-β secretion in the previous chapter. However, at least in in vitro 
suppression assay these changes did not appear to enhance their regulatory activity. In 
addition, responder T cells cultured with BiP for 4 days in the presence of anti-CD3/CD28 
beads reduced their proliferation compared to responder T cells cultured without BiP. The 
effect of BiP on responder T cells was observed in cone blood. Since responder T cells can be 
easily isolated in large numbers, these experiments were repeated using responder T cells 
from fresh blood.  
The aim of this chapter is to determine how soluble BiP can affect responder T cell 
function by reducing proliferation in the presence of TCR stimulation and co-stimulation in 
the form of anti-CD3/CD28 beads. Although proliferation was reduced, there was no change 
observed with the cytokine profile (IFN-γ, TNF-α and IL-10) from supernatants of the 
cultures. One plausible explanation of this observation is that BiP can induce regulatory T 
cell development within responder T cells thus reducing the proliferation of the remaining 
responder T cells. Induction of regulatory T cells from responder T cells indirectly by BiP was 
reported by Corrigall and colleagues (2009) via monocyte-derived dendritic cells. They 
observed that human monocyte-derived dendritic cells cultured with BiP can induce 
regulatory T cell development, which is characterised by an increase in the frequency of 
CTLA-4 positive cells but no change was observed in the frequency of Foxp3 positive cells. 
These induced regulatory T cells can suppress proliferation of autologous responder T cells. 
This work implies that BiP may induce TR1 regulatory T cells, which are characterised by the 
absence of Foxp3 but secrete IL-10. In addition, immunisation of mice with BiP has been 
shown to induce regulatory T cell development. Brownlie and colleagues (2006) 
demonstrated that BiP can induce IL-4 and IL-10 secreting regulatory T cells when mice were 
immunised with BiP while Foo (2011) reported that BiP can induce antigen-specific 
regulatory T cells. These cells have the ability to suppress the recall response of type II 
collagen (CII)-reactive cells in in vitro suppression assays. These CD4+CD25+Foxp3-PD-1+ 
cells can secrete IL-10, TGF-β and soluble CTLA-4, a novel splice variant of CTLA-4.  
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Furthermore, HSP60 has been shown to convert human CD4+CD25- responder T cells into 
CD4+CD25+Foxp3+ regulatory T cells (de Kleer et al, 2010). A study by van Herwijnen and 
co-workers (2012) showed that the HSP70 epitope can induce CD4+CD25+Foxp3+ which can 
suppress proteoglycan-induced arthritis in mice. 
5.2 Objectives 
The objectives of this chapter are therefore as follows:- 
 To confirm the effect of BiP in reducing responder T cell proliferation using cells from 
fresh blood rather than cone blood 
 To examine the potency of BiP on responder T cell proliferation by titrating of BiP 
effect on responder T cell proliferation 
 To examine the effects of BiP on responder T cell phenotype 
 To investigate whether any phenotypic change after BiP treatment can lead to a 
















5.3.1 BiP can reduce responder T cell proliferation in a dose dependent manner  
As previously shown in Figure 4.18(B) and confirmed here in Figure 5.1, responder T 
cells isolated from cone bloods can reduce their proliferation in the presence of anti-
CD3/CD28 beads with 10 ng/ml of BiP in culture. Responder T cells can be easily isolated 
with a high yield from fresh blood; therefore a dose-titration of BiP was performed on 
responder T cells isolated from fresh blood. Figure 5.2(A) shows that responder T cell 
proliferation was reduced in a dose-dependent manner when cultured with BiP in the 
presence of anti-CD3/CD28 as indicated by the mean proliferation in 6 donors even though 
a significant difference was observed only when comparing 0 and 0.001 ng/ml (p=0.03) and 
0.1 ng/ml (p=0.03). Furthermore, responder T cells cultured with BiP did not induce any 
changes to the cytokines measured from the culture as demonstrated in Figure 5.2 (B-D). 
IFN-γ (B) and IL-10 (D) levels from responder T cells cultured with BiP were quite constant 
among multiple donors while there is a huge variability of TNF-α levels (C) reported from 
multiple donors.  
5.3.2 Cell death does not account for the reduced proliferation induced by BiP 
To confirm that BiP can suppress responder T cell proliferation and this was not due 
to cell death, propidium iodide staining was performed. As illustrated in Figure 5.3, 
responder T cells cultured with BiP (Panel A) had a slightly lower percentage of dead cells 
(3.53%) compared to responder T cells cultured without BiP (5.24%) (Panel B). However, the 
mean percentage of dead cells between responder T cells cultured with BiP (12.8%) was 
slightly higher than responder T cells without BiP (11%) and the difference is not statistically 
significant (p=0.125, n=5) as shown in Panel C. 
5.3.3 BiP can increase the frequency of Foxp3+ cells but not CTLA-4+ cells within unstimulated 
responder T cell populations 
 Corrigall et al (2009) demonstrated that BiP can induce the development of induced 
regulatory T cells characterised by the presence of CTLA-4 and CD27 molecules. These 
regulatory T cells were induced by BiP-treated dendritic cells derived from monocytes. BiP 
can directly reduce responder T cell proliferation; therefore it can be hypothesised that BiP 
may induce a proportion of responder T cells to become regulatory T cells. Therefore, 
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intracellular staining of CTLA-4 and Foxp3 was performed on responder T cells cultured in 
the presence of anti-CD3/CD28 beads with or without BiP. To confirm that the antibody 
staining is working, a comparison was performed between antibody staining and isotype 
control. Figure 4.27(I) shows that anti-Foxp3 antibody was working compared to isotype 
control. Therefore, a comparison between anti-CTLA-4 antibody and isotype control was 
performed shown in Figure 5.4. Freshly isolated responder T cells stained with anti-CTLA-4 
antibody staining (orange line) overlaps with unstained sample (red line). However, isotype 
staining control (blue line) shows a shift to the right indicating that isotype control cannot 
be used to control for anti-CTLA-4 antibody staining. To control for anti-CTLA-4 staining, 
another strategy can be used. Fluorescence Minus One (FMO) contains all the flurochromes 
in a panel, except for the one that is being measured. In this co-stain experiment, anti-CTLA-
4 staining was controlled by comparing co-stain of both anti-CTLA-4 and Foxp3 antibodies 
with anti-Foxp3 antibody alone so that CTLA-4 gating can be performed.    
 Figure 5.5 illustrates the frequency of Foxp3+ and CTLA-4+ cells within responder T 
cells cultured in the presence of anti-CD3/CD28 beads. Data from one donor show that 
responder T cells cultured with BiP decreased Foxp3+ frequency (5.7%, Panel C) compared 
to responder T cells cultured without BiP (7.23%, Panel A). However, responder T cells 
cultured with BiP increase CTLA-4+ frequency from 21.7% (Panel B) to 24.4% (Panel D). To 
confirm that antibody staining is working, a comparison between antibody staining and 
appropriate control was performed. As shown in Panel (E-F), anti-Foxp3 and CTLA-4 
antibodies stained stimulated responder T cells (red line) compared to appropriate controls 
(blue line). However, the mean frequency of Foxp3+ and CTLA-4+ cells within stimulated 
responder T cells with BiP did not induce significant changes compared to responder T cells 
cultured without BiP. As shown in Panel (G-H), responder T cells cultured with BiP had 9.02% 
of Foxp3+ and 28.2% of CTLA-4+ cells compared to 11.02% of Foxp3+ and 25.8% of CTLA-4+ 
cells within stimulated responder T cells (Foxp3: p=0.07, n=7) (CTLA-4: p=0.2188, n=7).  
Human responder T cells can transiently express Foxp3 (Allan et al, 2007, Wang et al, 
2007, and McMurchy et al, 2013) and CTLA-4 (Tran et al, 2007) after activation. Therefore, 
the intracellular staining of Foxp3 and CTLA-4 was performed on responder T cells cultured 
in the absence of anti-CD3/CD28 beads with or without BiP. To control for Foxp3 and CTLA-4 
staining, comparison between Foxp3 and CTLA-4 antibody staining was performed against 
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appropriate controls as shown in Figure 5.6. Data were acquired and gated on lymphocyte 
gate (Panel A&D) then further sub-gated based on Foxp3 expression (Panel B&E) and CTLA-4 
expression (C&F). Responder T cells had more Foxp3+ cells with antibody staining (Panel B) 
compared to isotype control (Panel E) (2.26% versus 0.34%) while anti-CTLA-4 antibody 
staining (Panel C) stained more compared to FMO control (Panel F) (1.04% versus 0.20%). 
These data confirmed that both antibody stains are working. Using similar gating strategy as 
Figure 5.6, data as shown in Figure 5.7 was acquired and gated on lymphocyte gate (Panel 
A&D) and further sub gated on Foxp3 expression (Panel B&E) and CTLA-4 expression (Panel 
C&F). Foxp3 expression increased when responder T cells were cultured with BiP (2.27%, 
Panel E) compared to responder T cells cultured without BiP (0.41%, Panel B). Similarly, 
CTLA-4 expression increased as measured by the CTLA-4 frequency from 0.44% (Panel C) to 
1.06% (Panel F) when cultured with BiP. However, cumulative data from multiple donors 
suggest that responder T cells cultured with BiP can increase Foxp3+ cells (Panel G) (0.92% 
versus 2.21%, p=0.0078, n=8) but not CTLA-4+ cells (Panel H) (3.08% versus 3.41%,p=0.3125, 
n=8) which suggests a novel effect of BiP on responder T cells.     
5.3.4 BiP can increase the frequency of Foxp3+CD25+ cells and induce IL-10 secretion within 
unstimulated responder T cells  
 An increase of Foxp3+ cells in responder T cells cultured with BiP may suggest that 
BiP can convert responder T cells to become induced regulatory T cells. One of the most 
important markers used to identify regulatory T cells is the CD25 molecule. CD25 is an alpha 
chain of IL-2 receptor and it is constitutively expressed on regulatory T cells. Therefore, to 
confirm that BiP can induce regulatory T cell development from responder T cells, surface 
staining of CD25 and intracellular staining of Foxp3 were performed. However, as shown in 
Figure 4.24, BiP treated monocytes can reduce the proliferation of responder T cells after 2 
days in culture. Therefore, a kinetic experiment was performed to determine the effect of 
BiP on inducing Foxp3+CD25+ cells within responder T cells at 3 different time points; Day 2, 
4 and 6. 
 Before the kinetic experiment was performed, it was vital to see how long responder 
T cells can be cultured in media alone. Figure 5.8 illustrates that the percentage of dead cells 
in culture as indicated by the percentage of propidium iodide positive cells. Panel (A-C) 
show responder T cell culture without BiP at Day 2, 4 and 6 while responder T cells cultured 
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with BiP were shown in Panel (D-F). Data from Day 2 and 4 showed responder T cells 
cultured with BiP had slightly lower percentages of dead cells compared to responder T cells 
cultured without BiP (Day 2; 2.84% versus 3.33%, Day 4; 4.33% versus 5.01%). However, 
responder T cells cultured with BiP for 6 days had slightly higher percentages of dead cells 
compared to responder T cells cultured without BiP (8.41% versus 8.08%). This trend can be 
observed in the mean percentages of dead cells in multiple donors as shown in Panel G. 
Responder T cells cultured with BiP had lower propidium iodide+ cells at Day 2, 4 and 6 
compared to responder T cells cultured without BiP (Day 2; 2.99% versus 3.26%, Day 4; 
4.23% versus 5.04%, Day 6; 9.87% versus 10.07%). In addition, the data indicate a two fold 
increase of dead cells after 6 days (10%) in culture compared to 4 days (5%) in culture. After 
that, a co-stain of anti-Foxp3 and anti-CD25 antibody was performed on responder T cells. 
To validate the antibody staining, a comparison was performed between anti-Foxp3 
and anti-CD25 antibody staining (Panel A-B) with isotype control (Panel C-D) as shown in 
Figure 5.9. Responder T cells with anti-Foxp3 and CD25 antibody staining showed higher 
frequency of Foxp3+CD25+ (0.736%) compared to isotype control (0.13%). Then, the kinetic 
experiment was performed on responder T cells culture and a co-stain of anti-Foxp3 and 
anti-CD25 staining was performed (Figure 5.10). Responder T cells cultured without BiP 
were shown in Panel (A-C) while panel D-F show responder T cells cultured with BiP. BiP can 
induce an increase in Foxp3+CD25+ population within unstimulated responder T cells at all-
time points (Day 2; 0.639% versus 0.27%, Day 4; 1.56% versus 1.32%, Day 6; 2.21% versus 
1.89%). However, the cumulative data from multiple donors showed significant increase of 
Foxp3+CD25+ in responder T cells cultured with BiP at Day 2 and 4 but not at Day 6 (Panel 
G-J). BiP can induce higher Foxp3+CD25+ frequency (2.4%) within responder T cells 
compared to responder T cells cultured without BiP (1.6%) (p=0.03, n=6). This trend 
continues when responder T cells were cultured for 4 days. Responder T cells cultured with 
BiP had a  significantly higher frequency of Foxp3+CD25+ compared to responder T cells 
cultured without BiP (p=0.03, n=6). However, no difference was observed when comparing 
responder T cells cultured with or without BiP at Day 6 (p=0.6250, n=5). This could be 
explained by the fact that a two fold increase in dead cells after 6 days in culture compared 
to dead cells after 4 days in culture was observed. To support the contention that BiP may 
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convert responder T cells into regulatory T cells, cytokines associated with regulatory T cells 
were measured from the culture supernatants, namely IL-10 and TGF-β. 
 Figure 5.11 demonstrates IL-10 and TGF-β measured from the culture supernatants 
of responder T cells cultured with or without BiP. As previously mentioned, the latent TGF-
β1 isoform was measured in the cultures. Only 1 out of 5 donors produced IL-10 in the 
culture and the concentrations of IL-10 produced were very low (< 10 pg/ml) as shown in 
Panel A. However, IL-10 concentrations from one donor (red dot in Panel A) increased when 
responder T cells cultured with BiP at all-time points were compared to responder T cells 
cultured without BiP (Day 2; 0 pg/ml versus 2 pg/ml, Day 4; 0 pg/ml versus 2 pg/ml, Day 6; 0 
pg/ml versus 7 pg/ml). However, responder T cells cultured with BiP produced lower 
concentrations of TGF-β compared to responder T cells cultured without BiP at Days 2 and 4 
but not Day 6 as demonstrated in Panel B (Day 2; 96 pg/ml versus 117 pg/ml, Day 4; 334 
pg/ml versus 404 pg/ml, Day 6; 182 pg/ml versus 151 pg/ml). Since the effect of BiP on 
responder T cell proliferation was observed at Day 4 and the increase of the frequency of 
Foxp3+CD25+ within responder T cells cultured with BiP peaked at Day 4, the effect of BiP 
on responder T cell phenotype and function was investigated on Day 4. 
 The effect of BiP on responder T cell phenotype was examined after 4 days in culture 
by measuring the frequency of Foxp3+CD25+ cells within responder T cells. As illustrated in 
Figure 5.12, responder T cells cultured with BiP had higher frequency of Foxp3+CD25+ cells 
compared to responder T cells cultured without BiP. One donor demonstrates a 5 fold 
increase in Foxp3+CD25+ cells (0.7% compared with 3.5%, Panel A&C) when cultured with 
BiP while another donor had a slight increase in Foxp3+CD25+ from 4.65% to 5.28% (Panel 
B&D) when responder T cells were cultured with BiP. The mean frequency of Foxp3+CD25+ 
within responder T cells cultured with BiP had significantly higher frequency of 
Foxp3+CD25+ cells compared to responder T cells cultured without BiP (3.69% versus 2.38%, 
p=0.0039, n=9) as shown in Panel E. The increase in Foxp3+CD25+ may affect the function of 
BiP-induced Foxp3+CD25+ cells. IL-10 and TGF-β concentrations were measured from the 
culture supernatants as shown in Figure 5.13. IL-10 secreted from responder T cells cultured 
with BiP was higher than the IL-10 secretion from responder T cells cultured without BiP (2 
pg/ml versus 47 pg/ml, p=0.0039, n=9, Panel A) whereas no significant difference of TGF-β 
was observed between responder T cells cultured with or without BiP (440 pg/ml versus 483 
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pg/ml, p=0.3594, n=9, Panel B). In conclusion, BiP pre-treatment can induce an increase in 
the frequency Foxp3+CD25+ within responder T cells and induce secretion of IL-10 from the 
culture.  
5.3.5 IL-2 induce an increase of Foxp3+CD25+ cells within responder T cells but the combination of BiP 
and IL-2 can increase the frequency of Foxp3+CD25+ and inducing IL-10 secretion within unstimulated 
responder T cells 
 IL-2 is an important survival factor for the development of human induced regulatory 
T cells from responder T cells as reported by Zheng et al (2004). Therefore, to confirm that 
BiP-induced Foxp3+CD25+ cells were regulatory T cells, IL-2 was added to the culture of 
responder T cells. Data from the kinetic experiment demonstrated a two fold increase in 
dead cells in the responder T cell culture at Day 6 (Figure 5.8(G)) and BiP can only increase 
Foxp3+CD25+ cell frequency at Day 2 and 4 but not Day 6 (Figure 5.10). Hence, the role of 
IL-2 in inducing regulatory T cells was investigated by comparing responder T cells cultured 
in the absence or presence of IL-2 with or without BiP for 6 days as shown in Figure 5.14. 
Panel A&C show responder T cells cultured without IL-2 while panel B&D demonstrate 
responder T cells cultured with IL-2. Responder T cells cultured with BiP for 6 days had a 
lower percentage of Foxp3+CD25+ cells (0.60%) compared to responder T cells cultured 
without BiP (0.66%) (Panel A&C). In the presence of IL-2, responder T cells showed an 
increase of Foxp3+CD25+ cells (3.40%) compared to responder T cells cultured without IL-2 
(0.66%) (Panel A&B). Furthermore, the addition of IL-2 to the culture of responder T cells 
with BiP can further increase the frequency of Foxp+CD25+ cells (4.23%) compared to 
responder T cells cultured with IL-2 alone (3.40%). Data from 3 donors showed similar trend 
as shown in Panel E. Responder T cells cultured with BiP had lower frequency of 
Foxp3+CD25+ without IL-2 compared to responder T cells cultured without BiP (0.44% 
versus 0.54%). However, the addition of IL-2 increased the frequency of Foxp3+CD25+ cells 
within responder T cells from 2.16% to 2.61%.  
 The increase of Foxp3+CD25+ cells in responder T cells cultured with BiP at Day 4 
(Figure 5.13(A)) was in parallel with an increase of IL-10 secretion from responder T cells 
cultured with BiP (Figure 5.12(E)). Therefore, IL-10 concentrations were measured from 
responder T cells cultured with or without BiP in the presence or absence of IL-2. The 
cumulative data from 3 donors was demonstrated in Panel F. Responder T cells cultured 
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with or without BiP produced very low levels of IL-10. However, responder T cells cultured 
with BiP in the presence of IL-2 produced 20 fold higher IL-10 in the culture compared to 
responder T cells cultured without BiP in the presence of IL-2 (124 pg/ml versus 5 pg/ml).  
5.3.6 Responder T cells maintained an increased IL-10 secretion profile when cultured with BiP after 
being stimulated with anti-CD3/CD28 beads  
 To confirm the effect of BiP on responder T cells after 4 days in the culture, 
responder T cells were re-stimulated with anti-CD3/CD28 beads and the proliferation of 
these cells and cytokine profile was examined after 3 days as shown in Figure 5.15. The 
mean proliferation of stimulated responder T cells (BiP treatment) showed an increase in 
proliferation compared to stimulated responder T cells cultured (mock treatment) (17896 
CPM versus 15867 CPM) but the difference was not statistically significant (p=0.139, n=10) 
as shown in panel A. The similar trend can be observed with all cytokine measured IFN-γ 
(Panel B), TNF-α (Panel C) and IL-10 (Panel D). IFN-γ and TNF-α secretions from stimulated 
responder T cells (BiP treatment) were higher compared to mock-treated responder T cells 
(IFN-γ: 688 pg/ml versus 361 pg/ml, TNF-α: 243 pg/ml versus 226 pg/ml) but the difference 
was not statistically significant (IFN-γ: p=0.14, n=8, TNF-α: p=0.3, n=10). However, the 
increase in IL-10 secretion in BiP-treated responder T cells (220 pg/ml) compared to mock-
treated responder T cells (180 pg/ml) after re-stimulation with anti-CD3/CD28 beads is 
statistically significant (p=0.0098, n=10).  
5.3.7 BiP-induced Foxp3+CD25+ cells can downregulate TNF-α in the co-culture  
 The investigation of the effect of BiP on responder T cells demonstrated that BiP can 
induce Foxp3+CD25+ cells and IL-10 secretion. These findings further support the 
contention that BiP may convert responder T cells into regulatory T cells. In vitro 
suppression assay is the gold standard used to determine the suppressive capacity of 
induced regulatory T cells. Hence, BiP treated responder T cells were co-cultured with 
autologous responder T cells to determine the ability of BiP-induced Foxp3+CD25+ to 
suppress responder T cells. Figure 5.16 illustrates the in vitro suppression of BiP-treated 
responder T cells (4 day treatment) compared with responder T cells cultured without BiP. 
Co-culture of BiP-treated responder T cells with autologous responder T cells reduced the 
proliferation in the co-culture compared to mock-treated responder T cells as shown in 
Panel A (39560 CPM v 42759 CPM). Similarly, IFN-γ, TNF-α and IL-10 secretions from the co-
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culture of BiP-treated responder with autologous responder T cells were lower compared to 
mock-treated responder T cells (IFN-γ: Panel C, 5827 pg/ml versus 7773 pg/ml) (TNF-α: 
Panel E: 292 pg/ml versus 373 pg/ml) (Panel G: IL-10, 362 pg/ml versus 595 pg/ml).  
The cumulative data followed the same trend as the individual donor. The 
proliferation (Panel B), IFN-γ (Panel D) and IL-10 (Panel H) data from multiple donors 
indicates the variability of response although the mean proliferation, IFN-γ and IL-10 from 
multiple donors from the co-culture of BiP-treated responder T cells with autologous 
responder T cells were lower than mock-treated responder T cells (Proliferation: 16552 CPM 
versus 17580 CPM, IFN-γ: 2306 pg/ml versus 2766 pg/ml, IL-10: 336 pg/ml versus 350 
pg/ml). The variability in the response among donors made the reduction of proliferation, 
IFN-γ and IL-10 secretions induced by BiP treatment in responder T cells were not 
statistically significant (Proliferation: p=0.36, IFN-γ: p=1, IL-10: p=0.58, n=11 for all except 
IFN-γ, n=9). However, a different trend was observed with TNF-α secretion from the co-
culture. TNF-α levels were reduced in 10 of 11 donors in the co-culture of BiP-treated 
responder T cells with autologous responder T cells and the mean TNF-α from BiP-treated 
responder T cells was signifcantly lower compared to mock-treated responder T cells as 


























































 This chapter was based on the finding from the previous chapter as shown in Figure 
4.18(B) where responder T cells stimulated with anti-CD3/CD28 beads in the presence of BiP 
can reduce their proliferation compared to stimulated responder T cells alone. The titration 
of BiP showed that the proliferation of responder T cells stimulated with anti-CD3/CD28 
beads demonstrated a dose-dependent reduction of proliferation as show in Figure 5.2(A). 
However, the variability of response from multiple donors in cytokine secretion profile (IFN-
γ, TNF-α and IL-10, Figure 5.2(B-D)) made the difference between the mean of cytokine 
secretions of 0 ng/ml and various doses (1, 0.1, 0.01 and 0.001 ng/ml) of BiP statistically 
insignificant. These findings may indicate that BiP convert a small percentage of responder T 
cells to become regulatory T cells as Corrigall et al (2009) reported that BiP can induce 
regulatory T cell development via BiP-treated DC. Before further experiment was 
performed, viability staining was performed to determine if BiP may induce cell death in 
responder T cells. Data shown in Figure 5.3 demonstrate that BiP did not induce an increase 
of dead cells as indicated by propidium iodide staining further supporting the hypothesis 
that BiP may induce regulatory T cells. Vercoulen and colleagues (2009) showed that human 
regulatory T cells did not induce cell death in activated responder T cells.   
 Regulatory T cells induced by BiP-treated DC were characterised by the presence of 
CD25 and CD27 on their surface and increased intracellular CTLA-4 expression but not Foxp3 
expression (Corrigall et al, 2009). Therefore a co-stain of intracellular CTLA-4 and Foxp3 was 
performed on responder T cells stimulated with anti-CD3/CD28 beads as shown in Figure 
5.5. Clearly, the frequency of both CTLA-4+ and Foxp3+ cells were not modulated by BiP 
presence in the culture. However, as mentioned before, CTLA-4 and Foxp3 can be expressed 
by responder T cells after activation. Therefore, to see a direct effect of BiP on responder T 
cells, responder T cells were cultured in the absence of anti-CD3/CD28 beads with or 
without BiP as demonstrated in Figure 5.7. BiP presence in the culture significantly 
increased the frequency of Foxp3+ cells within responder T cells, but not CTLA-4+ cells. This 
observation suggest a novel effect of BiP on responder T cells and further strengthen the 
contention that BiP may induce regulatory T cell development.  
 To confirm this observation, a kinetic experiment of BiP effect was performed 
(shown in Figure 5.8-5.11). Human regulatory T cells can be identified by the presence of 
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CD25 and Foxp3 molecules; therefore a co-stain of these two antibodies were performed in 
the kinetic experiment. Figure 5.10 shows that BiP can induce an increase of Foxp3+CD25+ 
cells after 2 and 4 days in the culture but not after 6 days. In addition, percentages of dead 
cells in the culture increased two fold on Day 6 compared to Day 4. Therefore, responder T 
cell culture was repeated for 4 days and the data shown in Figure 5.12 with more donors 
(n=9 compared to n=5 in Figure 5.10) confirmed that BiP can induce an increase of 
Foxp3+CD25+ population within responder T cells. To support the contention that BiP can 
convert human CD4+CD25- cells into regulatory T cells, regulatory T cells-associated 
cytokines IL-10 and TGF-β were measured from the supernatants. IL-10 levels were only 
detected in one donor after BiP treatment in Figure 5.11(A) but data from Figure 5.13(A) 
indicated that responder T cells increased their IL-10 secretion when cultured with BiP. In 
contrast, TGF-β secretions from responder T cells cultured with BiP were approximately 
similar to responder T cells cultured without BiP (Figure 5.13(A)). To confirm BiP effect on 
responder T cells, responder T cells were cultured in the presence of IL-2 for 6 days as IL-2 is 
an important survival factor for regulatory T cells. Data from kinetic experiments (Figure 
5.10(J)) suggest that BiP cannot increase Foxp3+CD25+ cells at Day 6, hence this time point 
was chosen. Figure 5.14 show that IL-2 can increase Foxp3+CD25+ cells within responder T 
cells but not with IL-10 secretion. However, the combination of BiP and IL-2 in the culture 
could act in synergy to increase Foxp3+CD25+ population and simultaneously increase IL-10 
secretion indicating that BiP may act on responder T cells.  
 The function of BiP-induced Foxp3+CD25+ cells were examined to support the 
contention that BiP can induce regulatory T cell development. BiP-treated responder T cells 
were re-stimulated with anti-CD3/CD28 beads and their proliferation and cytokine profiles 
were investigated as illustrated in Figure 5.15. The most important observation from this 
figure is that responder T cells maintained enhanced IL-10 secretion even after re-
stimulation with anti-CD3/CD28 beads in the absence of BiP. This observation recapitulated 
the previous work by shown by Dr. Corrigall’s group. Bodman-Smith et al (2003) showed 
that BiP can induce IL-10 secretion in CD8+ T cells while Corrigall et al (2004) demonstrated 
that human PBMCs cultured with BiP can induce IL-10 secretion and human dendritic cells 
cultured with BiP can induce copious amounts of IL-10 as shown by Corrigall et al (2009).  
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Finally, it is essential to examine whether all these changes to responder T cells can 
lead to enhanced suppressive function in in vitro suppression assay. The data in Figure 
5.16(B) demonstrated that 7 out of 11 donors of BiP-induced Foxp3+CD25+ cells can 
suppress the proliferation of autologous responder T cells but the difference is not 
statistically significant. As shown in Figure 5.12(E), BiP can induce approximately 3.7% 
Foxp3+CD25+ cells within responder T cells compared to 2.3% Foxp3+CD25+ cells within 
responder T cells cultured without BiP. Therefore, the final ratio of Foxp3+CD25+ cells in the 
co-culture of BiP-treated responder T cells with autologous responder T cells is 
approximately 1 to 50. Verma et al (2009) demonstrated that natural or thymus-induced 
regulatory T cells activated with a specific alloantigen can suppress naive CD4+ T cells in the 
ration of 1:32-64. Therefore, it is plausible that the suppressive capacity of BiP-induced 
Foxp3+CD25+ was masked by the high ratio of Foxp3+CD25+ cells to responder T cells 
(CD4+CD25-Foxp3-) in the co-culture.  
Although no significant effect was observed on proliferation and other cytokine 
profile (IFN-γ and IL-10, Figure 5.16(D&H)), an effect can be observed in TNF-α levels 
measured from the co-culture. BiP-induced Foxp3+CD25+ cells can downregulate TNF-α 
secretion from non-treated responder T cells (Figure 5.16(F)). The downregulation of TNF-α 
from the co-culture by BiP-induced Foxp3+CD25+ cells may be related with enhanced IL-10 
secretion. This relationship was observed by Corrigall et al (2004) in which they showed that 
BiP can induce an increase in IL-10 and reduction in TNF-α concentrations measured from 
PBMC culture. Reciprocal evidence further supports the contention that IL-10 can regulate 
TNF-α level. Evans and colleagues (2014) demonstrated that culturing human CD4+ T cells 
with various TNF-α inhibitors can induce an increase in the frequency of IL-10+ cells within 
CD4+ T cells. To further confirm this effect, utilising the neutralising antibody against IL-10 
should be used in the co-culture to confirm that the downregulation of TNF-α from 
responder T cells is due to enhanced IL-10 secretion.       
 This chapter demonstrates that BiP can induce an increase in Foxp3+CD25+ cells and 
IL-10 secretion within responder T cells. This may lend support to the hypothesis that BiP 
can induce the development of regulatory T cells characterised by the presence of Foxp3 
and CD25 molecules. In addition, BiP-induced Foxp3+CD25+ cells showed specificity in 
cytokine secretion by secreting more IL-10 instead of TGF-β. By comparison, regulatory T 
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cells cultured with BiP for 4 days showed an increased in Foxp3 protein expression but 
secreted more TGF-β instead of IL-10 as demonstrated in the previous chapter. However, 
BiP-induced Foxp3+CD25+ cells failed to suppress the proliferation of the autologous 
responder T cells in the co-culture. Tran and co-workers (2007) argued that Foxp3 induction 
in human CD4+CD25- in the presence of TCR stimulation and TGF-β does not confer a 
regulatory phenotype and thus failed to suppress the proliferation of responder T cells. In 
contrast, Zheng and colleagues (2004) demonstrated that human CD4+CD25- cells can be 
induced to become CD4+CD25+ cells with regulatory phenotype and these regulatory cells 
can suppress using cell-to-cell contact and TGF-β and IL-10. However, these two papers 
demonstrated that Foxp3 can be induced in CD4+CD25- cells in the presence of TCR 
stimulation and cytokines namely IL-2 or TGF-β. 
 The results demonstrated that BiP may induce Foxp3+CD25+ regulatory T cells; 
therefore it is appropriate to compare the result with HSP-induced regulatory T cells. de 
Kleer et al (2010) showed that HSP60, an example of HSP, can induce Foxp3+ regulatory T 
cells after 6 days of responder T cell culture with HSP60 in the presence of monocytes. In 
addition, Aalberse and colleagues (2011) demonstrated that HSP60-induced Foxp3+ T cells 
from human cord blood can suppress effector T cell response in vitro. Furthermore, van 
Herwijnen and co-workers (2012) demonstrated that Foxp3+ regulatory T cells can be 
induced by HSP70 (a member of HSP70 family) immunisation in mice. Therefore, it is 
possible that BiP can induce Foxp3+ regulatory T cell development as reported with other 
HSPs.  
 The inability of BiP-induced Foxp3+CD25+ cells to suppress responder T cells may 
due to technical problem. To overcome this problem, BiP-induced Foxp3+CD25+ cells must 
be sorted before being co-cultured with autologous responder T cells with lower ratio. 
However, another marker has to be used to identify BiP-induced Foxp3+CD25+ cells as 
Foxp3 is an intracellular protein which cannot be used as a marker to sort this population. 
de Kleer et al (2010) indicated that CD30 molecules present on the surface of HSP60-
induced regulatory T cells could be used as an additional marker to sort HSP60-induced 
regulatory T cells before suppression assays were performed. In addition, van Herwijnen 
and co-workers (2012) demonstrated that HSP70-induced regulatory T cells in mice can be 
identified by the presence of Lymphocyte Activation Gene 3 (LAG3) molecules on their 
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surface, one of the surface molecules associated with the regulatory T cell mechanism of 
suppression. Therefore, it is crucial to identify another surface marker that can be used to 
sort BiP-induced Foxp3+CD25+ cells before these cells can be co-cultured with autologous 
responder T cells.    
 This chapter demonstrates BiP can induce Foxp3+CD25+ cells within responder T 
cells while the previous chapter shows that BiP may enhance Foxp3 expression in regulatory 
T cells. The similarity of BiP effects on responder and regulatory T cells can be seen on 
enhanced Foxp3 expression. As discussed in the previous chapter, BiP may bind to a 
receptor and mediate signalling via the STAT5 molecule as the downstream target of STAT5 
is the Foxp3 protein. In addition to comparing the suppressive capacity of BiP-treated 
responder T cells and mock-treated responder T cells, Foxp3 localisation can be examined to 
determine whether BiP-induced Foxp3+CD25+ cells were truly regulatory T cells as Foxp3 
protein measured using flow cytometry cannot determine the exact location of this protein. 
Magg et al (2012) reported that human CD4+CD25- T cells can express Foxp3 upon 
activation. However, they compared the localisation of Foxp3 protein between human 
CD4+CD25- after activation and CD4+CD25+ regulatory T cells and found that Foxp3 was 
localised in the cytoplasm in activated CD4+CD25- T cells while the Foxp3 protein in 
regulatory T cells was localised in the nucleus. The localisation of Foxp3 can help to reveal 
whether Fopx3 induction in BiP-treated responder T cells may convert responder T cells to 
regulatory T cells. 
 However, the obvious effect of BiP on responder T cells can be seen in the induction 
IL-10 secretion in the culture (Figure 5.13) and after re-stimulation with anti-CD3/CD28 
beads in the absence of BiP (Figure 5.15). The signalling pathway involved in IL-10 secretion 
in responder T cells can be demonstrated in the previous studies. Corrigall et al (2004) and 
Corrigall et al (2009) both showed that IL-10 secretion by PBMC and dendritic cells can be 
partially blocked using neutralising antibodies towards p38 MAPK. P38 MAPK is composed 
of 4 subunits; α, β, γ and δ and can be activated by activated by a variety of environmental 
stresses and inflammatory cytokines. Ng and colleagues (2013) showed in their review 
showed that IL-10 expression can be induced by various STAT molecules including STAT1, 3, 
4 and 6. Zhang et al (2004) showed that p38 MAPK is the upstream molecule involved in 
STAT1 phosphorylation and STAT1 phosphorylation was blocked in p38 MAPK mutant cells. 
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However, blocking p38 MAPK was effective in partial blockade of IL-10 secretion by BiP as 
shown by Corrigall et al (2004) and Corrigall et al (2009). Therefore, it is possible that IL-10 
induction in responder T cells utilises another signalling pathway involving one of the STAT 
molecules. The most likely pathway utilised by BiP to induce IL-10 secretion is via STAT3 
phosphorylation. Hossain and co-workers (2013) demonstrated that Foxp3 can act as a co-
transcription factor with STAT3 for IL-10 transcription in tumour-induced regulatory T cells. 
In addition, regulatory T cells derived from breast cancer patients can secrete IL-10. Taking 
these results together, BiP may induce IL-10 secretion by signalling through STAT1 and 
STAT3.  
 IL-10 secretion in BiP-induced Foxp3+CD25+ cells may further add support to the 
contention that BiP can convert responder T cells to regulatory T cells by a new pathway. 
Firstly, BiP can indirectly convert responder T cells to CD4+CD25+CD27+ regulatory T cells 
via dendritic cells derived monocytes cultured with BiP (Corrigall et al, 2009). In addition, an 
increase of TGF-β secretion by regulatory T cells cultured with BiP may indirectly convert 
responder T cells to regulatory T cells in the presence of BiP as Zheng et al (2002) showed 
that TGF-β and a low-dose antigen can induce human CD4+CD25- to become Th3 suppressor 
cells, an induced regulatory T cell characterised by the presence of Foxp3, and they can 
secrete TGF-β. Lastly, BiP may directly induce regulatory T cell development with or without 
IL-2 and these cells are characterised by the presence of Foxp3 protein and can secrete IL-10 
as demonstrated in this chapter. 
5.5 Conclusion 
The conclusions of this chapter are as follows:- 
 BiP can reduce proliferation of responder T cells stimulated with anti-CD3/CD28 
beads in a dose-dependent manner after 4 days in culture 
 BiP can induce Foxp3+CD25+ cells within a responder T cell population and induce IL-
10 secretion 
 BiP-induced Foxp3+CD25+ cells can downregulate TNF-α secretion from autologous 
















6.1 Soluble BiP is biologically active and its activity is not due to LPS contamination   
Soluble BiP may modulate regulatory T cells and can affect responder T cells in the 
previous chapters. Regulatory T cells cultured with BiP may enhance Foxp3 expression and 
induce TGF-β secretion. Furthermore, BiP can induce Foxp3+CD25+ cells within responder T 
cells and induce IL-10 secretion. These BiP-induced Foxp3+CD25+ cells may reduce TNF-α 
secretion from autologous responder T cells. However, this BiP effect was prominent in 
cytokine secretion in terms of IL-10 secretion compared to induction of Foxp3+CD25+ cells 
within responder T cells. BiP induced 30% more TGF-β in BiP-treated regulatory T cells 
compared to mock-treated regulatory T cells (Figure 4.31 (B)) while responder T cells 
cultured with BiP produced 25 times more IL-10 compared to responder T cells cultured 
without BiP (Figure 5.13 (A)).  In contrast, regulatory T cells cultured with BiP showed a 11% 
increase in Foxp3 expression although the increase is statistically insignificant (p=0.06) as 
measured by MFI (Figure 4.30(I)) compared to regulatory T cells cultured without BiP 
whereas BiP induces 50% more Foxp3+CD25+ cells when responder T cells were cultured 
with BiP compared to responder T cells cultured without BiP. This observation leads to the 
question of whether other factors can further influence BiP activity. 
 Posttranslational modification to BiP may be essential for BiP to exert its 
immunoregulatory properties. One of the ways to detect the presence of posttranslational 
modification to protein to is search for autoantibodies towards modified BiP. In addition to 
detecting anti-BiP antibody in RA patients, Shoda et al (2011) reported the presence of anti-
citrullinated BiP antibodies. Citrullination is a posttranslational modification to a protein 
where arginine residue is converted to non-coding amino acid citrulline. In the same study, 
higher levels of anti-citrullinated antibodies were detected in RA patients compared to anti-
BiP antibody. Lu et al (2010) demonstrated the pathogenicity of anti-citrullinated antibodies 
by binding to citrullinated BiP on the surface of monocytes to stimulate TNF-α secretion. In 
addition, Shoda et al (2011) showed that immunisation of citrullinated BiP in mice 
exacerbated arthritis in the CIA model emphasising the pro-inflammatory role of 
citrullinated BiP in RA development. This is clearly in contrast to the observation made in 
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the experiment where BiP can induce immunoregulatory phenotypes in regulatory and 
responder T cells.   
 The BiP protein used in the experiment was a protein prepared using Good 
Manufacturing Practice (GMP) protocol. GMP BiP was produced to ensure no contamination 
of endotoxin in the protein preparation. Therefore, the BiP effect on regulatory and 
responder T cells was not due to any endotoxin including LPS contamination. One of the 
problems in HSP or stress protein research is endotoxin contamination, especially LPS. 
Lewkowicz and colleagues (2006) examined the effect of LPS on human regulatory T cells. 
Regulatory T cells cultured with 0.1 up to 1000 ng/ml of LPS demonstrated a reduction in 
Foxp3 expression as measured by Foxp3 MFI and this effect was not dose-dependent. This is 
in contrast with the BiP effect observed on regulatory T cells where BiP can increase Foxp3 
expression when regulatory T cells were cultured with BiP.  
 To further confirm soluble BiP protein is biologically active, it is important to 
compare the BiP effect with unrelated proteins. The previous work done by our 
collaborator, Dr. Corrigall, demonstrated that the BiP effect is specific, and not simply due to 
protein structure. Previous works published by Corrigall et al (2001 and 2004) and Bodman-
Smith et al (2003) compared the effect of BiP on various immune cells with β-galactosidase, 
an unrelated protein. The comparison was made because BiP and β-galactosidase were 
produced and raised in the similar organism, Escherichia coli. In addition, Brownlie (2004) 
demonstrated that FiTC-labeled BiP can bind to various immune cells including monocytes, 
B cells, and T cells compared to FiTC-labeled Human Serum Albumin (HSA). She showed that 
BiP can bind up to 58% of monocytes, 14% of B cells and 4.7% of T cells confirming that BiP 
binding to its receptor was specific compared to HSA.   
6.2 Soluble BiP exerts its biological effect on regulatory and responder T cells by binding 
to a receptor   
 This observation brings us to the question of the identity of BiP receptor as Corrigall 
et al (2003) reported that the identity of the BiP receptor remains elusive. A literature 
search was performed to find any report of BiP receptors. Yang et al (2013) reported the 
interaction between BiP and other family members of HSP70 namely HSc70 and GRP75 and 
mannose receptor (MR), a member of C-type lectin receptor which is a pattern recognition 
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receptor. They showed MR binding with BiP in HeLa cells using co-immunoprecipitation 
technique. After searching the identity of the peptide sequence that binds to MR using 
proteomics and mass spectrometry, they confirmed the interaction between MR and BiP by 
Western blot analysis, ligand binding analysis and intracellular colocalisation using confocal 
microscopes. However, Geijtenbeek and Gringhuis (2009) reported that this receptor is only 
present in myeloid dendritic cells and macrophages and binds to high mannose, fucose and 
sulphated sugars. Based on this information, BiP certainly does not bind on MR as MR 
expression is limited to dendritic cells and macrophages and BiP is a protein whereas sugar 
is part of a carbohydrate. Therefore, it is highly unlikely BiP binds to MR to exert its effect on 
regulatory and responder T cells. 
 Recently the identity of the BiP receptor was revealed by our collaborator, Dr. 
Corrigall. BiP can bind to epidermal growth factor receptor (EGFR) before it can induce 
downstream signalling to mediate any effect. However, since this information is bound to 
intellectual property, we can only speculate whether EGFR can act as a BiP receptor by 
linking the effect of BiP on regulatory and responder T cells (cytokine secretion and Foxp3 
expression) with the possible transcription factor involved in mediating these effects. 
However, the distribution of EGFR expression on regulatory and responder T cells was first 
examined based on the current literature. As shown in Figure 4.24 (A), 2 hours of BiP pre-
treatment on monocytes can reduce the proliferation of responder T cells while it took 4 
days for BiP to exert its effect on regulatory T cells demonstrated by a small increase in 
Foxp3 expression (Figure 4.30 (I)) and TGF-β secretion (Figure 4.31) and responder T cells as 
illustrated by an increase in the frequency of Foxp3+CD25+ cells (Figure 5.12) and enhanced 
IL-10 secretion (Figure 5.13). Given the time difference taken by BiP on monocytes and 
regulatory and responder T cells, it is certainly related to the distribution of BiP receptors as 
earlier report (Corrigall et al (2003)) indicated that the BiP receptor is highly expressed in 
monocytes compared to T cells. Chan and co-workers (2009) demonstrated that EGFR 
protein is highly expressed on human CD14+ monocytes as it can be detected using flow 
cytometry compared to its very low expression in CD3+ T cells. However, Zaiss et al (2013) 
reported that the RNA of EGFR can be detected on both human regulatory and responder T 
cells compared to protein level as demonstrated by Chan et al (2009). Interestingly, EGFR 
RNA is expressed 5 times more in human regulatory T cells compared to responder T cells 
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and the expression of the receptor was increased in murine regulatory T under 
inflammatory conditions. This supports the contention that this BiP receptor, namely EGFR, 
is highly expressed on monocytes compared to regulatory or responder T cells. 
To further confirm that EGFR is a BiP receptor, the downstream signalling of EGFR 
was examined based on current literature. Then, the possible downstream signalling 
pathway utilised by EGFR was compared with our putative transcription factor involved in 
mediating the BiP effect as stated in the previous paragraph. The common effect of BiP on 
regulatory and responder T cells is inducing Foxp3 expression. As discussed in previous 
chapters, STAT5 is an important transcription factor involved in Foxp3 induction. Nakamura 
et al (1996) showed that EGFR signalling can induce phosphorylation in STAT5 and transduce 
a growth signal in haematopoietic cells. In addition, Beier and co-workers (2012) used EGFR 
expression as readout of STAT5 signalling in murine regulatory T cells. However, BiP induces 
a specific effect on regulatory and responder T cells in term of cytokine secretions. 
Regulatory T cells cultured with BiP may induce higher TGF-β while higher IL-10 secretion 
was induced in responder T cells cultured with BiP compared to responder T cells cultured 
without BiP. We speculated that BiP may induce secretion of TGF-β by signalling via p38 
MAPK kinase and GLI2 whereas signalling via STAT1 and STAT3 may be involved in the BiP 
induction of IL-10 within responder T cells. Haura and colleagues (2005) reported that EGFR 
signalling in breast cancer tumour can induce the activation of STAT1, STAT3 and STAT5. 
However, a report by Haura et al (2005) did not explain how TGF-β signalling may be 
initiated by GLI2 transcription.  
Based on this evidence, it is postulated that BiP binds to EGFR receptors to exert its 
effect on both regulatory and responder T cells. Ladanyi and Pao (2008) showed in their 
review how EGFR receptor signalling can activate STAT1 and STAT3 which may induce IL-10 
while STAT5 activation by EGFR may induce Foxp3 expression and p38 MAPK activation for 
TGF-β induction. This hypothetical signalling of BiP binding to EGFR is illustrated in Figure 
6.1 (regulatory T cells) and 6.2 (responder T cells). To confirm that BiP receptor is EGFR, anti-
EGFR antibody can be used to block BiP binding to EGFR in regulatory and responder T cells. 
However, the big question remains is how BiP signalling can yield different outcomes in 
regulatory and responder T cells in term of cytokine secretion. 
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6.3 Soluble BiP concentrations are reduced in RA patients and influenced by ageing; 
therefore it may not induce immunoregulatory phenotype in regulatory and responder 
T cells in RA patients 
Corrigall et al (2001) and Blass et al (2001) independently demonstrated the role of 
BiP as an autoantigen in RA. This raises an important question based on our observation on 
the effect of BiP on regulatory and responder T cells. In the previous two chapters, it was 
shown that BiP may modulate regulatory T cell phenotype and can affect responder T cell 
phenotype and function from healthy donors. One of the reasons why inflammation persists 
in RA patients is related to soluble BiP concentration. Although Blass et al (2001) showed 
that BiP was overexpressed in synovial section of RA patient compared to osteoarthritis (OA) 
patient, Shields et al (2011) reported that soluble BiP concentrations were significantly 
reduced in the circulation compared to OA patients. Lower concentration of soluble BiP 
could partly explained why inflammation persists in RA as BiP effect on regulatory and 
responder T cells and previous works (Corrigall et al, 2001, Bodman-Smith et al, 2003, 
Corrigall et al, 2004, Corrigall et al, 2009) demonstrated the immunoregulatory properties of 
BiP on various immune cells.  
 Another factor that may be important in the induction and secretion of BiP is age. 
The BiP effect on regulatory and responder T cells were obtained from cone bloods (age is 
unknown) and fresh bloods from young donors (20-35 years old). Therefore, it is plausible 
that soluble BiP induction and secretion is impaired in ageing hence the soluble BiP 
concentration produced is insufficient to induce immunoregulatory properties in regulatory 
and responder T cells as RA is more common in the elderly population. In response to acute 
sleep deprivation, Naidoo and colleagues (2008) reported that aged mice do not display an 
increase of BiP expression as UPR, the main inducer of BiP, can induce higher BiP expression 
in young mice after acute sleep deprivation. Furthermore, they showed that the basal 
expression of BiP decreased in aged mice compared to young mice. To confirm that aging 
can influence soluble BiP concentration in healthy donors, correlation analysis was 
performed between age and soluble BiP concentration from the Whitehall II cohort. Data 
from 68 donors did not demonstrate significant correlation between age and soluble BiP 
concentration. However, data from a larger cohort (n=189) demonstrated a significant 
correlation. Soluble BiP negatively correlates with age even though the correlation is a weak 
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correlation as indicated by the low correlation coefficient (R=-0.2027, p=0.0051). Correlation 
between age and soluble BiP concentration is demonstrated in Figure 6.3. This data explains 
that soluble BiP concentrations are reduced as the healthy donors from this cohort get 
older.  
6.4 RA microenvironment is important to influence regulatory and responder T cell 
phenotype and function in RA patients    
Synovial joints of RA patients are infiltrated with various immune cells and cytokines. 
One of the most important cytokines present in the joints is TNF-α. TNF-α has been shown 
to play various roles in the pathogenesis of RA as shown by Brennan and McInnes (2008). 
Not only is TNF-α responsible for inducing pro-inflammatory immune responses, TNF-α also 
plays a role in angiogenesis, endothelial cell activation, osteoclast activation and hepcidin 
induction and all of these process play an important role in RA pathogenesis. In addition, 
anti-TNF-α blockade has been licensed for use in RA patients. This underlines the 
importance of TNF-α in modulating the phenotype and function of immune cells especially 
regulatory and responder T cells.  
TNF-α has been shown to impair the ability of regulatory T cells to suppress the 
proliferation of responder T cells or cytokines secreted by responder T cells. Valencia and 
colleagues (2006) demonstrated that regulatory T cells from RA patients had reduced mRNA 
Foxp3 expression and failed to suppress the proliferation of responder T cells, and this effect 
is reversed upon anti-TNF-α therapy. In addition, in vitro co-culture of human regulatory and 
responder T cells with TNF-α impaired the ability of regulatory T cells to suppress the 
proliferation of responder T cells as shown by Valencia et al (2006) and van Amelsfort et al 
(2007). In addition, Ehrenstein and colleagues (2004) showed that regulatory T cells from RA 
patients failed to suppress TNF-α and IFN-γ secretions from responder T cells in co-culture 
with regulatory T cells before anti-TNF-α treatment. However, the regulatory T cell capacity 
to inhibit pro-inflammatory cytokines secreted from responder T cells was restored upon 
anti-TNF-α therapy. Furthermore, Ehrenstein et al (2004) and Huang et al (2012) reported 
an increase in regulatory T cell frequency after anti-TNF-α treatment compared to 
regulatory T cell frequency before the treatment.  
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The ability of TNF-α to modulate regulatory T cell function is dependent on its ability 
to bind on TNF receptor II (TNFRII) on regulatory T cells as reported by Valencia et al (2006). 
This receptor is constitutively expressed on unstimulated regulatory T cells and the 
expression of this receptor can be upregulated by TNF-α. Nie et al (2013) performed an 
elegant experiment demonstrating the molecular mechanism of TNF-α in inhibiting human 
regulatory T cell function. They showed that phosphorylation of Ser418 in the C-terminus 
DNA binding domain in Foxp3 gene is important for human regulatory T cell suppressive 
function. TNF-α has been shown to impair the suppressive function of regulatory T cells in 
RA patients by inducing the protein-phosphatase 1 (PP1) enzyme. This enzyme can 
dephosphorylate Ser418 on the Foxp3 gene thus impairing the suppressive function of 
regulatory T cells. This effect was confirmed in RA patients receiving anti-TNF-α blockade 
treatment in which regulatory T cell suppressive function was restored which was 
associated with decreased expression of PP1 and increased Foxp3 phosphorylation.  
Another possible mechanism of TNF-α inhibition on regulatory T cell function is by 
influencing the formation of immunological synapse (IS) between regulatory T cells and 
APCs. TNF-α inhibition of regulatory T cell function can be achieved by interrupting two 
signalling molecules in regulatory T cells, namely the protein kinase C- theta (PKC-θ) and the 
disc large homolog 1 (Dlgh1). PKC-θ is a major isoform of the protein kinase C that has been 
shown in to be involved in CD3-CD28 costimulation while Dlgh1 is a scaffold protein that 
may be involved in the regulation of T cell migration and receptor signalling. Zanin-Zhorov et 
al (2010) reported that PKC-θ sequestration in regulatory T cells during IS is necessary and 
the inhibition of PKC-θ in regulatory T cells was defective in RA patients. On the other hand, 
Zanin-Zhorov et al (2012) showed the opposite role of Dlgh1 during IS formation in 
regulatory T cells. Dlgh1 recruitment is necessary to mediate the suppressive activity of 
regulatory T cells and also was defective in regulatory T cells isolated from RA patients. 
Interestingly, defective PKC-θ sequestration and Dlgh1 recruitment can be reversed in 
regulatory T cells of RA patients by TNF-α inactivation.   
In addition to modulating regulatory T cell function, regulatory T cell phenotypes can 
be affected by the microenvironment in the joints of RA patients. Walter and colleagues 
(2013) demonstrated that co-culture of human regulatory T cells and in vitro activated 
monocytes which mimics the monocytes present in the joints of RA patients can induce 
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regulatory T cells to secrete more cytokines including TNF-α, IFN-γ, IL-17 and IL-10 even 
though these regulatory T cells still maintain their suppressive capacity. In addition, Wang 
and co-workers (2014) showed that IL-17 producing regulatory T cells were present in RA 
patients with normal suppressive function. They also demonstrated that Th17 
differentiation in vitro can be induced by the presence of IL-6 and IL-23 cytokines in in vitro 
culture. Gomez-Puerta et al (2013) reported that IL-6 concentration in the synovial fluid of 
RA patients was the highest concentration of cytokines measured compared to 16 other 
cytokines. In addition, the anti-IL-6 receptor antibody is now being licensed for use in clinics 
to treat RA.   
Several studies have reported the effect of tocilizumab, an anti-IL-6 receptor 
antibody towards correcting the balance between regulatory T cells and Th17 cells. Samson 
and colleagues (2012) reported that tocilizumab treatment on RA patients can significantly 
decrease Disease Activity Score in 28 joints (DAS 28), Th17 cell frequency and increase 
percentages of regulatory T cells in 15 patients. In contrast, Pesce et al (2013) only reported 
an increase in regulatory T cell frequency; but no change was observed in Th17 cell 
frequency. By using adalimumab or anti-TNF-α antibody, regulatory T cells from RA patients 
can restrain or suppress Th17 cells by inhibiting monocyte-derived IL-6 as shown by 
McGovern et al (2012). They demonstrated that anti-TNF-α antibody administration to RA 
patients can induce an increase in Foxp3+ regulatory T cells that lacks Helios expression. In 
addition, IL-6 blockade in RA patients has been shown to expand CD39+ regulatory T cell 
frequency as reported by Thiolat et al (2014). Further work by Herrath and colleagues 
(2014) showed that CD39+ regulatory T cells isolated from rheumatic joints had the ability 
to suppress pro-inflammatory cytokines from responder T cells namely IFN-γ, TNF-α and IL-
17A. Clearly, TNF-α and IL-6 play a significant role in modulating regulatory T cell phenotype 
and function in RA patients.  
In addition, these two cytokines also have been shown to affect responder T cells by 
modulating their function. TNF-α and IL-6 can partially induce hyperactivation of effector T 
cells from RA  patients hence rendering them  resistant to suppression by regulatory T cells 
as reported by Wehrens et al (2011). The increased resistance of effector T cells to 
suppression by regulatory T cells was because of enhanced activation of protein kinase B 
(PKB)/c-akt in effector T cells and Haufe and colleagues (2011) reported an increased 
222 
 
resistance to suppression of synovial CD4+CD25- T cells from juvenile idiopathic arthritis 
indicating that this phenomenon maybe common in autoinflammatory conditions. The 
effect of TNF-α modulation on effector or CD4+CD25- T cells was not only limited to 
affecting their function but can also influence their frequency. Anti-TNF-α therapy can 
induce decreased frequency of activated CD4+ T cells but not regulatory T cells as reported 
by Dombrecht et al (2006). Furthermore, anti-TNF-α treatment can induce a specialised 
population of regulatory T cells in RA patients from responder T cells as shown by Nadkarni 
et al (2007). These induced CD4+CD25+Foxp3+ regulatory T cells were characterised by the 
absence of CD62 Ligand (CD62L) molecules on their surface and can mediate suppression 
using TGF-β and IL-10. In conclusion, regulatory and responder T cell phenotype and 
function can be modulated in an RA microenvironment especially by TNF-α and IL-6 as 
demonstrated in Figure 6.4.    
6.5 How may soluble BiP restore defective regulatory and responder T cell function in 
RA patients?  
 As shown in the previous two chapters, soluble BiP may affect regulatory T cell 
phenotype but can influence responder T cell phenotype and function. Responder T cells 
cultured with BiP can induce an increase in Foxp3+CD25+ cells after 4 days. BiP-induced 
Foxp3+CD25+ cells can induce IL-10 secretion and these cells can downregulate TNF-α 
secretion from autologous responder T cells. The data showed that these cells may be 
induced regulatory T cells however the suppressive effect of these cells were variable as 
demonstrated in Chapter 5. To ensure that these cells are suppressive, additional surface 
markers need to be used to identify these cells before these cells can be sorted and co-
cultured with autologous responder T cells. Nevertheless, these cells demonstrated the 
ability to modulate TNF-α from autologous responder T cells. As demonstrated by anti-TNF-
α therapy, this clearly indicates that BiP may help in reducing the TNF-α level in RA 
microenvironment which may consequently lead to the resolution of inflammation. 
Furthermore, the reduction of TNF-α level may help to restore the defective function of 
regulatory T cells as demonstrated in the previous section. 
In addition, regulatory T cells cultured with BiP may increase Foxp3 expression and 
TGF-β secretion. TGF-β is a pleiotropic cytokine which can affect various immune cells but 
the main focus is on DC. Andersson and colleagues (2008) showed that the role of 
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CD4+Foxp3+ regulatory T cells in maintaining tolerance in mice is dependent on TGF-β by 
conferring infectious tolerance. Further work by Lan et al (2012) showed that tolerogenic DC 
can be induced by TGF-β secreted by polyclonal CD4+Foxp3+ regulatory T cells. The 
interaction between tolerogenic DC and polyclonal regulatory T cells was important to 
suppress lupus-like syndrome in mice. Based on this evidence, we hypothesised that 
regulatory T cell-derived TGF-β can induce an increase in IDO enzyme in DC especially in RA. 
Various evidence demonstrated an important role for the IDO enzyme in the animal model 
of arthritis. Criado and colleagues (2009) reported that arthritis induction using 
immunisation of type II collagen in IDO knockout mice showed a higher incidence of arthritis 
and exacerbated the severity of arthritis compared to normal mice. By using the IDO 
inhibitor, 1-methyl-trytophan (1MT), Szanto et al (2007) demonstrated the role of IDO in 
experimental arthritis using CIA model. Mice immunised with 1MT showed higher incidence 
of arthritis and experienced more severe arthritis compared to unimmunised mice. Another 
strategy employed to assess the role of IDO in experimental arthritis was by using gene 
therapy. Chen and colleagues (2011) showed that intra articular delivery of the IDO gene in 
rat-collagen induced arthritis can ameliorate arthritis in these rats. These articles showed 
the role played by IDO in the resolution of arthritis in animal models. 
Fallarino et al (2012) described the IDO enzyme as a moonlighting protein in their 
review as they showed that it can perform multiple biological functions. IDO enzyme is 
known to catalyse tryptophan, an essential amino acid to kyneurenine and its expression is 
associated with an immunosuppressive effect on T cell proliferation. Therefore, it is possible 
that IDO can exert other biological effects. It has been shown by Belladonna and colleagues 
(2008) that murine tolerogenic CD8+ DC cells can secrete TGF-β and induce IDO expression 
in immunogenic CD8- DC cells and turn them into tolerogenic DC. TGF-β can induce IDO 
expression in CD8- DC cells by activation of PI3K/Akt and non-canonical NFκB signalling. 
Furthermore, Pallotta et al (2011) showed that TGF-β can induce IDO expression and its 
regulatory phenotype in the murine model of transplantation. The regulatory phenotype in 
murine pDC was mediated by TGF-β binding to the immunoreceptor tyrosine-based 
inhibitory (ITIM) motif in pDC leading to the recruitment and activation of phosphatases. 
The downstream effect of this signalling was the activation of non-canonical activation of 
the NFκB signalling pathway and the secretion of Type 1 IFN. Type 1 IFN which consists of 
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IFNα and IFNβ served as a protective factor in RA as reviewed by Crow (2010). She 
demonstrated the various protective roles of Type 1 IFN especially IFNβ in animal models of 
arthritis and data from RA patients.      
TGF-β binding to ITIM motif can initiate the regulatory phenotype in DC. However, IL-
6 concentration is abundant in an RA microenvironment especially in the joints of RA 
patients. Grohmann et al (2001) showed that IL-6 can impair tolerogenic activity of murine 
CD8+ DC by reducing the expression of IDO in these cells. Further work by the same group 
(Pallotta et al, 2010) demonstrated that IL-6 can induce the expression of suppressor of 
cytokine signalling 3 (SOCS3) in murine DC and bind to another ITIM motif on IDO. 
Interaction of SOCS3 and ITIM motif in DC activated a cascade of downstream signalling 
which will lead to the degradation of IDO enzyme in DC. As demonstrated by Wang et al 
(2014), IL-6 is one of the cytokines needed for Th17 differentiation and Th17 cells have been 
implicated in the pathogenesis of RA. Sharma et al (2009) reported that in vitro 
differentiation of murine Th17 cells require the presence of IL-6 to convert regulatory T cells 
to Th17 phenotype. As reported in the previous paragraph, RA patients that received IL-6 
inhibition therapy can correct the balance in the ratio of regulatory T cells to Th17 cells. The 
last two paragraphs demonstrate the mechanisms of IDO action as a signalling protein.        
However, the effect of IDO is not only limited to functioning as a signalling protein. 
IDO can be induced in DC upon cell-to-cell contact with regulatory T cells. Fallarino et al 
(2003) showed that the engagement of CTLA-4 of murine regulatory T cells with B7 
expression or CD80/CD86 expression on DC can induce IDO expression. In addition, Hill et al 
(2007) reported that IDO expressing DC can expand human regulatory T cells by promoting 
the proliferation of regulatory T cells in vitro. However, Flores-Borja and colleagues (2008) 
reported that CTLA-4 defects in regulatory T cells of RA patients may contribute to impaired 
function of regulatory T cells. Further work by Cribbs and co-workers (2014) showed that a 
fault in the CTLA-4 gene of RA patients is responsible for downregulation of CTLA-4 
expression in regulatory T cells from RA patients. They demonstrated that CTLA-4 promoter 
methylation disabled regulatory T cells from inducing IDO expression in DC thus 
inflammation persists in RA patients as CTLA-4 had been shown to be important in 
mediating murine regulatory T cell suppression (Wing et al, 2008). Therefore, it would be 
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interesting to investigate whether BiP can have a direct effect on CTLA-4 expression on 
human regulatory T cells. 
Previous work by Corrigall et al (2009) demonstrated that human monocyte-derived 
DCs can induce IDO expression when cultured with BiP and these DCs can convert 
CD4+CD25- T cells into CD4+CD25+CTLA-4+ regulatory T cells. The ability of DC to induce 
regulatory T cell development is dependent on the product of tryptophan catabolism, 
kynurenine. Chen et al (2008) demonstrated that kynurenine can convert human 
CD4+CD25- T cells to CD4+CD25+Foxp3+ regulatory T cells and this effect was mediated by 
kynurenine binding to aryl hydrocarbon receptor (Mezrich et al (2010)). Furthermore, 
kynurenine had been demonstrated to exert an immunosuppressive effect on other 
immune cells by inhibiting the proliferation of human T cells (Frumento et al (2002) and 
Terness et al (2002)) and natural killer cells (Frumento et al (2002)). In conclusion, BiP may 
modulate regulatory and responder T cell functions and further induce the 
immunoregulatory phenotype as demonstrated in Figure 6.5.   
This work added more to the understanding of the immunoregulatory phenotypes 
that can be induced by soluble BiP on regulatory and responder T cells. Soluble BiP may 
enhance Foxp3 expression and TGF-β secretion in human regulatory T cells and can induce 
Foxp3+CD25+ cells and enhanced IL-10 secretion in human responder T cells.  As 
demonstrated by Foo (2011), BiP immunisation in mice can induce BiP-specific cells. These 
BiP-specific cells were CD4+Foxp3-CTLA-4+PD-1+ cells and can secrete IL-10, TGF-β and 
soluble CTLA-4. More importantly, these cells are regulatory in vitro as demonstrated by 
their ability to suppress the proliferation of the pathogenic CII cells. Further work by 
Brownlie et al (2006) showed that BiP-primed cells from immunised mice can increase the 
secretion of IL-4, IL-5 and IL-10 after re-stimulation with BiP in in vitro culture. In addition, 
BiP-immunised cells adoptively transferred into the CIA model can cure arthritis in the CIA 
model as measured by the mean severity score (Brownlie et al (2006)). These mechanisms 
and other immune mechanisms as discussed in Chapter 1 may contribute to the resolution 
of arthritis in experimental models of arthritis as demonstrated by various studies (Corrigall 
et al (2001), Brownlie et al (2006), Yoshida et al (2011) and Shields et al (2015)). It is too 
early to speculate on the efficacy of BiP injection as a treatment for RA as it is being used in 
Stage I of clinical trials. Therefore, it is essential to compare in vitro work performed on 
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various immune cells from healthy donors (Bodman Smith et al (2003), Corrigall et al (2004), 
Corrigall et al (2009) and our observation) to the RA patients who received BiP injections 




































7.0 Conclusion & Future Work 
7.1 Conclusion 
The main aim of this project was to investigate the effect of BiP on regulatory T cell 
frequency and function. Chapter 3 shows that soluble BiP concentration does not correlate 
with regulatory T cell frequency. However, correlation analysis revealed a linear relationship 
between two variables. The examples are soluble BiP concentrations correlate with IL-1β, 
TNF-α and IL-10 concentrations. Therefore, although soluble BiP concentration has no 
relationship with regulatory T cell frequency, it is possible that soluble BiP may affect or 
modulate regulatory T cell function. 
Therefore, the aim of Chapter 4 was to investigate the effect of BiP on regulatory T 
cell phenotype and function. Two hours of BiP pre-treatment does not modulate regulatory 
T cell function as does HSP60. However, regulatory T cells cultured with BiP for 4 days may 
enhance Foxp3 expression and increase TGF-β secretion but these effects were not 
translated to an enhanced suppressive capacity of regulatory T cells on responder T cells. 
Chapter 5 was based on the initial observation in Chapter 4 where responder T cells 
cultured in the presence of anti-CD3/CD28 beads with BiP can significantly reduce their 
proliferation. Phenotypic analysis revealed an increase in Foxp3+CD25+ cells within 
unstimulated responder T cells cultured with BiP. These cells can secrete IL-10 and can 
downregulate TNF-α secretion from autologous responder T cells in co-culture.  
In conclusion, BiP may modulate regulatory T cell phenotype and can affect 
responder T cell phenotype and function.  
7.2 Future Works 
 To further investigate the effect of BiP on regulatory and responder T cells, future 
work will mainly focus on following up Chapter 4 and Chapter 5. The list of the future works 






Chapter 4 – The effect of soluble BiP on regulatory T cell phenotype and function:- 
 To confirm Foxp3 expression and TGF-β secretion by 4 days of BiP treatment on 
regulatory T cells by measuring using Foxp3 and TGF-β mRNA using reverse 
transcription polymerase chain reaction (RT-PCR) 
 Investigating the effect of soluble BiP on CTLA-4 expression in regulatory T cells as 
CTLA-4 expression in regulatory T cells of RA patients was decreased 
 Investigating the effect of BiP-treated regulatory T cells on responder T cell 
proliferation in the presence of APC (monocytes) 
 Investigating the effect of BiP-treated regulatory T cells on IDO expression in DC 
Chapter 5 – The effect of soluble BiP on responder T cell phenotype and function:- 
 Investigate the surface markers associated with BiP-induced Foxp3+CD25+ cells 
before these cells can be sorted to assess their suppressive capacity 
 To confirm that TNF-α downregulation by BiP-induced Foxp3+CD25+ cells is because 
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9.1 List of recipes and buffers 
 
9.1.1 Cell isolation 
MACS buffer - MACS buffer – Dulbecco’s PBS 1X without Calcium and Magnesium (PAA, 
Pasching, Austria) + 2 mM of EDTA (Lonza) and 0.5% Bovine Serum Albumin (gold standard) 
(PAA) 
9.1.2 FACS 
Washing buffer - Dulbecco’s PBS 1X without Calcium and Magnesium (PAA) + 0.1% sodium 
azide (Sigma Aldrich) 
Staining buffer – Washing buffer added + 2% BSA (PAA) 
Washing buffer – 1x PBS (PAA) added with 0.5% sodium azide (Acros Organics, Short Hills, 
USA) 
9.1.3 ELISA  
Washing buffer for IFN-γ, TNF-α, IL-1β and supernatant TGF-β1 – 5 mL  Tween 20 (Fischer 
Scientific, Waltham, USA) was added into 10 L of 1x PBS  
10x PBS – 80 g of sodium chloride (VWR International, Radnor, USA), 2 g of potassium 
chloride (VWR), 29 g of di-sodium hydrogen phosphate and 2 g of potassium dihydrogen 
phosphate (VWR) were added into 1 L of deionized water and pH was adjusted to 6.7 
2N Sulphuric Acid (H2SO4) – 110 mL of concentrated sulphuric acid (Fisher Scientific, 
Loughborough, UK) was added into purified water up to 1L.     
2N Hydrochloric Acid (HCI) – 88.8 mL of concentrated hydrochloric acid (Fisher Scientific) 
was added into purified water up to 1L. 
2N Sodium hydroxide (NaOH) – 40 g of sodium hydroxide (BDH, Poole, England) was added 
into purified water up to 1L. 
Washing buffer for circulating BiP – 2% BSA (PAA) in 1X PBS (from 10X PBS) + 0.05% Tween 
(Fischer Scientific) 
